{"PMC7355331": [["IntroductionThe tourism sector is often considered a labour area in which temporary and low-skilled jobs abound.", [["a labour area", "PROBLEM", 51, 64]]], ["However, it has also been highlighted that there are processes that relativize this image.", [["this image", "TEST", 79, 89]]], ["Moreover, in recent decades, the tourism sector has undergone significant organizational and technological changes (disintermediation, globalization, importance of internet and mobile devices, robotization, among others).", [["mobile devices", "TREATMENT", 177, 191], ["robotization", "TREATMENT", 193, 205], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["organizational", "OBSERVATION_MODIFIER", 74, 88]]], ["There has been a reconsideration of the concept of qualifications in service activities and an improvement in educational levels of the workforce in many tourism destinations (Baum, 2015).IntroductionThis paper analyzes the educational and experience requirements associated with job offers in the tourism sector.", [["improvement", "OBSERVATION_MODIFIER", 95, 106]]], ["Additionally, an important feature that stands out about the tourism sector is its internal heterogeneity.", [["internal", "OBSERVATION_MODIFIER", 83, 91], ["heterogeneity", "OBSERVATION", 92, 105]]], ["Therefore, this study considers the implications of occupations to the contract types and salaries in tourism job offers, as well as experience and educational levels.Theoretical frameworkSince the 1980s, profound changes have been observed in European labour markets; fundamentally the slide from a fordist model to a global, deregulated, flexible and delocalised one (Urry, 2014).", [["this study", "TEST", 11, 21], ["profound changes", "PROBLEM", 205, 221], ["profound", "OBSERVATION_MODIFIER", 205, 213], ["changes", "OBSERVATION", 214, 221]]], ["One of the most notable changes concerns the increase in non-standard jobs (Eurofound, 2017).", [["most notable", "OBSERVATION_MODIFIER", 11, 23], ["increase", "OBSERVATION_MODIFIER", 45, 53]]], ["For Bosch (2004), there has been a decline in standard employment traditionally associated with rigidity and a lack of dynamism.", [["rigidity", "DISEASE", 96, 104], ["a decline", "PROBLEM", 33, 42], ["rigidity", "PROBLEM", 96, 104], ["decline", "OBSERVATION_MODIFIER", 35, 42]]], ["Such standard employment can be defined as stable, socially protected and full time; conditions (working hours, salary, social transfers) are regulated by collective agreements or social laws.", [["stable", "OBSERVATION_MODIFIER", 43, 49]]], ["The uncertainty and dynamism of current economies lead to a permanent demand for adaptation and change in companies and people.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["a permanent demand", "TREATMENT", 58, 76]]], ["Thus, full-time indefinite employment, which in previous decades was the norm in industrial societies, has progressively been displaced by different forms of flexible employment (part-time, fixed-term, dependent self-employment).Theoretical frameworkMoreover, other repercussions of this global, flexible and liquid model of business organization are also observable (Bauman, 2013).", [["this global, flexible and liquid model of business organization", "PROBLEM", 283, 346], ["flexible", "OBSERVATION_MODIFIER", 296, 304], ["liquid model", "OBSERVATION_MODIFIER", 309, 321]]], ["A second change, which maintains a close connection with this work objectives, is the polarisation of working conditions between wage earners, and the growing number of employees and self-employed whose objective and/or experiential situation lies in precariousness (Anghel, De la Rica, & Lacuesta, 2014; Goos, Manning, & Salomons, 2009).", [["A second change", "PROBLEM", 0, 15], ["second", "OBSERVATION_MODIFIER", 2, 8], ["change", "OBSERVATION", 9, 15]]], ["This debate also affects its definition; thus, it has been stated that there are distinct meanings of the term precarity -as a labour condition, a class category, and an ontological experience-, being also undoubtedly its political dimension (Millar, 2017).", [["a labour condition", "PROBLEM", 125, 143], ["distinct", "OBSERVATION_MODIFIER", 81, 89]]], ["This polysemy in the concept leads some authors to propose the study of drivers and patterns of precarization as a more useful object of study than \u2018precarity\u2019 (Alberti, Bessa, Hardy, Trappmann, & Umney, 2018).", [["the study", "TEST", 59, 68]]], ["The condition of precariousness would expand beyond the contractual situation of a part of the employees, giving rise to a new conformation in the global informational capitalism.Theoretical frameworkAnother change is related to overqualification and the incorporation of university students into new work areas.", [["precariousness", "PROBLEM", 17, 31], ["overqualification", "PROBLEM", 229, 246]]], ["Thus, Tholen, Relly, Warhurst, & Commander, 2016state that there is an increasing number of degrees as well as graduates who enter occupations traditionally not envisaged for them.", [["Tholen", "CHEMICAL", 6, 12], ["Tholen", "SIMPLE_CHEMICAL", 6, 12], ["increasing", "OBSERVATION_MODIFIER", 71, 81]]], ["Ladkin (2006, 2011), Baum, 2007, Baum, 2015, Lucas (2004) and previously Riley, Ladkin, & Szivas, 2002summarize much of the evidence and debate about such employment.", [["Ladkin", "TREATMENT", 80, 86], ["Szivas", "TREATMENT", 90, 96]]], ["Riley et al. (2002) and Ladkin (2006) argue that the internal diversity of the tourism sector in terms of subsectors of activity, size of companies or fluctuations in demand, among others, leads to the existence of different jobs, qualifications and workers.", [["internal", "OBSERVATION_MODIFIER", 53, 61], ["diversity", "OBSERVATION_MODIFIER", 62, 71], ["size", "OBSERVATION_MODIFIER", 130, 134]]], ["Consistent evidence shows that many of these jobs are part of a set of unattractive jobs; because they mainly offer low salaries (Garc\u00eda-Pozo, Campos-Soria, S\u00e1nchez-Ollero, & Marchante-Lara, 2011; Lee & Kang, 1998; Riley & Szivas, 2003; Santos & Varejao, 2007), little stability, longer working hours (Lillo-Ba\u00f1uls & Casado-D\u00edaz, 2011; Lucas, 2004; Park, Yaduma, Lockwood, & Williams, 2016) or a lot of rotation (Lam, 2002).", [["S\u00e1nchez-Ollero, & Marchante-Lara, 2011; Lee & Kang, 1998; Riley & Szivas, 2003; Santos & Varejao", "SPECIES", 157, 253], ["Garc\u00eda", "TEST", 130, 136], ["stability", "OBSERVATION_MODIFIER", 269, 278]]], ["The approach of Robinson et al. (2019) is very illustrative, connecting the analysis of working conditions in the tourism sector with the concept of decent work and social dimension of sustainability.Theoretical frameworkHowever, although it is usual to highlight the low qualifications present in the sector, there is also a somewhat different perspective.", [["very illustrative", "PROBLEM", 42, 59], ["low", "OBSERVATION_MODIFIER", 268, 271], ["somewhat", "OBSERVATION_MODIFIER", 326, 334], ["different", "OBSERVATION_MODIFIER", 335, 344]]], ["Therefore, not only formal education but also informal qualifications acquired through experience must be taken into account (Marhuenda, Martinez, & Navas, 2004).Theoretical frameworkThe truth is that the expansion of service activities has led some authors to rethink the definitions of employment, qualifications and skills (Korczynski, 2005; Witz, Warhurst, & Nickson, 2003).", [["expansion", "OBSERVATION_MODIFIER", 205, 214]]], ["All these factors affect policies on human resources (Lucas, 2004; Marco-Lajara & \u00dabeda-Garc\u00eda, 2013).Theoretical frameworkThis is partly the reason for the problems in linking the skills offered by the education system to those demanded by the tourism sector, and which has led to a certain mutual indifference from both sides (Strietska-Ilina & Tessaring, 2005; Viktorovna & Avtandilovna, 2014).", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["the problems", "PROBLEM", 153, 165]]], ["Indeed, this points to a mismatch between, on the one hand, the specific educational offer and students' expectations (Cervera-Taulet & Ruiz-Molina, 2008; Hjalager, 2003) and, on the other, companies' needs (Marhuenda et al., 2004).", [["mismatch", "OBSERVATION", 25, 33]]], ["Even so, there is evidence that there are highly-qualified people in the tourism sector (Ladkin, 2011; Marrero-Rodr\u00edguez, 2015; Riley & Szivas, 2003), although operational and medium levels predominate.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["Marrero", "TEST", 103, 110], ["highly", "OBSERVATION_MODIFIER", 42, 48], ["medium levels", "OBSERVATION", 176, 189]]], ["Consequently, authors such as Ladkin (2011) and Churchward and Riley (2002) insist on the importance of considering occupations to better understand the issue of qualifications in the tourism sector.Theoretical frameworkRegarding salaries in the sector, different topics have been addressed such as gender discrimination (Campos-Soria, Ortega-Aguaza, & Ropero-Garcia, 2009; Garc\u00eda-Pozo, Campos-Soria, S\u00e1nchez-Ollero, & Marchante-Lara, 2012; Mu\u00f1oz-Bullon, 2009; Thrane, 2008) or the comparison between tourism and other sectors (Campos-Soria, Garc\u00eda-Pozo, S\u00e1nchez-Ollero, & Benavides-Chic\u00f3n, 2011; Silva & Freire-Guimar\u00e3es, 2017).", [["Garc\u00eda", "TEST", 374, 380]]], ["With regard to the latter, lower average salaries are observed in the tourism sector than in other sectors, these salaries are mainly attributed to the low level of formal education and the presence of low-skilled jobs in tourism (Robinson et al., 2019).", [["lower", "OBSERVATION_MODIFIER", 27, 32]]], ["There are, however, lower internal inequality levels in the tourism sector due to the downward trend in salaries for even the most qualified individuals (Casado-Diaz & Simon, 2016).", [["lower internal inequality levels", "PROBLEM", 20, 52], ["lower", "OBSERVATION_MODIFIER", 20, 25], ["internal", "OBSERVATION_MODIFIER", 26, 34], ["inequality", "OBSERVATION_MODIFIER", 35, 45], ["levels", "OBSERVATION_MODIFIER", 46, 52], ["downward", "OBSERVATION_MODIFIER", 86, 94], ["trend", "OBSERVATION_MODIFIER", 95, 100]]], ["It has been mentioned though, that some differences with respect to other sectors are due to segmentation elements (Silva & Freire-Guimar\u00e3es, 2017).Theoretical frameworkTo summarize, the tourism labour market has an important component of secondary employment (Atkinson, 1984; Carnoy, Castells, & Benner, 1997; Doeringer & Piore, 1985; Osterman, 1987; Villa, 1984), which can affect the demands and requirements of tourism companies.", [["secondary employment", "OBSERVATION", 239, 259]]], ["Therefore, this study will focus on the types of contracts and average salaries offered, and their relationship with the requirements for formal education and experience; all mediated by the functions to be performed, i.e., the occupations (Lambert & Bihagen, 2014; Levenson & Zoghi, 2010).", [["this study", "TEST", 11, 21], ["formal education", "TREATMENT", 138, 154]]], ["In this regard, it should be noted that most academic research on tourism employment rarely reaches this level of disaggregation.", [["disaggregation", "PROBLEM", 114, 128]]], ["However, it partially accompanies this discussion by offering a snapshot of the moment in which companies' employee preferences are expressed.Theoretical frameworkAs mentioned, the main academic objective of this paper is to analyze companies' employee preferences in the tourism sector, focusing on the internal heterogeneity, and the relative importance that education and experience have on the offer of salaries and contracts.", [["main", "OBSERVATION_MODIFIER", 181, 185]]], ["Even if it is a sector with an abundance of low-skilled jobs and low salaries, companies' preferences will allow the internal dynamics of the sector to be addressed in more detail.Theoretical frameworkFrom the previous academic literature, the following hypotheses are proposed:H1Offers of non-standard contracts predominate.H2Average salaries for standard contracts are higher than for non-standard contracts.H3High salaries and standard contracts are more likely in managers and professionals than in other occupational groups.H4Requirements of experience and educational level are unequally distributed according to occupations.H5The required experience is more important than formal educational requirements.H6Though the best job offers are associated with formal educational requirements, job offers are much more linked to experience.", [["more likely", "UNCERTAINTY", 453, 464]]]], "c4e1545ed0590073cac29802bd2153a548b575e9": [["IntroductionRecently, Watts and Strogatz have proposed the small-world network model to discover the large-clustering and small-distance properties, which universally exists in many natural and artificial networks, ranging from the Internet, the World Wide Web, human society, power grids, to economic and biological systems [1, 2] .", [["human", "ORGANISM", 262, 267], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 262, 267], ["the large-clustering and small-distance properties", "PROBLEM", 97, 147], ["small", "OBSERVATION_MODIFIER", 59, 64], ["large", "OBSERVATION_MODIFIER", 101, 106], ["small", "OBSERVATION_MODIFIER", 122, 127], ["-distance properties", "OBSERVATION_MODIFIER", 127, 147]]], ["In the small-world model, the regular lattices are responsible for large clustering, and a very small density of long-range connections has a drastic influence on short average distance [3, 4] .IntroductionThe spreading of viruses, diseases and even disasters has been observed in many real large-scale and small-world networks [5] .", [["large clustering", "PROBLEM", 67, 83], ["a very small density of long-range connections", "PROBLEM", 89, 135], ["a drastic influence", "PROBLEM", 140, 159], ["viruses", "PROBLEM", 223, 230], ["diseases", "PROBLEM", 232, 240], ["small", "OBSERVATION_MODIFIER", 7, 12], ["responsible for", "UNCERTAINTY", 51, 66], ["large", "OBSERVATION_MODIFIER", 67, 72], ["clustering", "OBSERVATION", 73, 83], ["very", "OBSERVATION_MODIFIER", 91, 95], ["small", "OBSERVATION_MODIFIER", 96, 101], ["density", "OBSERVATION", 102, 109], ["long-range", "OBSERVATION_MODIFIER", 113, 123], ["drastic", "OBSERVATION_MODIFIER", 142, 149], ["influence", "OBSERVATION_MODIFIER", 150, 159], ["viruses", "OBSERVATION", 223, 230], ["small", "OBSERVATION_MODIFIER", 307, 312]]], ["For example, the progress in science and technology cannot hold back the spread of infectious biological viruses in human society; on the contrary, the current networking age makes the diseases easily propagate all around the world [6] .", [["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["the diseases", "PROBLEM", 181, 193], ["infectious", "OBSERVATION", 83, 93]]], ["The current outbreak of H1N1 flu was first detected in Mexico City on March 18, 2009 .", [["H1N1 flu", "DISEASE", 24, 32], ["H1N1 flu", "ORGANISM", 24, 32], ["H1N1 flu", "SPECIES", 24, 32], ["H1N1 flu", "SPECIES", 24, 32], ["H1N1 flu", "PROBLEM", 24, 32], ["H1N1", "OBSERVATION", 24, 28]]], ["The World Health Organization (WHO) declared an H1N1 pandemic on June 11, 2009 , moving the alert level to phase 6, marking the first global pandemic since the 1968 Hong Kong flu.", [["Hong Kong flu", "SPECIES", 165, 178]]], ["Up till now, the virus has already propagated in all regions of the world.", [["the virus", "PROBLEM", 13, 22], ["virus", "OBSERVATION", 17, 22]]], ["In 2003, the spread of Severe Acute Respiratory Syndrome (SARS) leads to 8096 known infected cases and 774 deaths worldwide, declared by the WHO in the concluding report.", [["Acute Respiratory Syndrome", "DISEASE", 30, 56], ["SARS", "DISEASE", 58, 62], ["deaths", "DISEASE", 107, 113], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 23, 63], ["Severe Acute Respiratory Syndrome", "PROBLEM", 23, 56], ["Severe", "OBSERVATION_MODIFIER", 23, 29], ["Acute", "OBSERVATION_MODIFIER", 30, 35], ["Respiratory Syndrome", "OBSERVATION", 36, 56], ["infected", "OBSERVATION_MODIFIER", 84, 92]]], ["The spread of computer viruses and worms on the Internet is another urgent problem.IntroductionThere were more than $30 billion in damage caused by the Sobig worm, and the entire Internet came to a halt in a very short period given without any countermeasures to control the worms [7] .", [["worms", "SPECIES", 35, 40], ["worms", "SPECIES", 275, 280], ["damage", "PROBLEM", 131, 137], ["spread", "OBSERVATION_MODIFIER", 4, 10]]], ["The cascading financial crisis of the East Asia and the avalanching blackouts in the electric grid of North America are also the typical examples of failure propagation in the small-world networks [8] [9] [10] .", [["failure propagation", "PROBLEM", 149, 168], ["cascading", "OBSERVATION_MODIFIER", 4, 13], ["financial crisis", "OBSERVATION", 14, 30], ["small", "OBSERVATION_MODIFIER", 176, 181]]], ["In the view of wide occurrence of spreading behaviors in the small-world networks, it becomes a very interesting issue to investigate the spreading of viruses, diseases and even disasters in the network [11] [12] [13] .IntroductionMuch work has concentrated on the dynamics of spreading in small-world network.", [["spreading behaviors", "PROBLEM", 34, 53], ["viruses", "PROBLEM", 151, 158], ["diseases", "PROBLEM", 160, 168], ["spreading", "OBSERVATION_MODIFIER", 34, 43], ["small", "OBSERVATION_MODIFIER", 61, 66], ["viruses", "OBSERVATION", 151, 158], ["small", "OBSERVATION_MODIFIER", 290, 295]]], ["Moukarzel proposed a novel linear model of disease spreading in d-dimensional small-world lattices, which produces an exponential growth of infection to the limit of network scale [14] .", [["Moukarzel", "CHEMICAL", 0, 9], ["infection", "DISEASE", 140, 149], ["Moukarzel", "TREATMENT", 0, 9], ["disease spreading in d-dimensional small-world lattices", "PROBLEM", 43, 98], ["an exponential growth of infection", "PROBLEM", 115, 149], ["linear", "OBSERVATION_MODIFIER", 27, 33], ["disease", "OBSERVATION", 43, 50], ["small", "OBSERVATION_MODIFIER", 78, 83], ["exponential", "OBSERVATION_MODIFIER", 118, 129], ["growth", "OBSERVATION_MODIFIER", 130, 136], ["infection", "OBSERVATION", 140, 149]]], ["The investigations on the outbreak of SARS in 2003 have shown that the high clustering of small-world human social network is one of the keys to transmit SARS [15] [16] [17] .", [["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 154, 158], ["human", "ORGANISM", 102, 107], ["social network", "MULTI-TISSUE_STRUCTURE", 108, 122], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["The investigations", "TEST", 0, 18], ["small", "OBSERVATION_MODIFIER", 90, 95]]], ["In fact, when the epidemic diseases propagate among humans or the computer viruses spread through the Internet, the administrative authorities usually take some counter measures to control the unfavorable prevalence.", [["humans", "ORGANISM", 52, 58], ["humans", "SPECIES", 52, 58], ["humans", "SPECIES", 52, 58], ["the epidemic diseases", "PROBLEM", 14, 35], ["some counter measures", "TREATMENT", 156, 177]]], ["Prof. Li et al. have carried out some pioneering researches on the stability of the spreading dynamics in smallworld network when control strategies are applied, and made great achievements.", [["Li", "CHEMICAL", 6, 8], ["smallworld network", "MULTI-TISSUE_STRUCTURE", 106, 124]]], ["It was recently reported that there exist oscillating infective behaviors with some unsuitable recovery rates in the epidemiology [18] , indicating the possible oscillations resulted from control strategies applied by the administrative authorities.", [["oscillating infective behaviors", "PROBLEM", 42, 73], ["oscillations", "PROBLEM", 161, 173], ["control strategies", "TREATMENT", 188, 206], ["infective", "OBSERVATION", 54, 63]]], ["However, Prof. Li inherent after studying the stability of spreading models with linear and nonlinear feedback controllers [8] .", [["Li", "CHEMICAL", 15, 17], ["linear and nonlinear feedback controllers", "TREATMENT", 81, 122]]], ["Prof. Li et al. further investigated three linear delayed SIR models for different cases of recovery response, and found that the unsuitable recovery strength may lead to oscillations [6] .IntroductionIn this Letter, based on the small-world spreading model used in Ref.", [["Li", "CHEMICAL", 6, 8], ["small", "OBSERVATION_MODIFIER", 230, 235]]], ["[8] , we investigate the stability of spreading dynamics when advanced predictive control strategy is applied to suppress the propagation of diseases, viruses and disasters.", [["spreading dynamics", "PROBLEM", 38, 56], ["advanced predictive control strategy", "TREATMENT", 62, 98], ["diseases", "PROBLEM", 141, 149], ["viruses", "PROBLEM", 151, 158], ["stability", "OBSERVATION_MODIFIER", 25, 34], ["diseases", "OBSERVATION", 141, 149]]], ["We try to investigate the stability condition of the small-world spreading model with predictive controller applied, and whether the epidemic oscillations in predictive-controlled small-world spreading model are avoidable.Predictive control problem and algorithmOver the last two decades, predictive control strategy has emerged as a powerful control technique in a wide variety of application areas [19, 20] .", [["predictive controller", "TREATMENT", 86, 107], ["the epidemic oscillations", "PROBLEM", 129, 154], ["Predictive control problem", "PROBLEM", 222, 248], ["predictive control strategy", "TREATMENT", 289, 316], ["a powerful control technique", "TREATMENT", 332, 360], ["small", "OBSERVATION_MODIFIER", 53, 58], ["small", "OBSERVATION_MODIFIER", 180, 185]]], ["The first calculated control input is actually implemented, the horizons are moved one sample period towards the future and the optimization process is repeated at the next time step.Predictive control problem and algorithmConsider a single-input-single-output analytical system governed by the following:Predictive control problem and algorithm(1)Predictive control problem and algorithmThe future system outputs y p (t + i) for i = 1, . . . , H p , are predicted over the prediction horizon H p using a model of the system.", [["H", "CHEMICAL", 445, 446], ["Predictive control problem", "TREATMENT", 183, 209], ["algorithm", "TEST", 214, 223], ["Predictive control problem", "TREATMENT", 305, 331], ["Predictive control problem", "TREATMENT", 348, 374], ["algorithm", "TEST", 379, 388], ["a model of the system", "TREATMENT", 503, 524], ["system", "ANATOMY", 518, 524]]], ["These values depend on the current process state and the fu-Predictive control problem and algorithmis the control horizon.", [["the fu-Predictive control problem", "TREATMENT", 53, 86], ["algorithmis the control horizon", "TREATMENT", 91, 122]]], ["The control variable is manipulated only within the control horizon and remains constant afterwards, i.e.,Predictive control problem and algorithmtimizing a given objective function.", [["variable", "OBSERVATION_MODIFIER", 12, 20], ["constant", "OBSERVATION_MODIFIER", 80, 88]]], ["The objective function defines the goal over the prediction horizon in combination with a cost function on the control effort over the control horizon.", [["the prediction horizon", "TREATMENT", 45, 67], ["the control horizon", "TREATMENT", 131, 150]]], ["A general objective function is the following quadratic formPredictive control problem and algorithmwhere P i and Q i are positive definite weight matrices.", [["quadratic formPredictive control problem", "TREATMENT", 46, 86]]], ["The first term accounts for minimizing the variance between the predictive output and the desired output of the system, while the second term, u(k) = u(k) \u2212 u(k \u2212 1), represents a penalty on the control effort (related, for instance, to energy).", [["the predictive output", "TEST", 60, 81], ["u(k", "TEST", 150, 153], ["u(k \u2212", "TEST", 157, 162]]], ["(2) is mostly used in combination with input or output constraints.Small-world spreading model with delayed predictive controllerTo investigate the spreading dynamics of small-world evolving networks in the whole probability spectrum 0 p 1, we describe a general spreading model for small-world network with delayed predictive controller applied.", [["output constraints", "PROBLEM", 48, 66], ["Small-world spreading model", "PROBLEM", 67, 94], ["small-world network", "PROBLEM", 283, 302], ["delayed predictive controller", "TREATMENT", 308, 337], ["small", "OBSERVATION_MODIFIER", 170, 175]]], ["Because the generative algorithm of the small-world network may result in the formulation of isolated clusters, we hold the following assumption that the small-world evolving network is always connected without any isolated cluster for all 0 p 1.Small-world spreading model with delayed predictive controllerRecall that there exists an infective disease which spreads with a constant radial velocity v = 1 from an original infected node in small-world evolving network [22] .", [["node", "ANATOMY", 432, 436], ["Small-world spreading model", "PROBLEM", 246, 273], ["an infective disease", "PROBLEM", 333, 353], ["a constant radial velocity v", "PROBLEM", 373, 401], ["an original infected node", "PROBLEM", 411, 436], ["small", "OBSERVATION_MODIFIER", 40, 45], ["small", "OBSERVATION_MODIFIER", 154, 159], ["infective", "OBSERVATION_MODIFIER", 336, 345], ["disease", "OBSERVATION", 346, 353], ["radial velocity", "OBSERVATION_MODIFIER", 384, 399], ["infected", "OBSERVATION_MODIFIER", 423, 431], ["node", "OBSERVATION", 432, 436], ["small", "OBSERVATION_MODIFIER", 440, 445]]], ["The random rewiring in the small-world model means in the propagation process that, each time the infective node spreads through the forthcoming edge in the nearest-neighbor ring, it may be linked with another node through the rewired long-range connection with probability 0 p 1.", [["node", "ANATOMY", 108, 112], ["node", "ANATOMY", 210, 214], ["infective node", "MULTI-TISSUE_STRUCTURE", 98, 112], ["The random rewiring", "TREATMENT", 0, 19], ["the infective node", "PROBLEM", 94, 112], ["another node", "PROBLEM", 202, 214], ["rewiring", "OBSERVATION", 11, 19], ["small", "OBSERVATION_MODIFIER", 27, 32], ["propagation process", "OBSERVATION", 58, 77], ["infective", "OBSERVATION_MODIFIER", 98, 107], ["node", "OBSERVATION", 108, 112], ["edge", "OBSERVATION_MODIFIER", 145, 149], ["neighbor ring", "OBSERVATION", 165, 178], ["may be", "UNCERTAINTY", 183, 189], ["node", "OBSERVATION", 210, 214]]], ["Therefore, based on the mean-field approach, the total volume of infected individuals V (t) in the one-dimensional smallworld evolving model satisfiesSmall-world spreading model with delayed predictive controllerwhere the time delay \u03b4 > 0 is due to the long-range spatial distance [23] .", [["total", "OBSERVATION_MODIFIER", 49, 54], ["volume", "OBSERVATION_MODIFIER", 55, 61], ["infected", "OBSERVATION", 65, 73], ["Small", "OBSERVATION_MODIFIER", 150, 155]]], ["(3) we can easily find that the infected volume V (t) grows exponentially and finally can cover the whole network if no counter measure is taken.", [["infected", "OBSERVATION", 32, 40]]], ["Faced with the cascading spread of diseases or disasters, authorities usually implement the control strategies to struggle against the propagation, which, for example, result in the decrease of infected individuals by the increasing recovery of SARS patients, or the slaughter of infected animals [8] .", [["SARS", "DISEASE", 245, 249], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 250, 258], ["diseases", "PROBLEM", 35, 43], ["disasters", "PROBLEM", 47, 56], ["infected individuals", "PROBLEM", 194, 214], ["SARS", "PROBLEM", 245, 249], ["decrease", "OBSERVATION_MODIFIER", 182, 190], ["infected", "OBSERVATION", 194, 202], ["increasing", "OBSERVATION_MODIFIER", 222, 232], ["infected", "OBSERVATION_MODIFIER", 280, 288]]], ["Therefore, we translate the reactions taken by the authorities to the following spreading equation with a feedback controller:Small-world spreading model with delayed predictive controllerwhere the controller takes effect after the time delay > 0.", [["the reactions", "PROBLEM", 24, 37], ["Small", "OBSERVATION_MODIFIER", 126, 131]]], ["Without loss of its generality, we assume = \u03b4.", [["loss of its generality", "PROBLEM", 8, 30]]], ["(4), we haveSmall-world spreading model with delayed predictive controllerIn predictive control strategy, the predictive model of system behaviors is very important.", [["Small", "OBSERVATION_MODIFIER", 12, 17]]], ["(5), we derive the i-step-ahead predictive value of the infected volume at time kSmall-world spreading model with delayed predictive controllerThe objective function of predictive control is defined to be min u(k+i)Small-world spreading model with delayed predictive controllerwhere H p is the prediction horizon, H u is the control horizon, q i and r i are the weighting values, V s (k + i) is the set value of the infected individuals at time k + i, and u(k + i) is the increment of control input at time k + i satisfying u(kSmall-world spreading model with delayed predictive controllerFrom Eq.", [["the infected volume", "PROBLEM", 52, 71], ["predictive control", "TREATMENT", 169, 187], ["Small-world spreading model", "PROBLEM", 215, 242], ["V s", "TEST", 380, 383], ["k", "TEST", 507, 508], ["infected", "OBSERVATION", 416, 424]]], ["(6) we can know that V (k + i|k) is related to u(k) only for i \u03b4 + 1 because of the input time-delay \u03b4.", [["V", "TEST", 21, 22]]], ["For simplicity, here we apply the one-step-ahead predictive control to investigate the stability of spreading dynamics, i.e. H p = \u03b4 + 1 and H u = 1, and the control performance is adjusted by changing the parameters q H p and r 0 .Small-world spreading model with delayed predictive controllerUse Eq.", [["predictive control", "TREATMENT", 49, 67], ["spreading dynamics", "TEST", 100, 118], ["Small-world spreading model", "PROBLEM", 232, 259]]], ["Therefore, the optimal increment of control at time k isSmall-world spreading model with delayed predictive controllerAs we know, predictive control is a class of feedback control strategies.", [["Small-world spreading model", "PROBLEM", 56, 83], ["feedback control strategies", "TREATMENT", 163, 190], ["Small", "OBSERVATION_MODIFIER", 56, 61]]], ["In the following, we analyze the stability of small-world spreading model with the predictive controller applied.Stability of small-world spreading model with predictive controllerBy using Laplace transform variable z, we can respectively rewrite Eqs.", [["small-world spreading model", "PROBLEM", 46, 73], ["the predictive controller", "TREATMENT", 79, 104], ["small-world spreading model", "PROBLEM", 126, 153], ["Laplace transform variable z", "TREATMENT", 189, 217], ["stability", "OBSERVATION_MODIFIER", 33, 42], ["small", "OBSERVATION_MODIFIER", 46, 51], ["small", "OBSERVATION_MODIFIER", 126, 131]]], ["(9) and (5) as (10) andStability of small-world spreading model with predictive controllerTherefore, small-world spreading model with the one-stepahead predictive controller is a closed-loop system, whose structure diagram is shown in Fig. 1 , and the parameters in Fig. 1 are listed as follows:Stability of small-world spreading model with predictive controllerTheorem.", [["small-world spreading model", "PROBLEM", 36, 63], ["small-world spreading model", "PROBLEM", 101, 128], ["a closed-loop system", "TREATMENT", 177, 197], ["small-world spreading model", "PROBLEM", 308, 335], ["small", "OBSERVATION_MODIFIER", 36, 41], ["small", "OBSERVATION_MODIFIER", 101, 106], ["closed", "OBSERVATION", 179, 185], ["loop system", "OBSERVATION", 186, 197], ["Fig", "OBSERVATION_MODIFIER", 266, 269], ["small", "OBSERVATION_MODIFIER", 308, 313]]], ["Small-Stability of small-world spreading model with predictive controllerProof.", [["small-world spreading model", "PROBLEM", 19, 46], ["-Stability", "OBSERVATION_MODIFIER", 5, 15], ["small", "OBSERVATION_MODIFIER", 19, 24], ["-world", "OBSERVATION_MODIFIER", 24, 30]]], ["As shown in Fig. 1 , the transfer functions from two inputs to output are G 1 (z) = F DG1+F D H+F DGL and G 2 (z) = E(1+F D H)1+F D H+F DGL respectively.", [["H", "CHEMICAL", 94, 95], ["H", "CHEMICAL", 124, 125], ["D H", "CHEMICAL", 130, 133], ["DGL", "CHEMICAL", 136, 139], ["output", "TEST", 63, 69], ["G", "TEST", 74, 75], ["DG1", "TEST", 86, 89], ["D H", "TEST", 92, 95], ["DGL", "TEST", 98, 101], ["G", "TEST", 106, 107], ["z", "TEST", 111, 112], ["E", "TEST", 116, 117], ["D H", "TEST", 122, 125], ["D H", "TEST", 130, 133], ["DGL", "TEST", 136, 139]]], ["From the classic control theory, we can know that the system is stable if and only if the poles of the system are all inside the unit circle [24, 25] .", [["stable", "OBSERVATION_MODIFIER", 64, 70]]], ["(12) it is discovered that the stability of spreading behaviors in small-world network with predictive controller applied is closely related to the parameters r, q H p , \u03b4 and p.", [["spreading behaviors", "PROBLEM", 44, 63], ["predictive controller", "TREATMENT", 92, 113], ["stability", "OBSERVATION_MODIFIER", 31, 40], ["spreading", "OBSERVATION_MODIFIER", 44, 53], ["small", "OBSERVATION_MODIFIER", 67, 72]]], ["21+F D H+F DGL and G 2 (z) = E(1+F D H)We choose \u03b4 = 1 and V s (k + H p ) = 1, and performed large simulations with different control parameter values of r, q H p and p to demonstrate the above stability condition.", [["H", "CHEMICAL", 7, 8], ["DGL", "TEST", 11, 14], ["G", "TEST", 19, 20], ["V s", "TEST", 59, 62], ["the above stability condition", "PROBLEM", 184, 213], ["above stability", "OBSERVATION", 188, 203]]], ["In the simulations, the output constraint V (k) 0 is considered.", [["the output constraint V (k)", "TEST", 20, 47]]], ["The spreading dynamics are depicted in Fig. 2 , which are the results from single runs and the corresponding poles' magnitudes of the closed-loop system are listed in Table 1 , with the different control parameters values.", [["the closed-loop system", "TREATMENT", 130, 152], ["poles", "OBSERVATION_MODIFIER", 109, 114], ["magnitudes", "OBSERVATION_MODIFIER", 116, 126], ["closed", "OBSERVATION", 134, 140], ["loop system", "OBSERVATION", 141, 152]]], ["The procedure of numerical simulation can be described as follows:1+F D H+F DGL and G 2 (z) = E(1+F D H)Step 1: Choose the values of parameters r, q, p, V s (k + H p );1+F D H+F DGL and G 2 (z) = E(1+F D H)Step 2: At time k, achieve the optimal control increment u opt (k) by Eq.", [["H", "CHEMICAL", 72, 73], ["E(1+F D H", "CHEMICAL", 94, 103], ["H", "CHEMICAL", 162, 163], ["H", "CHEMICAL", 174, 175], ["F D H", "CHEMICAL", 200, 205], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 66, 79], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 168, 181], ["numerical simulation", "TREATMENT", 17, 37], ["D H", "TEST", 70, 73], ["DGL", "TEST", 76, 79], ["G", "TEST", 84, 85], ["parameters", "TEST", 133, 143], ["V s", "TEST", 153, 156], ["k", "TEST", 158, 159], ["DGL", "TEST", 178, 181], ["G", "TEST", 186, 187], ["z", "TEST", 191, 192], ["E", "TEST", 196, 197], ["Step", "TEST", 206, 210], ["k", "TEST", 222, 223]]], ["(9);1+F D H+F DGL and G 2 (z) = E(1+F D H)Step 3: Add u opt (k) to u(k \u2212 1) to generate the control law u(k) at the current time k;1+F D H+F DGL and G 2 (z) = E(1+F D H)Step 4: Calculate V (k + \u03b4 + 1) according to Eq.", [["H", "CHEMICAL", 10, 11], ["E(1+F D H", "CHEMICAL", 32, 41], ["H", "CHEMICAL", 137, 138], ["F D H", "CHEMICAL", 163, 168], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 4, 17], ["G 2 (z)", "SIMPLE_CHEMICAL", 22, 29], ["1+F D H", "SIMPLE_CHEMICAL", 34, 41], ["DGL", "TEST", 14, 17], ["G", "TEST", 22, 23], ["Step", "TEST", 42, 46], ["u", "TEST", 67, 68], ["k", "TEST", 69, 70], ["k", "TEST", 106, 107], ["k", "TEST", 129, 130], ["D H", "TEST", 135, 138], ["+F", "TEST", 138, 140], ["DGL", "TEST", 141, 144], ["G", "TEST", 149, 150], ["z", "TEST", 154, 155], ["E", "TEST", 159, 160], ["D H", "TEST", 165, 168], ["Step", "TEST", 169, 173], ["Calculate V", "TEST", 177, 188], ["k", "TEST", 190, 191], ["\u03b4", "TEST", 194, 195]]], ["(5), in which V (k + \u03b4) and V (k) have already been obtained respectively at the previous times k \u2212 1 and k \u2212 \u03b4 \u2212 1, and then the output constraint is considered;1+F D H+F DGL and G 2 (z) = E(1+F D H)Step 5: k + 1 \u2192 k; go to Step 2 if the control process is not finished.1+F D H+F DGL and G 2 (z) = E(1+F D H)First, we fix the controller parameters r and q H p at a pair of constant values, and observe the stability of small-world spreading model with predictive controller when the rewiring probability p is varied.", [["H", "CHEMICAL", 168, 169], ["H", "CHEMICAL", 198, 199], ["1+F D H+F", "CHEMICAL", 271, 280], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 271, 284], ["V (k + \u03b4", "TEST", 14, 22], ["V (k", "TEST", 28, 32], ["k", "TEST", 96, 97], ["k", "TEST", 106, 107], ["the output constraint", "TEST", 126, 147], ["DGL", "TEST", 172, 175], ["G", "TEST", 180, 181], ["Step", "TEST", 200, 204], ["k", "TEST", 208, 209], ["k", "TEST", 216, 217], ["F D H", "TEST", 273, 278], ["DGL", "TEST", 281, 284], ["G", "TEST", 289, 290], ["small", "OBSERVATION_MODIFIER", 420, 425]]], ["Fixing r = 10 and q H p = 1, we select p = 0.2, p = 0.1 and p = 0.05 respectively.", [["p", "TEST", 48, 49]]], ["When r = 10, q H p = 1 and p = 0.2, two poles of the closed-loop system are outside of the unit circle as shown in Table 1 .", [["r", "TEST", 5, 6], ["p", "TEST", 27, 28], ["the closed-loop system", "TREATMENT", 49, 71], ["closed", "OBSERVATION", 53, 59], ["loop", "OBSERVATION", 60, 64]]], ["We can see that, the predictive controlled small-world spreading model oscillates, and furthermore it is discovered from the simulations that the spreading behavior even diverges if the output constraint is not considered.", [["the spreading behavior", "PROBLEM", 142, 164], ["the output constraint", "TEST", 182, 203], ["small", "OBSERVATION_MODIFIER", 43, 48], ["not considered", "UNCERTAINTY", 207, 221]]], ["When r = 10, q H p = 1 and p = 0.1, three roots of polynomial T (z) = 0 are all inside the unit circle, so the closed-loop system is stable as shown in Fig. 2(c) .", [["roots", "ANATOMY", 42, 47], ["r", "TEST", 5, 6], ["p", "TEST", 27, 28], ["polynomial T (z)", "TEST", 51, 67], ["the closed-loop system", "TREATMENT", 107, 129], ["closed", "OBSERVATION", 111, 117], ["loop", "OBSERVATION", 118, 122], ["stable", "OBSERVATION_MODIFIER", 133, 139]]], ["Further decreasing the rewiring probability p to 0.05 results in a more stable spreading dynamics, which can be found by comparing Fig. 2(c) with Fig. 2(e) .", [["decreasing", "OBSERVATION_MODIFIER", 8, 18], ["rewiring", "OBSERVATION_MODIFIER", 23, 31], ["stable", "OBSERVATION_MODIFIER", 72, 78]]], ["The stability of the predictive controlled small-world spreading model is illustrated in Figs.", [["stability", "OBSERVATION_MODIFIER", 4, 13], ["small", "OBSERVATION_MODIFIER", 43, 48]]], ["2(b), 2(d) and 2(f) when fixing r = 5, q H p = 1 and varying p from 0.2 to 0.1 and then to 0.05.", [["q H p", "TEST", 39, 44]]], ["Large simulations are performed and a similar phenomenon is discovered that, with the fixed controller parameters r and q H p , the dynamics of the smallworld spreading model with predictive controller become more and more stable when rewiring probability p decreases from a larger value to a smaller one.1+F D H+F DGL and G 2 (z) = E(1+F D H)Second, by fixing the parameters p and q H p , we examine the influences of parameter r on the spreading behavior.", [["1+F D H+F", "CHEMICAL", 305, 314], ["H", "CHEMICAL", 341, 342], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 305, 318], ["G 2 (z)", "SIMPLE_CHEMICAL", 323, 330], ["Large simulations", "PROBLEM", 0, 17], ["a similar phenomenon", "PROBLEM", 36, 56], ["F D H", "TEST", 307, 312], ["DGL", "TEST", 315, 318], ["G", "TEST", 323, 324], ["stable", "OBSERVATION_MODIFIER", 223, 229], ["larger", "OBSERVATION_MODIFIER", 275, 281], ["smaller", "OBSERVATION_MODIFIER", 293, 300]]], ["Comparing Fig. 2(a) with Fig. 2(b), Fig. 2(c) with Fig. 2(d) , and Fig. 2 (e) with Fig. 2(f) , it is easily discovered that decreasing r can help the former unstable oscillation of the infected volume V (k) be convergent to the set value, and bring a more stable spreading dynamics to the former stable system.", [["infected", "OBSERVATION", 185, 193], ["stable", "OBSERVATION", 296, 302]]], ["(7), we learn that decreasing parameter r can ease the suppression of control increment.", [["decreasing parameter r", "TREATMENT", 19, 41], ["the suppression of control increment", "TREATMENT", 51, 87]]], ["And this means that the fluctuations of actions taken by the authorities are allowed be larger, which can certainly make the spreading dynamics more stable.1+F D H+F DGL and G 2 (z) = E(1+F D H)Third, with the fixed parameters p and r, we increase the parameter q H p to observe the stability of the spreading dynamics.", [["1+F D H+F", "CHEMICAL", 156, 165], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 156, 169], ["F D H", "TEST", 158, 163], ["DGL", "TEST", 166, 169], ["G", "TEST", 174, 175], ["z", "TEST", 179, 180], ["the fixed parameters", "TEST", 206, 226], ["the spreading dynamics", "PROBLEM", 296, 318], ["larger", "OBSERVATION_MODIFIER", 88, 94]]], ["(7) we can find that the increase of parameter q H p can decrease the difference between the infected individuals and the set value.1+F D H+F DGL and G 2 (z) = E(1+F D H)For some certain values of control parameters r and q H p , the spreading behavior is unstable when the rewiring probability p lies within a certain range of the whole spectrum 0 p 1, with the phenomenon that control performance changes for the worse with the increase of p.", [["1+F D H+F", "CHEMICAL", 132, 141], ["H", "CHEMICAL", 168, 169], ["1+F D H+F DGL", "SIMPLE_CHEMICAL", 132, 145], ["the infected individuals", "PROBLEM", 89, 113], ["F D H", "TEST", 134, 139], ["DGL", "TEST", 142, 145], ["G", "TEST", 150, 151], ["D H", "TEST", 166, 169], ["the spreading behavior", "PROBLEM", 230, 252], ["infected", "OBSERVATION", 93, 101], ["unstable", "OBSERVATION_MODIFIER", 256, 264]]], ["However, we can find that the suitable control parameters, for example r = 1, q H p = 1, can lead to the stable dynamics of small-world spreading model even when p varies within the whole spectrum.ConclusionIn this Letter, we have explored the stability of small-world spreading model when predictive control strategy is applied.", [["small-world spreading model", "PROBLEM", 124, 151], ["small-world spreading model", "PROBLEM", 257, 284], ["predictive control strategy", "TREATMENT", 290, 317], ["stable", "OBSERVATION_MODIFIER", 105, 111], ["small", "OBSERVATION_MODIFIER", 124, 129], ["small", "OBSERVATION_MODIFIER", 257, 262]]], ["The sufficient and necessary stability condition is given, which is closely related to the control parameters r, q H p , and the smallworld rewiring probability p.", [["stability", "OBSERVATION", 29, 38]]], ["Decreasing r, increasing q H p , and decreasing p are valid for stabilizing the oscillations of the infected individuals V (k) to the set value.", [["Decreasing r", "PROBLEM", 0, 12], ["r", "OBSERVATION_MODIFIER", 11, 12], ["infected", "OBSERVATION", 100, 108]]], ["We have discovered that, the epidemic oscillations in predictive-controlled small-world spreading model are avoidable even when p varies within the whole spectrum if the suitable control parameters are applied; and on the contrary, the unsuitable control parameters can lead to spreading oscillations when p lies within a certain range.ConclusionHow to stabilize the spreading behavior in small-world network is still open because there are many complicated spreading mech- anisms in the real networks and moreover how to translate the advanced control strategies to the practical measures taken by the authorities deserves more explorations.", [["the epidemic oscillations", "PROBLEM", 25, 50], ["spreading oscillations", "PROBLEM", 278, 300], ["the spreading behavior", "PROBLEM", 363, 385], ["the advanced control strategies", "TREATMENT", 532, 563], ["the practical measures", "TREATMENT", 567, 589], ["epidemic", "OBSERVATION_MODIFIER", 29, 37], ["oscillations", "OBSERVATION_MODIFIER", 38, 50], ["small", "OBSERVATION_MODIFIER", 76, 81], ["small", "OBSERVATION_MODIFIER", 389, 394], ["complicated", "OBSERVATION_MODIFIER", 446, 457], ["spreading", "OBSERVATION_MODIFIER", 458, 467], ["mech", "OBSERVATION", 468, 472]]]], "ced064d01a6e6678d73084b4478432875203893a": [["IntroductionSince the COVID-19 infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan City, the capital of Hubei province of China, 1,2 on December 2019 and WHO declared it a pandemic, 3, 4 collaborative work was conducted worldwide by research institutions and pharma industry aiming at developing antiviral medication and vaccine in the global battle against this unprecedented dangerous threat to planet's life.", [["infectious disease", "DISEASE", 31, 49], ["acute respiratory syndrome coronavirus", "DISEASE", 71, 109], ["SARS-CoV-2", "ORGANISM", 113, 123], ["severe acute respiratory syndrome coronavirus", "SPECIES", 64, 109], ["SARS-CoV-2", "SPECIES", 113, 123], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 60, 109], ["SARS", "TEST", 113, 117], ["CoV", "TEST", 118, 121], ["pharma industry", "TREATMENT", 320, 335], ["antiviral medication", "TREATMENT", 357, 377], ["vaccine", "TREATMENT", 382, 389], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory syndrome", "OBSERVATION", 77, 97]]], ["Along with such effort whose concrete results are still to come, mathematical simulation can significantly assist governments in adopting the most adequate solutions to suppress infection spread and minimize medical burden as well as dramatic economic and social consequences.IntroductionMost population dynamics studies on COVID-19 pandemic as well as on other epidemics carried out in the past adopted a mathematical framework based on a continuous time picture.", [["infection", "DISEASE", 178, 187], ["infection spread", "PROBLEM", 178, 194], ["medical burden", "PROBLEM", 208, 222], ["COVID", "TEST", 324, 329], ["pandemic", "PROBLEM", 333, 341], ["infection", "OBSERVATION", 178, 187]]], ["Still, a more realistic approach should aim at quantitatively predicting or at least reproducing the new infection cases, and these are reported daily.", [["infection", "DISEASE", 105, 114], ["the new infection cases", "PROBLEM", 97, 120], ["new", "OBSERVATION_MODIFIER", 101, 104], ["infection", "OBSERVATION", 105, 114]]], ["Therefore, a discrete time representation appears to be more adequate.", [["appears to be", "UNCERTAINTY", 42, 55]]], ["From this perspective, quantifying the errors arising from the simplified continuous time assumption is a significant question that deserves consideration.", [["the errors", "PROBLEM", 35, 45]]], ["However, to the best of author's knowledge, this issue was not addressed in previous COVID-19 studies.", [["previous COVID", "TEST", 76, 90]]], ["For this reason, it represents the focus of the present 2 paper.The Logistic ModelEvolution in time of epidemics was extensively investigated in the literature, most often within the celebrated SIR model or many of its extensions.", [["The Logistic ModelEvolution", "TREATMENT", 64, 91], ["epidemics", "PROBLEM", 103, 112]]], ["5-10 An important problem with such approaches is the (too) large number of input parameters they need in order to make reliable predictions, and their values are difficult to validate before disease end.", [["5-10", "CHEMICAL", 0, 4]]], ["[12] [13] [14] [15] Along with numerous applications in various other fields, [16] [17] [18] [19] [20] [21] this model turned out to be also useful in previous studies on epidemics, 22-25 also including COVID-19 pandemic.", [["[16] [17] [18] [19] [20", "CHEMICAL", 78, 101], ["[12] [13] [14] [15] Along", "SIMPLE_CHEMICAL", 0, 25], ["[16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 78, 107], ["this model", "TEST", 108, 118], ["previous studies", "TEST", 151, 167], ["epidemics", "TEST", 171, 180], ["COVID", "TEST", 203, 208], ["pandemic", "PROBLEM", 212, 220]]], ["[26] [27] [28] As compared to various SIR-based approaches, the logistic growth model possesses a great advantage: it can be directly validated against ongoing epidemiological reports.", [["[26] [27] [28] As", "CHEMICAL", 0, 17], ["[26] [27] [28", "SIMPLE_CHEMICAL", 0, 13]]], ["28 In the continuous time description, logistic growth in time of an infected population obeys a first-order differential equationThe Logistic ModelHere, \u03ba stands for the intrinsic infection rate, which characterizes the unlimited exponential (Malthus-type) population increase occurring in an infinite environment.", [["infection", "DISEASE", 181, 190], ["an infected population", "PROBLEM", 66, 88], ["the intrinsic infection rate", "PROBLEM", 167, 195], ["infected", "OBSERVATION", 69, 77], ["infection", "OBSERVATION", 181, 190], ["unlimited", "OBSERVATION_MODIFIER", 221, 230], ["exponential", "OBSERVATION_MODIFIER", 231, 242], ["increase", "OBSERVATION_MODIFIER", 269, 277]]], ["In real situations, exponential growth is suppressed because the effective infection rate\u03ba = (dn/dt)/n gradually decreases as the number of infections increases.", [["infection", "DISEASE", 75, 84], ["infections", "DISEASE", 140, 150], ["exponential growth", "PROBLEM", 20, 38], ["the effective infection rate\u03ba", "PROBLEM", 61, 90], ["infections", "PROBLEM", 140, 150], ["effective", "OBSERVATION_MODIFIER", 65, 74], ["infection", "OBSERVATION", 75, 84], ["gradually", "OBSERVATION_MODIFIER", 103, 112], ["decreases", "OBSERVATION_MODIFIER", 113, 122], ["infections", "OBSERVATION", 140, 150]]], ["The parenthesis entering the RHS of equation (1) resembles the Pauli blocking factor passionately discussed in charge transport in Fermi systems.", [["Pauli blocking factor", "PROTEIN", 63, 84]]], ["[29] [30] [31] [32] [33] It represents the simplest possible way to model a population dependent infection rate\u03ba = f (n), namely to assume that it linearly decreases as n increases and eventually levels off at the maximum value N, which defines the so-called carrying capacity.The Logistic ModelEpidemiologists refer to n = n(t) as the total (cumulative) number of cases and t\u022f n(t) \u2261 dn(t)/dt as the daily number of (new) infections.", [["infection", "DISEASE", 97, 106], ["infections", "DISEASE", 423, 433], ["[29] [30] [31] [32] [33]", "SIMPLE_CHEMICAL", 0, 24], ["a population dependent infection rate\u03ba", "PROBLEM", 74, 112], ["dt", "PROBLEM", 391, 393], ["new) infections", "PROBLEM", 418, 433], ["infections", "OBSERVATION", 423, 433]]], ["The latter term stems from discrete time counterpart of the temporal derivativeThe Logistic ModelBy replacing the derivative entering the LHS of equation (1) by its finite difference counterpart of the RHS of equation (2) we arrive at the discrete time formulation of logistic growthThe Logistic ModelThe advantage of the continuous time description of logistic growth is that equation (1) can be integrated out in closed analytical form with the well known resultsThe Logistic ModelNotice that, whether in continuous or discrete time, in addition to the two model parameters \u03ba and N, an \"initial\" condition is needed to determine the time evolution n = n(t) via equations (1) or (3), respectively.", [["an \"initial\" condition", "PROBLEM", 585, 607]]], ["Most commonly this is imposed byThe Logistic ModelIn continuous time description this is often recast in terms of the half-time defined by n(t)| t=T 1/2 = N/2 which yieldsThe Logistic Model4 Inspection of equations (1) or (3) reveals that results for the normalized number of cumulative cases n(t)/N and daily cases (\u1e45/N or [n(t + 1) \u2212 n(t)] /N, respectively) as a function of the reduced time t/T 1/2 can be depicted as curves depending on a single parameter, namely \u03ba;The Logistic Modelthe value n 0 /N merely serves to appropriately set the time origin.", [["cumulative cases", "TEST", 276, 292], ["cases", "TEST", 310, 315]]], ["To be specific, guided by our recent study, 28 in all the figures presented below we used n 0 /N \u2248 1/1500.", [["our recent study", "TEST", 26, 42]]], ["However, as just said, this particular choice does by no means affect the generality of the results reported below.The Logistic ModelTo start our analysis, we chose a value of infection rate \u03ba = 0.14 day \u22121 , which turned out to describe a regime of moderate restrictions during Slovenia COVID-19 epidemic.", [["infection", "DISEASE", 176, 185], ["Slovenia COVID-19", "SPECIES", 279, 296], ["our analysis", "TEST", 142, 154], ["infection rate", "TEST", 176, 190]]], ["28 Results for the cumulative and daily number of cases obtained within the continuous time and discrete time using the value \u03ba = 0.14 day \u22121 can be compared in Figs rather than the reduced time t/T 1/2 .", [["the value \u03ba", "TEST", 116, 127]]], ["The difference visible in Figs.", [["difference", "OBSERVATION_MODIFIER", 4, 14], ["visible", "OBSERVATION_MODIFIER", 15, 22], ["Figs", "OBSERVATION_MODIFIER", 26, 30]]], ["1 and 2 is not so clear when using t instead of t/T 1/2 on the x axis (see Fig. 3a ).", [["clear", "OBSERVATION", 18, 23]]], ["However, it becomes observable when the curves are shifted by T 1/2 , that is, are plotted versus t \u2212 T 1/2 (see Fig. 3b ) Still, the \u03ba-dependence of the peak heights (they are proportional to \u03ba, see equation (5)) makes observation somewhat difficult.The Logistic ModelFinally, the point we want to make is obvious in Fig. 3c .", [["peak heights", "OBSERVATION", 154, 166]]], ["To conclude, the above finding contradicts the expectation based on naive intuition that faster population dynamics is poor(er) describable in continuous time, or, put differently, that slower infections are better described within a continuous time approach.A Technical RemarkIn arriving at equation (2) n(t + 1) \u2212 n(t)), we could have chosen the backward finite difference (dn(t)/dt \u2192 n(t) \u2212 n(t \u2212 1)) or the symmetric finite difference (dn(t)/dt \u2192 [n(t + 1) \u2212 n(t \u2212 1)] /2).A Technical RemarkThe backward difference leads toA Technical RemarkAlthough difference in numerical results obtained by employing equation (8) and equation (2) are not notable, equation (8) does complain neither with the idea of logistic growth (see above) nor to the causality principle.A Technical RemarkLeading toA Technical Remarkthe symmetric finite difference (which is a better choice for calculating numerical derivatives in other cases) is even more problematic here.", [["infections", "DISEASE", 193, 203], ["naive intuition", "TREATMENT", 68, 83], ["slower infections", "PROBLEM", 186, 203], ["the symmetric finite difference", "TEST", 407, 438], ["employing equation", "TEST", 598, 616], ["logistic growth", "PROBLEM", 707, 722], ["calculating numerical derivatives", "TREATMENT", 874, 907], ["slower", "OBSERVATION_MODIFIER", 186, 192], ["infections", "OBSERVATION", 193, 203], ["symmetric", "OBSERVATION_MODIFIER", 816, 825], ["finite", "OBSERVATION_MODIFIER", 826, 832], ["difference", "OBSERVATION_MODIFIER", 833, 843]]], ["In addition to the drawback noted in connection with equation (8), unrealistically, the symmetric difference version of equation (9) does not allow to uniquely predict time evolution n(t) merely based on a single initial condition (n(0) = n 0 ); equation (9) is a relationship between populations at three consecutive days:A Technical Remarkn(t + 1), n(t), and n(t \u2212 1).ConclusionBased on the present results obtained within a logistic growth model, we conclude that the most notable inaccuracy brought about by the continuous time description of epidemics -which is mathematically more convenient than the discrete time description -is the prediction that the maximum number\u1e45 of daily infections occurs earlier in time: T d 1/2 \u2192 T c 1/2 < T d 1/2 .", [["infections", "DISEASE", 686, 696], ["epidemics", "PROBLEM", 547, 556], ["daily infections", "PROBLEM", 680, 696], ["symmetric", "OBSERVATION_MODIFIER", 88, 97], ["infections", "OBSERVATION", 686, 696]]], ["This backward shift in time \u03c4 \u2261 T c 1/2 \u2212 T d 1/2 < 0 (which does not affect the height of the epi peak) amounts to \u03c4 \u2248 \u22122.65 day, a robust estimate, which was found to be independent of the infection rate \u03ba ranging from large values deduced for situations where COVID-19 infections growth exponentially in time to small values obtained at complete lockdown.", [["infection", "DISEASE", 191, 200], ["infections", "DISEASE", 272, 282], ["the infection rate", "PROBLEM", 187, 205], ["COVID", "TEST", 263, 268], ["infections growth", "PROBLEM", 272, 289], ["infection", "OBSERVATION", 191, 200]]], ["28 This finding contradicts naive intuition expecting that faster infections (larger \u03ba) are poorer described within continuous time approaches than slower infections (smaller \u03ba).ConclusionTo end, let us emphasize that, although conducted in conjunction with the actual unprecedented crisis caused by COVID-19 pandemic, the present study reports results applying to logistic growth in general.", [["infections", "DISEASE", 66, 76], ["infections", "DISEASE", 155, 165], ["faster infections", "PROBLEM", 59, 76], ["slower infections", "PROBLEM", 148, 165], ["the actual unprecedented crisis", "PROBLEM", 258, 289], ["COVID", "TEST", 300, 305], ["the present study", "TEST", 319, 336], ["naive intuition", "OBSERVATION", 28, 43], ["faster", "OBSERVATION_MODIFIER", 59, 65], ["infections", "OBSERVATION", 66, 76], ["larger", "OBSERVATION_MODIFIER", 78, 84], ["slower", "OBSERVATION_MODIFIER", 148, 154], ["infections", "OBSERVATION", 155, 165], ["smaller", "OBSERVATION_MODIFIER", 167, 174]]]], "PMC7129026": [], "0f56357652d2777cf61c018a24b02b352263779a": [["IntroductionCo-infection with Aspergillus spp. in critically ill ventilated patients and in association with severe viral pneumonia, including influenza and SARS, is well described [1] [2] .", [["Aspergillus spp", "DISEASE", 30, 45], ["critically ill", "DISEASE", 50, 64], ["viral pneumonia", "DISEASE", 116, 131], ["influenza", "DISEASE", 143, 152], ["SARS", "DISEASE", 157, 161], ["Aspergillus spp", "ORGANISM", 30, 45], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["IntroductionCo-infection", "PROBLEM", 0, 24], ["Aspergillus spp", "PROBLEM", 30, 45], ["severe viral pneumonia", "PROBLEM", 109, 131], ["influenza", "PROBLEM", 143, 152], ["SARS", "PROBLEM", 157, 161], ["Aspergillus spp", "OBSERVATION", 30, 45], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["viral", "OBSERVATION_MODIFIER", 116, 121], ["pneumonia", "OBSERVATION", 122, 131]]], ["Influenza associated invasive pulmonary aspergillosis (IAPA) may occur in the absence of other known predisposing host risk factors, and influenza infection may be an independent risk factor for invasive aspergillosis, with an incidence of 19% compared to 5% in a matched comparison of patients in ICU with pneumonia, with and without influenza respectively [1] .IntroductionThe observation of aspergillosis in cases of severe COVID-19 pneumonia has been highlighted in emerging reports and observational case series from China and Europe [3] [4] .", [["invasive pulmonary aspergillosis", "ANATOMY", 21, 53], ["invasive aspergillosis", "ANATOMY", 195, 217], ["Influenza", "DISEASE", 0, 9], ["invasive pulmonary aspergillosis", "DISEASE", 21, 53], ["IAPA", "DISEASE", 55, 59], ["influenza infection", "DISEASE", 137, 156], ["aspergillosis", "DISEASE", 204, 217], ["pneumonia", "DISEASE", 307, 316], ["influenza", "DISEASE", 335, 344], ["aspergillosis", "DISEASE", 394, 407], ["COVID", "DISEASE", 427, 432], ["pneumonia", "DISEASE", 436, 445], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 30, 53], ["aspergillosis", "CANCER", 204, 217], ["patients", "ORGANISM", 286, 294], ["aspergillosis", "CANCER", 394, 407], ["Influenza", "SPECIES", 0, 9], ["patients", "SPECIES", 286, 294], ["Influenza associated invasive pulmonary aspergillosis", "PROBLEM", 0, 53], ["influenza infection", "PROBLEM", 137, 156], ["invasive aspergillosis", "PROBLEM", 195, 217], ["pneumonia", "PROBLEM", 307, 316], ["influenza", "PROBLEM", 335, 344], ["aspergillosis", "PROBLEM", 394, 407], ["severe COVID", "PROBLEM", 420, 432], ["pneumonia", "PROBLEM", 436, 445], ["invasive", "OBSERVATION_MODIFIER", 21, 29], ["pulmonary", "ANATOMY", 30, 39], ["aspergillosis", "OBSERVATION", 40, 53], ["invasive", "OBSERVATION_MODIFIER", 195, 203], ["aspergillosis", "OBSERVATION", 204, 217], ["pneumonia", "OBSERVATION", 307, 316], ["aspergillosis", "OBSERVATION", 394, 407], ["severe", "OBSERVATION_MODIFIER", 420, 426], ["pneumonia", "OBSERVATION", 436, 445]]], ["Koehler et al. described 5 cases of putative invasive pulmonary aspergillosis in 19 patients with ARDS and severe COVID-19 in Germany [5] .", [["invasive pulmonary aspergillosis", "ANATOMY", 45, 77], ["invasive pulmonary aspergillosis", "DISEASE", 45, 77], ["ARDS", "DISEASE", 98, 102], ["COVID", "DISEASE", 114, 119], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 54, 77], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["putative invasive pulmonary aspergillosis", "PROBLEM", 36, 77], ["ARDS", "PROBLEM", 98, 102], ["severe COVID", "PROBLEM", 107, 119], ["invasive", "OBSERVATION_MODIFIER", 45, 53], ["pulmonary", "ANATOMY", 54, 63], ["aspergillosis", "OBSERVATION", 64, 77], ["severe", "OBSERVATION_MODIFIER", 107, 113]]], ["A prospective observational study of COVID-19 in France reported putative invasive aspergillosis in 9 of 27 ventilated cases (33%) [6] .", [["invasive aspergillosis", "ANATOMY", 74, 96], ["aspergillosis", "DISEASE", 83, 96], ["aspergillosis", "CANCER", 83, 96], ["A prospective observational study", "TEST", 0, 33], ["COVID", "TEST", 37, 42], ["putative invasive aspergillosis", "PROBLEM", 65, 96], ["invasive", "OBSERVATION_MODIFIER", 74, 82], ["aspergillosis", "OBSERVATION", 83, 96]]], ["Early COVID-19 reports from China reported 7 of 221 ICU patients with aspergillosis [7] .", [["aspergillosis", "DISEASE", 70, 83], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Early COVID", "TEST", 0, 11], ["aspergillosis", "PROBLEM", 70, 83], ["aspergillosis", "OBSERVATION", 70, 83]]], ["Whether SARS-CoV-2 predisposes the host to invasive aspergillosis as an independent host factor is not known yet, and the true incidence, outcomes and pathophysiological mechanisms for invasive disease have not been elucidated in this setting [8] .IntroductionDiagnosis of aspergillosis requires a high level of suspicion as clinical and radiological signs may be similar to those of COVID-19, and sampling and safe laboratory processing of respiratory cultures is required.", [["invasive aspergillosis", "ANATOMY", 43, 65], ["respiratory cultures", "ANATOMY", 441, 461], ["SARS", "DISEASE", 8, 12], ["aspergillosis", "DISEASE", 52, 65], ["aspergillosis", "DISEASE", 273, 286], ["SARS-CoV-2", "ORGANISM", 8, 18], ["aspergillosis", "CANCER", 52, 65], ["aspergillosis", "CANCER", 273, 286], ["SARS-CoV", "SPECIES", 8, 16], ["SARS", "PROBLEM", 8, 12], ["invasive aspergillosis", "PROBLEM", 43, 65], ["invasive disease", "PROBLEM", 185, 201], ["aspergillosis", "PROBLEM", 273, 286], ["radiological signs", "TEST", 338, 356], ["COVID", "TEST", 384, 389], ["respiratory cultures", "TEST", 441, 461], ["invasive", "OBSERVATION_MODIFIER", 43, 51], ["aspergillosis", "OBSERVATION", 52, 65], ["aspergillosis", "OBSERVATION", 273, 286]]], ["The positive predictive value of upper respiratory tract Aspergillus spp. cultures for true invasive disease is not known, as tracheal colonization is well recognized [8] .", [["cultures", "ANATOMY", 74, 82], ["tracheal", "ANATOMY", 126, 134], ["invasive disease", "DISEASE", 92, 108], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 33, 56], ["tracheal", "ORGAN", 126, 134], ["upper respiratory tract Aspergillus spp", "PROBLEM", 33, 72], ["cultures", "TEST", 74, 82], ["true invasive disease", "PROBLEM", 87, 108], ["tracheal colonization", "PROBLEM", 126, 147], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["upper", "ANATOMY_MODIFIER", 33, 38], ["respiratory tract", "ANATOMY", 39, 56], ["Aspergillus spp", "OBSERVATION", 57, 72], ["invasive disease", "OBSERVATION", 92, 108], ["tracheal", "ANATOMY", 126, 134], ["colonization", "OBSERVATION", 135, 147]]], ["Screening and early diagnosis might be enhanced with non-culture methods as recommended by Gangneux et al. [9] .", [["non-culture methods", "TREATMENT", 53, 72]]], ["However the sensitivity and performance of serum galactomannan assays, Aspergillus PCR and 1,3-B-D-glucan assay may be variable in non-immunocompromised cases and in early reports of CAPA [5] [6][8] [10] .IntroductionTreatment of critically ill COVID-19 patients with evidence of Aspergillus spp. in bronchoalveolar lavage or serum is supported by expert groups in Europe pending further research [8] .", [["serum", "ANATOMY", 43, 48], ["bronchoalveolar lavage", "ANATOMY", 300, 322], ["serum", "ANATOMY", 326, 331], ["1,3-B-D-glucan", "CHEMICAL", 91, 105], ["CAPA", "CHEMICAL", 183, 187], ["critically ill", "DISEASE", 230, 244], ["Aspergillus spp", "DISEASE", 280, 295], ["CAPA", "CHEMICAL", 183, 187], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["1,3-B-D-glucan", "SIMPLE_CHEMICAL", 91, 105], ["CAPA [5] [6][8", "SIMPLE_CHEMICAL", 183, 197], ["patients", "ORGANISM", 254, 262], ["Aspergillus spp", "ORGANISM", 280, 295], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 300, 322], ["serum", "ORGANISM_SUBSTANCE", 326, 331], ["patients", "SPECIES", 254, 262], ["the sensitivity", "TEST", 8, 23], ["serum galactomannan assays", "TEST", 43, 69], ["Aspergillus PCR", "TEST", 71, 86], ["B-D-glucan assay", "TEST", 95, 111], ["critically ill COVID", "TREATMENT", 230, 250], ["Aspergillus spp", "PROBLEM", 280, 295], ["bronchoalveolar lavage", "TEST", 300, 322], ["Aspergillus spp", "OBSERVATION", 280, 295], ["bronchoalveolar lavage", "OBSERVATION", 300, 322]]], ["Experience with empirical or directed use of antifungal agents in the setting of COVID-19 is required, particularly in regards to efficacy, duration of treatment and possible adverse drug reactions in the setting of hepatotoxicity (a not uncommon feature of severe COVID-19), renal compromise, renal dialysis, arrhythmias, and electrolyte imbalance.", [["renal", "ANATOMY", 276, 281], ["renal", "ANATOMY", 294, 299], ["adverse drug reactions", "DISEASE", 175, 197], ["hepatotoxicity", "DISEASE", 216, 230], ["renal compromise", "DISEASE", 276, 292], ["arrhythmias", "DISEASE", 310, 321], ["COVID-19", "CHEMICAL", 81, 89], ["COVID-19", "CHEMICAL", 265, 273], ["renal", "ORGAN", 276, 281], ["renal", "ORGAN", 294, 299], ["empirical", "TREATMENT", 16, 25], ["antifungal agents", "TREATMENT", 45, 62], ["COVID", "TEST", 81, 86], ["treatment", "TREATMENT", 152, 161], ["adverse drug reactions", "PROBLEM", 175, 197], ["hepatotoxicity", "PROBLEM", 216, 230], ["severe COVID", "PROBLEM", 258, 270], ["renal compromise", "PROBLEM", 276, 292], ["renal dialysis", "TREATMENT", 294, 308], ["arrhythmias", "PROBLEM", 310, 321], ["electrolyte imbalance", "PROBLEM", 327, 348], ["hepatotoxicity", "OBSERVATION", 216, 230], ["renal", "ANATOMY", 276, 281], ["compromise", "OBSERVATION", 282, 292], ["renal", "ANATOMY", 294, 299], ["dialysis", "OBSERVATION", 300, 308], ["arrhythmias", "OBSERVATION", 310, 321], ["electrolyte imbalance", "OBSERVATION", 327, 348]]], ["Drug interactions with concurrent critical care agents or new or proposed COVID-19 specific therapies may influence the choice of an antifungal agent.Case reportA 66-year-old woman presented with fever after close contact with a confirmed COVID-19 case in April 2020.", [["fever", "DISEASE", 196, 201], ["woman", "ORGANISM", 175, 180], ["woman", "SPECIES", 175, 180], ["concurrent critical care agents", "TREATMENT", 23, 54], ["proposed COVID", "TREATMENT", 65, 79], ["specific therapies", "TREATMENT", 83, 101], ["an antifungal agent", "TREATMENT", 130, 149], ["fever", "PROBLEM", 196, 201]]], ["SARS-CoV-2 RNA was detected in nasopharyngeal and throat swab by RT-PCR method described by Corman [11] .", [["nasopharyngeal", "ANATOMY", 31, 45], ["throat swab", "ANATOMY", 50, 61], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["nasopharyngeal", "CANCER", 31, 45], ["throat swab", "ORGANISM_SUBSTANCE", 50, 61], ["SARS-CoV-2 RNA", "RNA", 0, 14], ["SARS", "TEST", 0, 4], ["nasopharyngeal and throat swab", "TEST", 31, 61], ["PCR method", "TEST", 68, 78], ["nasopharyngeal", "ANATOMY", 31, 45], ["throat", "ANATOMY", 50, 56]]], ["E-gene Ct 22.04 & RdRp Ct 35.09, Roche LightCycler 480.", [["E-gene Ct 22.04", "DNA", 0, 15], ["E", "TEST", 0, 1], ["gene Ct", "TEST", 2, 9], ["RdRp Ct", "TEST", 18, 25], ["Roche LightCycler", "TEST", 33, 50]]], ["Initial supportive treatment for COVID-19 was supervised at home.Case reportOn day+8, symptoms of fever, headache, fatigue, muscle aches, mild abdominal pain, diarrhoea, and vomiting developed, and the patient presented to hospital.", [["muscle", "ANATOMY", 124, 130], ["abdominal", "ANATOMY", 143, 152], ["fever", "DISEASE", 98, 103], ["headache", "DISEASE", 105, 113], ["fatigue", "DISEASE", 115, 122], ["muscle aches", "DISEASE", 124, 136], ["abdominal pain", "DISEASE", 143, 157], ["diarrhoea", "DISEASE", 159, 168], ["vomiting", "DISEASE", 174, 182], ["muscle", "ORGANISM_SUBDIVISION", 124, 130], ["abdominal", "ORGANISM_SUBDIVISION", 143, 152], ["patient", "ORGANISM", 202, 209], ["patient", "SPECIES", 202, 209], ["Initial supportive treatment", "TREATMENT", 0, 28], ["COVID", "TEST", 33, 38], ["symptoms", "PROBLEM", 86, 94], ["fever", "PROBLEM", 98, 103], ["headache", "PROBLEM", 105, 113], ["fatigue", "PROBLEM", 115, 122], ["muscle aches", "PROBLEM", 124, 136], ["mild abdominal pain", "PROBLEM", 138, 157], ["diarrhoea", "PROBLEM", 159, 168], ["vomiting", "PROBLEM", 174, 182], ["fever", "OBSERVATION", 98, 103], ["muscle", "ANATOMY", 124, 130], ["mild", "OBSERVATION_MODIFIER", 138, 142], ["abdominal", "ANATOMY", 143, 152], ["pain", "OBSERVATION", 153, 157], ["diarrhoea", "OBSERVATION", 159, 168]]], ["Medical history was significant for hypertension and osteopenia.", [["hypertension", "DISEASE", 36, 48], ["osteopenia", "DISEASE", 53, 63], ["hypertension", "PROBLEM", 36, 48], ["osteopenia", "PROBLEM", 53, 63], ["significant for", "UNCERTAINTY", 20, 35], ["hypertension", "OBSERVATION", 36, 48], ["osteopenia", "OBSERVATION", 53, 63]]], ["Prescribed medications included perindopril/amlodipine and cholecalciferol (vitamin D3).", [["perindopril", "CHEMICAL", 32, 43], ["amlodipine", "CHEMICAL", 44, 54], ["cholecalciferol", "CHEMICAL", 59, 74], ["vitamin D3", "CHEMICAL", 76, 86], ["perindopril", "CHEMICAL", 32, 43], ["amlodipine", "CHEMICAL", 44, 54], ["cholecalciferol", "CHEMICAL", 59, 74], ["vitamin D3", "CHEMICAL", 76, 86], ["perindopril", "SIMPLE_CHEMICAL", 32, 43], ["amlodipine", "SIMPLE_CHEMICAL", 44, 54], ["cholecalciferol", "SIMPLE_CHEMICAL", 59, 74], ["vitamin D3", "SIMPLE_CHEMICAL", 76, 86], ["medications", "TREATMENT", 11, 22], ["perindopril", "TREATMENT", 32, 43], ["amlodipine", "TREATMENT", 44, 54], ["cholecalciferol (vitamin D3)", "TREATMENT", 59, 87]]], ["There was no history of immunosuppression, no chronic organ dysfunction, nor a history of fungal colonization on respiratory culture performed in 2017.", [["organ", "ANATOMY", 54, 59], ["chronic organ dysfunction", "DISEASE", 46, 71], ["organ", "ORGAN", 54, 59], ["immunosuppression", "TREATMENT", 24, 41], ["chronic organ dysfunction", "PROBLEM", 46, 71], ["fungal colonization", "PROBLEM", 90, 109], ["respiratory culture", "TEST", 113, 132], ["no history of", "UNCERTAINTY", 10, 23], ["immunosuppression", "OBSERVATION", 24, 41], ["no", "UNCERTAINTY", 43, 45], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["organ", "ANATOMY", 54, 59], ["dysfunction", "OBSERVATION", 60, 71], ["fungal", "OBSERVATION_MODIFIER", 90, 96], ["colonization", "OBSERVATION", 97, 109]]], ["She was independent in her activities of daily living.Case reportFeatures on examination were fever (40\u00b0C), respiratory rate 26/min, pulse 80/min, blood pressure 120/70mmHg, with low oxygen saturation (SpO2 89% on room air).", [["respiratory", "ANATOMY", 108, 119], ["blood", "ANATOMY", 147, 152], ["fever", "DISEASE", 94, 99], ["oxygen", "CHEMICAL", 183, 189], ["oxygen", "CHEMICAL", 183, 189], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["examination", "TEST", 77, 88], ["fever", "PROBLEM", 94, 99], ["respiratory rate", "TEST", 108, 124], ["pulse", "TEST", 133, 138], ["blood pressure", "TEST", 147, 161], ["low oxygen saturation", "PROBLEM", 179, 200], ["SpO2", "TEST", 202, 206]]], ["There was increase in work of breathing and bibasal coarse crepitations noted on lung auscultation.", [["lung", "ANATOMY", 81, 85], ["crepitations", "DISEASE", 59, 71], ["lung", "ORGAN", 81, 85], ["increase in work of breathing", "PROBLEM", 10, 39], ["bibasal coarse crepitations", "PROBLEM", 44, 71], ["lung auscultation", "TEST", 81, 98], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["work of breathing", "OBSERVATION", 22, 39], ["bibasal", "ANATOMY_MODIFIER", 44, 51], ["coarse crepitations", "OBSERVATION", 52, 71], ["lung", "ANATOMY", 81, 85], ["auscultation", "OBSERVATION", 86, 98]]], ["The remainder of the physical examination was normal.", [["the physical examination", "TEST", 17, 41], ["remainder", "OBSERVATION_MODIFIER", 4, 13], ["normal", "OBSERVATION", 46, 52]]], ["Arterial blood gas sampling on room air demonstrated pH of 7.44, PaO2 70 mmHg, PaCo2 34 mmHg, lactate 0.9 mmol/L (PaO2/FiO2= 334).", [["Arterial blood", "ANATOMY", 0, 14], ["lactate", "CHEMICAL", 94, 101], ["lactate", "CHEMICAL", 94, 101], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["lactate", "SIMPLE_CHEMICAL", 94, 101], ["Arterial blood gas", "TEST", 0, 18], ["pH", "TEST", 53, 55], ["PaO2", "TEST", 65, 69], ["mmHg", "TEST", 73, 77], ["PaCo2", "TEST", 79, 84], ["mmHg", "TEST", 88, 92], ["lactate", "TEST", 94, 101], ["PaO2", "TEST", 114, 118], ["FiO2", "TEST", 119, 123]]], ["White blood cell count (WCC) 5.3 X 10 9 /L, neutrophil differential count 3.9 x 10 9 /L, and lymphocyte count 1.2 x 10 9 /L. Liver function tests demonstrated AST 52U/L, ALT 32 U/L, GGT 61U/L, and LDH 429 U/L. Renal function was normal.", [["White blood cell", "ANATOMY", 0, 16], ["neutrophil", "ANATOMY", 44, 54], ["lymphocyte", "ANATOMY", 93, 103], ["Liver", "ANATOMY", 125, 130], ["Renal", "ANATOMY", 210, 215], ["White blood cell", "CELL", 0, 16], ["neutrophil", "CELL", 44, 54], ["lymphocyte", "CELL", 93, 103], ["Liver", "ORGAN", 125, 130], ["Renal", "ORGAN", 210, 215], ["neutrophil", "CELL_TYPE", 44, 54], ["AST", "PROTEIN", 159, 162], ["White blood cell count", "TEST", 0, 22], ["WCC", "TEST", 24, 27], ["neutrophil differential count", "TEST", 44, 73], ["lymphocyte count", "TEST", 93, 109], ["Liver function tests", "TEST", 125, 145], ["AST", "TEST", 159, 162], ["L", "TEST", 167, 168], ["ALT", "TEST", 170, 173], ["U", "TEST", 177, 178], ["L", "TEST", 179, 180], ["GGT", "TEST", 182, 185], ["L", "TEST", 190, 191], ["LDH", "TEST", 197, 200], ["U/L.", "TEST", 205, 209], ["Renal function", "TEST", 210, 224], ["Liver", "ANATOMY", 125, 130], ["Renal", "ANATOMY", 210, 215], ["normal", "OBSERVATION", 229, 235]]], ["Blood cultures performed on admission isolated Facklamia hominis and urine culture isolated Escherichia coli; both organisms were susceptible to ceftriaxone.", [["Blood cultures", "ANATOMY", 0, 14], ["urine culture", "ANATOMY", 69, 82], ["ceftriaxone", "CHEMICAL", 145, 156], ["ceftriaxone", "CHEMICAL", 145, 156], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Facklamia hominis", "ORGANISM", 47, 64], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["Escherichia coli", "ORGANISM", 92, 108], ["ceftriaxone", "SIMPLE_CHEMICAL", 145, 156], ["Facklamia hominis", "SPECIES", 47, 64], ["Escherichia coli", "SPECIES", 92, 108], ["Facklamia hominis", "SPECIES", 47, 64], ["Escherichia coli", "SPECIES", 92, 108], ["Blood cultures", "TEST", 0, 14], ["Facklamia hominis", "PROBLEM", 47, 64], ["urine culture", "TEST", 69, 82], ["Escherichia coli", "PROBLEM", 92, 108], ["both organisms", "PROBLEM", 110, 124], ["ceftriaxone", "TREATMENT", 145, 156], ["Escherichia coli", "OBSERVATION", 92, 108]]], ["Chest radiology demonstrated poorly defined pulmonary opacities bilaterally, located principally in the lower lung fields and the right mid lung field (Fig 2.a) .Case reportThe patient was admitted to a dedicated COVID-19 respiratory ward as she had risk factors associated with worse COVID-19 outcomes (age >60 years, hypertension, and the history of smoking) and met clinical criteria for severe COVID-19 pneumonia [7] [12] [13] .", [["pulmonary opacities", "ANATOMY", 44, 63], ["lower lung", "ANATOMY", 104, 114], ["right mid lung", "ANATOMY", 130, 144], ["hypertension", "DISEASE", 319, 331], ["smoking", "CHEMICAL", 352, 359], ["COVID-19", "CHEMICAL", 398, 406], ["pneumonia", "DISEASE", 407, 416], ["COVID-19", "CHEMICAL", 398, 406], ["pulmonary opacities", "PATHOLOGICAL_FORMATION", 44, 63], ["lung", "ORGAN", 110, 114], ["lung", "ORGAN", 140, 144], ["patient", "ORGANISM", 177, 184], ["patient", "SPECIES", 177, 184], ["Chest radiology", "TEST", 0, 15], ["poorly defined pulmonary opacities bilaterally", "PROBLEM", 29, 75], ["risk factors", "PROBLEM", 250, 262], ["worse COVID", "PROBLEM", 279, 290], ["hypertension", "PROBLEM", 319, 331], ["severe COVID", "PROBLEM", 391, 403], ["pneumonia", "PROBLEM", 407, 416], ["poorly defined", "OBSERVATION_MODIFIER", 29, 43], ["pulmonary", "ANATOMY", 44, 53], ["opacities", "OBSERVATION", 54, 63], ["bilaterally", "ANATOMY_MODIFIER", 64, 75], ["lower", "ANATOMY_MODIFIER", 104, 109], ["lung", "ANATOMY", 110, 114], ["fields", "ANATOMY_MODIFIER", 115, 121], ["right", "ANATOMY_MODIFIER", 130, 135], ["mid", "ANATOMY_MODIFIER", 136, 139], ["lung", "ANATOMY", 140, 144], ["field", "ANATOMY_MODIFIER", 145, 150], ["pneumonia", "OBSERVATION", 407, 416]]], ["Ceftriaxone 1g daily and Azithromycin 500mg daily was commenced for possible bacterial co-infection in addition to supplemental oxygen and subcutaneous enoxaparin sodium for venous thromboembolism prophylaxis.", [["subcutaneous", "ANATOMY", 139, 151], ["venous", "ANATOMY", 174, 180], ["Ceftriaxone", "CHEMICAL", 0, 11], ["Azithromycin", "CHEMICAL", 25, 37], ["bacterial co-infection", "DISEASE", 77, 99], ["oxygen", "CHEMICAL", 128, 134], ["enoxaparin sodium", "CHEMICAL", 152, 169], ["venous thromboembolism", "DISEASE", 174, 196], ["Ceftriaxone", "CHEMICAL", 0, 11], ["Azithromycin", "CHEMICAL", 25, 37], ["oxygen", "CHEMICAL", 128, 134], ["enoxaparin sodium", "CHEMICAL", 152, 169], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["Azithromycin", "SIMPLE_CHEMICAL", 25, 37], ["oxygen", "SIMPLE_CHEMICAL", 128, 134], ["enoxaparin", "SIMPLE_CHEMICAL", 152, 162], ["sodium", "SIMPLE_CHEMICAL", 163, 169], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 180], ["Ceftriaxone", "TREATMENT", 0, 11], ["Azithromycin", "TREATMENT", 25, 37], ["bacterial co-infection", "PROBLEM", 77, 99], ["supplemental oxygen", "TREATMENT", 115, 134], ["subcutaneous enoxaparin sodium", "TREATMENT", 139, 169], ["venous thromboembolism prophylaxis", "TREATMENT", 174, 208], ["possible", "UNCERTAINTY", 68, 76], ["bacterial", "OBSERVATION_MODIFIER", 77, 86], ["co-infection", "OBSERVATION", 87, 99], ["venous", "ANATOMY", 174, 180], ["thromboembolism", "OBSERVATION", 181, 196]]], ["No specific therapy targeting COVID-19 infection was initiated (as per local guidelines).Case reportOn day+10 of illness the patient's condition deteriorated rapidly with progressive dyspnoea and increasing oxygen requirement.", [["COVID-19", "CHEMICAL", 30, 38], ["infection", "DISEASE", 39, 48], ["illness", "DISEASE", 113, 120], ["dyspnoea", "DISEASE", 183, 191], ["oxygen", "CHEMICAL", 207, 213], ["oxygen", "CHEMICAL", 207, 213], ["COVID-19", "GENE_OR_GENE_PRODUCT", 30, 38], ["patient", "ORGANISM", 125, 132], ["oxygen", "SIMPLE_CHEMICAL", 207, 213], ["patient", "SPECIES", 125, 132], ["specific therapy", "TREATMENT", 3, 19], ["COVID", "TEST", 30, 35], ["infection", "PROBLEM", 39, 48], ["progressive dyspnoea", "PROBLEM", 171, 191], ["increasing oxygen requirement", "PROBLEM", 196, 225], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["therapy", "OBSERVATION", 12, 19], ["infection", "OBSERVATION", 39, 48], ["progressive", "OBSERVATION_MODIFIER", 171, 182], ["dyspnoea", "OBSERVATION", 183, 191], ["increasing", "OBSERVATION_MODIFIER", 196, 206], ["oxygen requirement", "OBSERVATION", 207, 225]]], ["She was admitted to a newly commissioned COVID-19 intensive care unit (ICU) for supportive management.", [["supportive management", "TREATMENT", 80, 101]]], ["On examination, temperature was 39.5 O C, respiratory rate 40/min, oxygen saturation 91% on high flow nasal prongs (HFNP) with FiO2 40%, and 40 L/m of airflow with a moderate increase in her work of breathing.", [["nasal", "ANATOMY", 102, 107], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["examination", "TEST", 3, 14], ["temperature", "TEST", 16, 27], ["respiratory rate", "TEST", 42, 58], ["oxygen saturation", "TEST", 67, 84], ["high flow nasal prongs", "TREATMENT", 92, 114], ["FiO2", "TREATMENT", 127, 131], ["airflow", "TREATMENT", 151, 158], ["a moderate increase", "PROBLEM", 164, 183], ["her work of breathing", "PROBLEM", 187, 208], ["moderate", "OBSERVATION_MODIFIER", 166, 174], ["increase", "OBSERVATION_MODIFIER", 175, 183]]], ["No clinical signs of heart failure were detected.", [["heart", "ANATOMY", 21, 26], ["heart failure", "DISEASE", 21, 34], ["heart", "ORGAN", 21, 26], ["heart failure", "PROBLEM", 21, 34], ["heart", "ANATOMY", 21, 26], ["failure", "OBSERVATION", 27, 34]]], ["A trans-thoracic echocardiogram was performed and demonstrated normal biventricular function with mild right ventricular dilatation.", [["biventricular", "ANATOMY", 70, 83], ["right ventricular", "ANATOMY", 103, 120], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 103, 120], ["A trans-thoracic echocardiogram", "TEST", 0, 31], ["mild right ventricular dilatation", "PROBLEM", 98, 131], ["thoracic", "ANATOMY", 8, 16], ["normal", "OBSERVATION", 63, 69], ["biventricular function", "OBSERVATION", 70, 92], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["right ventricular", "ANATOMY", 103, 120], ["dilatation", "OBSERVATION", 121, 131]]], ["Arterial blood gas on FiO2 of 40% demonstrated pH 7.46, PaO2 59 mmHg (PaO2/FiO2= 148) and PaCO2 31 mmHg suggestive of moderate acute ARDS.", [["Arterial blood", "ANATOMY", 0, 14], ["ARDS", "DISEASE", 133, 137], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Arterial blood gas", "TEST", 0, 18], ["FiO2", "TEST", 22, 26], ["pH", "TEST", 47, 49], ["PaO2", "TEST", 56, 60], ["mmHg", "TEST", 64, 68], ["PaO2", "TEST", 70, 74], ["FiO2", "TEST", 75, 79], ["PaCO2", "TEST", 90, 95], ["mmHg", "TEST", 99, 103], ["moderate acute ARDS", "PROBLEM", 118, 137], ["suggestive of", "UNCERTAINTY", 104, 117], ["moderate", "OBSERVATION_MODIFIER", 118, 126], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["ARDS", "OBSERVATION", 133, 137]]], ["Awake prone positioning [14] was performed for alveolar recruitment with no significant improvement in oxygenation, therefore elective endotracheal intubation and mechanical ventilation were instituted.", [["alveolar", "ANATOMY", 47, 55], ["endotracheal", "ANATOMY", 135, 147], ["alveolar", "MULTI-TISSUE_STRUCTURE", 47, 55], ["alveolar recruitment", "TREATMENT", 47, 67], ["elective endotracheal intubation", "TREATMENT", 126, 158], ["mechanical ventilation", "TREATMENT", 163, 185], ["alveolar", "ANATOMY", 47, 55], ["no", "UNCERTAINTY", 73, 75], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["improvement", "OBSERVATION_MODIFIER", 88, 99], ["oxygenation", "OBSERVATION_MODIFIER", 103, 114], ["endotracheal intubation", "OBSERVATION", 135, 158], ["mechanical ventilation", "OBSERVATION", 163, 185]]], ["Post intubation, she was managed with lung-protective ventilation (Tidal volume 4-6 ml/kg, PEEP 12 cmH2O and Plateau pressure <30 cmH2O) aiming for PaO2>60 mmHg and pH>7.2 as per ARDS net protocol [15] .", [["lung", "ANATOMY", 38, 42], ["ARDS", "DISEASE", 179, 183], ["lung", "ORGAN", 38, 42], ["intubation", "TREATMENT", 5, 15], ["lung-protective ventilation", "TREATMENT", 38, 65], ["Tidal volume", "TEST", 67, 79], ["PEEP", "TREATMENT", 91, 95], ["Plateau pressure", "TEST", 109, 125], ["PaO2", "TEST", 148, 152], ["pH", "TEST", 165, 167], ["ARDS net protocol", "TEST", 179, 196], ["lung", "ANATOMY", 38, 42]]], ["There was further deterioration in ventilatory parameters, and she fulfilled the severe ARDS criteria as per Berlin definition (PaO2/FiO2=82 mmHg, PEEP=12 cmH2O) [16] .Case reportOn day+16 of illness, worsening respiratory function and hypercapnoea were observed.", [["respiratory", "ANATOMY", 211, 222], ["ARDS", "DISEASE", 88, 92], ["illness", "DISEASE", 192, 199], ["hypercapnoea", "DISEASE", 236, 248], ["further deterioration in ventilatory parameters", "PROBLEM", 10, 57], ["the severe ARDS criteria", "PROBLEM", 77, 101], ["Berlin definition", "TEST", 109, 126], ["PaO2", "TEST", 128, 132], ["FiO2", "TEST", 133, 137], ["PEEP", "TEST", 147, 151], ["illness", "PROBLEM", 192, 199], ["worsening respiratory function", "PROBLEM", 201, 231], ["hypercapnoea", "PROBLEM", 236, 248], ["deterioration", "OBSERVATION_MODIFIER", 18, 31], ["ventilatory parameters", "OBSERVATION", 35, 57], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["ARDS", "OBSERVATION", 88, 92], ["worsening", "OBSERVATION_MODIFIER", 201, 210], ["respiratory function", "OBSERVATION", 211, 231]]], ["Fever was absent, but increased inflammatory markers were observed: C reactive protein 351mg/L, deranged LFTs (ALT= 125 U/L, AST=154 U/L, GGT=611 U/L, ALP= 229 U/L) , raised ferritin (1295 ug/L), raised D-dimer 0.99mg/L and fibrinogen 5.8g/L. Chest radiology revealed significant progression of bilateral consolidative opacities (Fig 2.b) .", [["Fever", "DISEASE", 0, 5], ["opacities", "DISEASE", 319, 328], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 68, 86], ["ferritin", "GENE_OR_GENE_PRODUCT", 174, 182], ["D-dimer", "GENE_OR_GENE_PRODUCT", 203, 210], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 224, 234], ["inflammatory markers", "PROTEIN", 32, 52], ["C reactive protein", "PROTEIN", 68, 86], ["LFTs", "PROTEIN", 105, 109], ["ALT", "PROTEIN", 111, 114], ["AST", "PROTEIN", 125, 128], ["ALP", "PROTEIN", 151, 154], ["ferritin", "PROTEIN", 174, 182], ["fibrinogen", "PROTEIN", 224, 234], ["Fever", "PROBLEM", 0, 5], ["increased inflammatory markers", "PROBLEM", 22, 52], ["reactive protein", "TEST", 70, 86], ["deranged LFTs", "TEST", 96, 109], ["ALT", "TEST", 111, 114], ["U/L", "TEST", 120, 123], ["AST", "TEST", 125, 128], ["U/L", "TEST", 133, 136], ["GGT", "TEST", 138, 141], ["U/L", "TEST", 146, 149], ["ALP", "TEST", 151, 154], ["U/L", "TEST", 160, 163], ["raised ferritin", "TEST", 167, 182], ["raised D-dimer", "TEST", 196, 210], ["fibrinogen", "TEST", 224, 234], ["Chest radiology", "TEST", 243, 258], ["bilateral consolidative opacities", "PROBLEM", 295, 328], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["inflammatory", "OBSERVATION_MODIFIER", 32, 44], ["Chest", "ANATOMY", 243, 248], ["significant", "OBSERVATION_MODIFIER", 268, 279], ["progression", "OBSERVATION_MODIFIER", 280, 291], ["bilateral", "ANATOMY_MODIFIER", 295, 304], ["consolidative", "OBSERVATION_MODIFIER", 305, 318], ["opacities", "OBSERVATION", 319, 328]]], ["Respiratory tract specimens were obtained by non-bronchoscopic endotracheal aspirate (ETT) to assess for presence of persistent SARS-CoV-2 RNA and to exclude ventilator-associated pneumonia, and a 7-day course of Piperacillin/Tazobactam was initiated.", [["Respiratory tract specimens", "ANATOMY", 0, 27], ["SARS", "DISEASE", 128, 132], ["pneumonia", "DISEASE", 180, 189], ["Piperacillin/Tazobactam", "CHEMICAL", 213, 236], ["Piperacillin", "CHEMICAL", 213, 225], ["Tazobactam", "CHEMICAL", 226, 236], ["Respiratory tract specimens", "CANCER", 0, 27], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 63, 84], ["Piperacillin/Tazobactam", "SIMPLE_CHEMICAL", 213, 236], ["SARS-CoV-2 RNA", "RNA", 128, 142], ["Respiratory tract specimens", "TEST", 0, 27], ["non-bronchoscopic endotracheal aspirate", "TEST", 45, 84], ["persistent SARS", "PROBLEM", 117, 132], ["CoV-2 RNA", "PROBLEM", 133, 142], ["ventilator-associated pneumonia", "PROBLEM", 158, 189], ["Piperacillin", "TREATMENT", 213, 225], ["Tazobactam", "TREATMENT", 226, 236], ["persistent", "OBSERVATION_MODIFIER", 117, 127], ["SARS", "OBSERVATION", 128, 132], ["pneumonia", "OBSERVATION", 180, 189]]], ["Based on anecdotal evidence from the PROSEVA trial, prone ventilation was initiated, and some improvement in ventilatory parameters was noted [17] .", [["the PROSEVA trial", "TREATMENT", 33, 50], ["prone ventilation", "TREATMENT", 52, 69], ["ventilatory parameters", "TEST", 109, 131], ["improvement", "OBSERVATION_MODIFIER", 94, 105], ["ventilatory parameters", "OBSERVATION", 109, 131]]], ["Microbiology results revealed persistent SARS-CoV-2 RNA on RT-PCR (Corman method) [11] .", [["SARS-CoV-2 RNA", "RNA", 41, 55], ["Microbiology", "TEST", 0, 12], ["persistent SARS", "PROBLEM", 30, 45], ["CoV", "TEST", 46, 49], ["RT", "TEST", 59, 61], ["PCR", "TEST", 62, 65], ["persistent", "OBSERVATION_MODIFIER", 30, 40], ["SARS", "OBSERVATION", 41, 45]]], ["No viral culture or quantitative viral load was performed.", [["viral culture", "TEST", 3, 16], ["quantitative viral load", "PROBLEM", 20, 43], ["viral culture", "OBSERVATION", 3, 16], ["viral load", "OBSERVATION", 33, 43]]], ["Fungal elements were seen on Gram staining of the ETT sample.", [["ETT sample", "ANATOMY", 50, 60], ["Fungal elements", "PROBLEM", 0, 15], ["Gram staining", "TEST", 29, 42], ["the ETT sample", "TEST", 46, 60]]], ["Green colonies of Aspergillus fumigatus complex were isolated at 48 hours on Horse blood agar and Chocolate agar, demonstrating uniseriate conidial heads with phialides limited to the upper two thirds of the vesicle (culture mount stained with lactophenol cotton blue).", [["blood", "ANATOMY", 83, 88], ["vesicle", "ANATOMY", 208, 215], ["lactophenol cotton blue", "CHEMICAL", 244, 267], ["Aspergillus fumigatus", "ORGANISM", 18, 39], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["vesicle", "CELLULAR_COMPONENT", 208, 215], ["Aspergillus fumigatus", "SPECIES", 18, 39], ["Aspergillus fumigatus", "SPECIES", 18, 39], ["Aspergillus fumigatus complex", "PROBLEM", 18, 47], ["Horse blood agar", "TEST", 77, 93], ["Chocolate agar", "TEST", 98, 112], ["uniseriate conidial heads with phialides", "PROBLEM", 128, 168], ["culture mount", "TEST", 217, 230], ["lactophenol cotton blue", "TREATMENT", 244, 267], ["colonies", "OBSERVATION", 6, 14], ["Aspergillus fumigatus", "OBSERVATION", 18, 39], ["conidial heads", "OBSERVATION", 139, 153], ["upper", "ANATOMY_MODIFIER", 184, 189], ["vesicle", "ANATOMY", 208, 215]]], ["Three subsequent ETT cultures isolated Aspergillus fumigatus complex, increasing the clinical suspicion for invasive aspergillosis.", [["invasive aspergillosis", "ANATOMY", 108, 130], ["Aspergillus fumigatus", "DISEASE", 39, 60], ["aspergillosis", "DISEASE", 117, 130], ["Aspergillus fumigatus", "ORGANISM", 39, 60], ["aspergillosis", "CANCER", 117, 130], ["ETT cultures", "CELL_LINE", 17, 29], ["Aspergillus fumigatus", "SPECIES", 39, 60], ["Aspergillus fumigatus", "SPECIES", 39, 60], ["Three subsequent ETT cultures", "TEST", 0, 29], ["Aspergillus fumigatus complex", "PROBLEM", 39, 68], ["invasive aspergillosis", "PROBLEM", 108, 130], ["Aspergillus fumigatus", "OBSERVATION", 39, 60], ["suspicion for", "UNCERTAINTY", 94, 107], ["invasive", "OBSERVATION_MODIFIER", 108, 116], ["aspergillosis", "OBSERVATION", 117, 130]]], ["On day+20, with new onset of fever, and progressive bilateral consolidation seen on chest radiography (Fig.2.c) , the decision was made to initiate a cautious trial of intravenous Voriconazole (6 mg/kg loading followed by 3mg/kg twice daily), despite concerns regarding abnormal liver function tests.Case reportThe patient was observed to make rapid clinical and radiological progress over the next 7 days (Fig. 2.d) .", [["chest", "ANATOMY", 84, 89], ["intravenous", "ANATOMY", 168, 179], ["liver", "ANATOMY", 279, 284], ["fever", "DISEASE", 29, 34], ["Voriconazole", "CHEMICAL", 180, 192], ["abnormal liver function", "DISEASE", 270, 293], ["Voriconazole", "CHEMICAL", 180, 192], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 179], ["Voriconazole", "SIMPLE_CHEMICAL", 180, 192], ["liver", "ORGAN", 279, 284], ["patient", "ORGANISM", 315, 322], ["patient", "SPECIES", 315, 322], ["fever", "PROBLEM", 29, 34], ["progressive bilateral consolidation", "PROBLEM", 40, 75], ["chest radiography", "TEST", 84, 101], ["intravenous Voriconazole", "TREATMENT", 168, 192], ["abnormal liver function tests", "PROBLEM", 270, 299], ["fever", "OBSERVATION", 29, 34], ["progressive", "OBSERVATION_MODIFIER", 40, 51], ["bilateral", "ANATOMY_MODIFIER", 52, 61], ["consolidation", "OBSERVATION", 62, 75], ["chest", "ANATOMY", 84, 89], ["liver", "ANATOMY", 279, 284]]], ["Fevers settled, inflammatory markers improved, and liver function normalized.", [["liver", "ANATOMY", 51, 56], ["Fevers", "DISEASE", 0, 6], ["liver", "ORGAN", 51, 56], ["inflammatory markers", "PROTEIN", 16, 36], ["Fevers", "PROBLEM", 0, 6], ["inflammatory markers", "TEST", 16, 36], ["liver function", "TEST", 51, 65], ["inflammatory", "OBSERVATION_MODIFIER", 16, 28], ["markers", "OBSERVATION_MODIFIER", 29, 36], ["improved", "OBSERVATION_MODIFIER", 37, 45], ["liver", "ANATOMY", 51, 56], ["normalized", "OBSERVATION_MODIFIER", 66, 76]]], ["Steady-state Voriconazole trough levels were observed (2.72mg/L).", [["Voriconazole", "CHEMICAL", 13, 25], ["Voriconazole", "CHEMICAL", 13, 25], ["Voriconazole", "SIMPLE_CHEMICAL", 13, 25], ["Voriconazole trough levels", "TEST", 13, 39]]], ["Treatment was de-escalated to oral Voriconazole (300mg twice daily) once tolerating oral diet.", [["oral", "ANATOMY", 30, 34], ["oral", "ANATOMY", 84, 88], ["Voriconazole", "CHEMICAL", 35, 47], ["Voriconazole", "CHEMICAL", 35, 47], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["Voriconazole", "SIMPLE_CHEMICAL", 35, 47], ["oral", "ORGANISM_SUBDIVISION", 84, 88], ["Treatment", "TREATMENT", 0, 9], ["oral Voriconazole", "TREATMENT", 30, 47]]], ["After a period of ward rehabilitation and two negative SARS-CoV-2 RT-PCR clearance swabs as per local public health guidelines, the patient was discharged home on day +38.Case reportOn day+45, a contrast-enhanced computed tomography (CECT) of the chest was performed to assess for disease progression and complications.", [["chest", "ANATOMY", 247, 252], ["patient", "ORGANISM", 132, 139], ["chest", "ORGAN", 247, 252], ["patient", "SPECIES", 132, 139], ["ward rehabilitation", "TREATMENT", 18, 37], ["CoV", "TEST", 60, 63], ["a contrast-enhanced computed tomography (CECT) of the chest", "TEST", 193, 252], ["disease progression", "PROBLEM", 281, 300], ["complications", "PROBLEM", 305, 318], ["chest", "ANATOMY", 247, 252]]], ["CECT demonstrated bilateral organising pneumonia and fibrosis (Fig 3) with a probable small segmental pulmonary embolism in the left upper lobe, which are known sequelae of COVID-19 pneumonia.", [["pulmonary", "ANATOMY", 102, 111], ["left upper lobe", "ANATOMY", 128, 143], ["pneumonia", "DISEASE", 39, 48], ["fibrosis", "DISEASE", 53, 61], ["pulmonary embolism in the left upper lobe", "DISEASE", 102, 143], ["pneumonia", "DISEASE", 182, 191], ["pulmonary", "ORGAN", 102, 111], ["upper lobe", "ORGAN", 133, 143], ["CECT", "TEST", 0, 4], ["bilateral organising pneumonia", "PROBLEM", 18, 48], ["fibrosis", "PROBLEM", 53, 61], ["small segmental pulmonary embolism in the left upper lobe", "PROBLEM", 86, 143], ["COVID-19 pneumonia", "PROBLEM", 173, 191], ["bilateral", "ANATOMY_MODIFIER", 18, 27], ["pneumonia", "OBSERVATION", 39, 48], ["fibrosis", "OBSERVATION", 53, 61], ["probable", "UNCERTAINTY", 77, 85], ["small", "OBSERVATION_MODIFIER", 86, 91], ["segmental", "ANATOMY_MODIFIER", 92, 101], ["pulmonary", "ANATOMY", 102, 111], ["embolism", "OBSERVATION", 112, 120], ["left upper lobe", "ANATOMY", 128, 143], ["sequelae", "OBSERVATION_MODIFIER", 161, 169], ["pneumonia", "OBSERVATION", 182, 191]]], ["Voriconazole was ceased at that stage (total duration of treatment was one month), due to the risk of drug-drug interaction with proposed anti-coagulation therapy (Apixaban) and abnormal liver function testing (Voriconazole trough level 3.6mg/L).", [["liver", "ANATOMY", 187, 192], ["Voriconazole", "CHEMICAL", 0, 12], ["Apixaban", "CHEMICAL", 164, 172], ["abnormal liver function", "DISEASE", 178, 201], ["Voriconazole", "CHEMICAL", 211, 223], ["Voriconazole", "CHEMICAL", 0, 12], ["Apixaban", "CHEMICAL", 164, 172], ["Voriconazole", "CHEMICAL", 211, 223], ["Voriconazole", "SIMPLE_CHEMICAL", 0, 12], ["Apixaban", "SIMPLE_CHEMICAL", 164, 172], ["liver", "ORGAN", 187, 192], ["Voriconazole", "SIMPLE_CHEMICAL", 211, 223], ["Voriconazole", "TREATMENT", 0, 12], ["treatment", "TREATMENT", 57, 66], ["proposed anti-coagulation therapy", "TREATMENT", 129, 162], ["Apixaban", "TREATMENT", 164, 172], ["abnormal liver function testing", "PROBLEM", 178, 209], ["Voriconazole trough level", "TEST", 211, 236], ["liver", "ANATOMY", 187, 192]]], ["At the time of this report the patient remains well, off anti-fungal therapy, with mild dry cough and improved effort tolerance, and no systemic features.DiscussionThis report illustrates the successful management of a case of severe COVID-19, in a wellprepared intensive care unit and with the benefit of the published experience of other groups.", [["dry cough", "DISEASE", 88, 97], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["anti-fungal therapy", "TREATMENT", 57, 76], ["mild dry cough", "PROBLEM", 83, 97], ["systemic features", "PROBLEM", 136, 153], ["severe COVID", "PROBLEM", 227, 239], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["dry", "OBSERVATION_MODIFIER", 88, 91], ["cough", "OBSERVATION", 92, 97], ["no", "UNCERTAINTY", 133, 135], ["systemic", "OBSERVATION_MODIFIER", 136, 144]]], ["The diagnosis of aspergillosis in this case was confounded in the presence of viral pneumonitis and inflammation, ARDS, vascular thrombosis, and highly transmissible virus.DiscussionThe bilateral pulmonary opacities on CECT would be consistent with pulmonary infection however the radiographic appearance cannot determine the causative pathogen.", [["vascular", "ANATOMY", 120, 128], ["pulmonary", "ANATOMY", 196, 205], ["pulmonary", "ANATOMY", 249, 258], ["aspergillosis", "DISEASE", 17, 30], ["pneumonitis", "DISEASE", 84, 95], ["inflammation", "DISEASE", 100, 112], ["ARDS", "DISEASE", 114, 118], ["vascular thrombosis", "DISEASE", 120, 139], ["pulmonary opacities", "DISEASE", 196, 215], ["pulmonary infection", "DISEASE", 249, 268], ["aspergillosis", "CANCER", 17, 30], ["vascular", "MULTI-TISSUE_STRUCTURE", 120, 128], ["pulmonary", "ORGAN", 196, 205], ["pulmonary", "ORGAN", 249, 258], ["aspergillosis", "PROBLEM", 17, 30], ["viral pneumonitis", "PROBLEM", 78, 95], ["inflammation", "PROBLEM", 100, 112], ["ARDS", "PROBLEM", 114, 118], ["vascular thrombosis", "PROBLEM", 120, 139], ["highly transmissible virus", "PROBLEM", 145, 171], ["The bilateral pulmonary opacities", "PROBLEM", 182, 215], ["CECT", "TEST", 219, 223], ["pulmonary infection", "PROBLEM", 249, 268], ["the causative pathogen", "PROBLEM", 322, 344], ["aspergillosis", "OBSERVATION", 17, 30], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["pneumonitis", "OBSERVATION", 84, 95], ["inflammation", "OBSERVATION", 100, 112], ["ARDS", "OBSERVATION", 114, 118], ["vascular", "ANATOMY", 120, 128], ["thrombosis", "OBSERVATION", 129, 139], ["highly", "OBSERVATION_MODIFIER", 145, 151], ["transmissible", "OBSERVATION_MODIFIER", 152, 165], ["virus", "OBSERVATION", 166, 171], ["bilateral", "ANATOMY_MODIFIER", 186, 195], ["pulmonary", "ANATOMY", 196, 205], ["opacities", "OBSERVATION", 206, 215], ["consistent with", "UNCERTAINTY", 233, 248], ["pulmonary", "ANATOMY", 249, 258], ["infection", "OBSERVATION", 259, 268]]], ["Routine computed tomography (CT) imaging is generally not recommended by most radiology societies and was not utilised in this case for practical reasons.", [["Routine computed tomography (CT) imaging", "TEST", 0, 40]]], ["CT appearances of COVID-19 pneumonia may be considered typical, indeterminate or atypical.", [["pneumonia", "DISEASE", 27, 36], ["CT appearances", "TEST", 0, 14], ["COVID", "TEST", 18, 23], ["19 pneumonia", "PROBLEM", 24, 36], ["pneumonia", "OBSERVATION", 27, 36], ["may be considered", "UNCERTAINTY", 37, 54], ["indeterminate", "OBSERVATION_MODIFIER", 64, 77], ["atypical", "OBSERVATION_MODIFIER", 81, 89]]], ["CT may help distinguish between \"typical\" COVID pneumonia (bilateral peripheral ground glass opacity which may be rounded or associated with intralobular septal thickening giving a crazy paving pattern) and \"typical\" invasive pulmonary aspergillosis (nodular consolidation with a ground glass halo)[5] [18] .DiscussionRevised EORTC/MSG guidelines for the diagnosis of invasive fungal disease are not validated in critically ill patients in the absence of a recognized predisposing host factor [19] .", [["intralobular septal", "ANATOMY", 141, 160], ["pulmonary", "ANATOMY", 226, 235], ["pneumonia", "DISEASE", 48, 57], ["peripheral ground glass opacity", "DISEASE", 69, 100], ["pulmonary aspergillosis", "DISEASE", 226, 249], ["invasive fungal disease", "DISEASE", 368, 391], ["critically ill", "DISEASE", 413, 427], ["intralobular septal", "TISSUE", 141, 160], ["pulmonary", "ORGAN", 226, 235], ["aspergillosis", "PATHOLOGICAL_FORMATION", 236, 249], ["patients", "ORGANISM", 428, 436], ["patients", "SPECIES", 428, 436], ["CT", "TEST", 0, 2], ["typical\" COVID pneumonia", "PROBLEM", 33, 57], ["bilateral peripheral ground glass opacity", "PROBLEM", 59, 100], ["intralobular septal thickening", "PROBLEM", 141, 171], ["typical\" invasive pulmonary aspergillosis", "PROBLEM", 208, 249], ["nodular consolidation", "PROBLEM", 251, 272], ["a ground glass halo)", "TREATMENT", 278, 298], ["EORTC/MSG guidelines", "TREATMENT", 326, 346], ["invasive fungal disease", "PROBLEM", 368, 391], ["pneumonia", "OBSERVATION", 48, 57], ["bilateral", "ANATOMY_MODIFIER", 59, 68], ["peripheral", "ANATOMY_MODIFIER", 69, 79], ["ground glass opacity", "OBSERVATION", 80, 100], ["may be", "UNCERTAINTY", 107, 113], ["rounded", "OBSERVATION_MODIFIER", 114, 121], ["intralobular", "ANATOMY_MODIFIER", 141, 153], ["septal", "ANATOMY_MODIFIER", 154, 160], ["thickening", "OBSERVATION", 161, 171], ["typical", "OBSERVATION_MODIFIER", 208, 215], ["\"", "OBSERVATION_MODIFIER", 215, 216], ["invasive", "OBSERVATION_MODIFIER", 217, 225], ["pulmonary", "ANATOMY", 226, 235], ["aspergillosis", "OBSERVATION", 236, 249], ["nodular", "OBSERVATION_MODIFIER", 251, 258], ["consolidation", "OBSERVATION", 259, 272], ["ground glass halo", "OBSERVATION_MODIFIER", 280, 297], ["invasive", "OBSERVATION_MODIFIER", 368, 376], ["fungal disease", "OBSERVATION", 377, 391]]], ["An alternative clinical algorithm to identify putative invasive aspergillosis and discriminate between significant infection and tracheal colonisation in critically ill patients was evaluated by Blot et al. [20] in the AspICU Study, and modified for influenza by Schauwvlieghe et al. [1] has been utilized for CAPA by Koehler et al [5] .", [["invasive aspergillosis", "ANATOMY", 55, 77], ["tracheal", "ANATOMY", 129, 137], ["aspergillosis", "DISEASE", 64, 77], ["infection", "DISEASE", 115, 124], ["critically ill", "DISEASE", 154, 168], ["influenza", "DISEASE", 250, 259], ["aspergillosis", "CANCER", 64, 77], ["tracheal", "ORGAN", 129, 137], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["An alternative clinical algorithm", "TEST", 0, 33], ["putative invasive aspergillosis", "PROBLEM", 46, 77], ["significant infection", "PROBLEM", 103, 124], ["tracheal colonisation", "PROBLEM", 129, 150], ["the AspICU Study", "TEST", 215, 231], ["influenza", "PROBLEM", 250, 259], ["CAPA", "TREATMENT", 310, 314], ["invasive", "OBSERVATION_MODIFIER", 55, 63], ["aspergillosis", "OBSERVATION", 64, 77], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["infection", "OBSERVATION", 115, 124], ["tracheal", "ANATOMY", 129, 137], ["colonisation", "OBSERVATION", 138, 150]]], ["Fungal culture in upper respiratory tract samples and tracheal aspirates has low sensitivity and specificity for invasive fungal disease, but bronchoscopy in the presence of SARS-CoV-2 infection may increase the risk of virus aerosolisation and transmission, and may increase the risk of pulmonary de-recruitment and was therefore not performed.", [["upper respiratory tract samples", "ANATOMY", 18, 49], ["tracheal aspirates", "ANATOMY", 54, 72], ["pulmonary", "ANATOMY", 288, 297], ["fungal disease", "DISEASE", 122, 136], ["SARS", "DISEASE", 174, 178], ["infection", "DISEASE", 185, 194], ["upper respiratory tract samples", "ORGANISM_SUBSTANCE", 18, 49], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 54, 72], ["SARS-CoV-2", "ORGANISM", 174, 184], ["pulmonary", "ORGAN", 288, 297], ["SARS-CoV-2", "SPECIES", 174, 184], ["Fungal culture", "TEST", 0, 14], ["upper respiratory tract samples", "TEST", 18, 49], ["tracheal aspirates", "TEST", 54, 72], ["low sensitivity", "PROBLEM", 77, 92], ["invasive fungal disease", "PROBLEM", 113, 136], ["bronchoscopy", "TEST", 142, 154], ["SARS", "PROBLEM", 174, 178], ["CoV", "PROBLEM", 179, 182], ["2 infection", "PROBLEM", 183, 194], ["virus aerosolisation", "PROBLEM", 220, 240], ["pulmonary de-recruitment", "PROBLEM", 288, 312], ["upper", "ANATOMY_MODIFIER", 18, 23], ["respiratory tract", "ANATOMY", 24, 41], ["tracheal", "ANATOMY", 54, 62], ["aspirates", "OBSERVATION", 63, 72], ["invasive", "OBSERVATION_MODIFIER", 113, 121], ["fungal disease", "OBSERVATION", 122, 136], ["SARS", "OBSERVATION", 174, 178], ["infection", "OBSERVATION", 185, 194], ["virus aerosolisation", "OBSERVATION", 220, 240], ["pulmonary", "ANATOMY", 288, 297], ["de-recruitment", "OBSERVATION", 298, 312]]], ["This case did not fulfil all criteria for proven or putative invasive fungal infection, as bronchoscopic sampling for culture, cytology, fungal PCR or galactomannan was not performed, and serum galactomannan or other non-culture techniques or biopsy were not done.", [["serum", "ANATOMY", 188, 193], ["fungal infection", "DISEASE", 70, 86], ["serum", "ORGANISM_SUBSTANCE", 188, 193], ["galactomannan", "GENE_OR_GENE_PRODUCT", 194, 207], ["putative invasive fungal infection", "PROBLEM", 52, 86], ["bronchoscopic sampling", "TEST", 91, 113], ["culture", "TEST", 118, 125], ["cytology", "TEST", 127, 135], ["fungal PCR", "TEST", 137, 147], ["galactomannan", "TEST", 151, 164], ["serum galactomannan", "TEST", 188, 207], ["other non-culture techniques", "TEST", 211, 239], ["biopsy", "TEST", 243, 249], ["invasive", "OBSERVATION_MODIFIER", 61, 69], ["fungal", "OBSERVATION_MODIFIER", 70, 76], ["infection", "OBSERVATION", 77, 86]]], ["Diagnostic discrimination between putative invasive aspergillosis and tracheal colonisation, or earlier diagnosis may have been enhanced with serum galactomannan testing.DiscussionThe decision to initiate an anti-fungal agent was made on clinical grounds of worsening respiratory function in spite of appropriate antibiotics and increasing ventilatory support, with evidence of colonisation with Aspergillus fumigatus complex isolated from multiple tracheal aspirate samples.", [["invasive aspergillosis", "ANATOMY", 43, 65], ["tracheal", "ANATOMY", 70, 78], ["serum", "ANATOMY", 142, 147], ["respiratory", "ANATOMY", 268, 279], ["tracheal aspirate samples", "ANATOMY", 449, 474], ["aspergillosis", "DISEASE", 52, 65], ["aspergillosis", "CANCER", 52, 65], ["tracheal", "ORGAN", 70, 78], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["Aspergillus fumigatus", "ORGANISM", 396, 417], ["tracheal aspirate samples", "MULTI-TISSUE_STRUCTURE", 449, 474], ["Aspergillus fumigatus complex", "PROTEIN", 396, 425], ["Aspergillus fumigatus", "SPECIES", 396, 417], ["Aspergillus fumigatus", "SPECIES", 396, 417], ["Diagnostic discrimination", "TEST", 0, 25], ["putative invasive aspergillosis", "PROBLEM", 34, 65], ["tracheal colonisation", "PROBLEM", 70, 91], ["serum galactomannan testing", "TEST", 142, 169], ["an anti-fungal agent", "TREATMENT", 205, 225], ["worsening respiratory function", "PROBLEM", 258, 288], ["appropriate antibiotics", "TREATMENT", 301, 324], ["increasing ventilatory support", "TREATMENT", 329, 359], ["colonisation", "PROBLEM", 378, 390], ["Aspergillus fumigatus complex", "PROBLEM", 396, 425], ["multiple tracheal aspirate samples", "TEST", 440, 474], ["invasive", "OBSERVATION_MODIFIER", 43, 51], ["aspergillosis", "OBSERVATION", 52, 65], ["tracheal", "ANATOMY", 70, 78], ["colonisation", "OBSERVATION", 79, 91], ["worsening", "OBSERVATION_MODIFIER", 258, 267], ["respiratory function", "OBSERVATION", 268, 288], ["ventilatory support", "OBSERVATION", 340, 359], ["evidence of", "UNCERTAINTY", 366, 377], ["colonisation", "OBSERVATION", 378, 390], ["Aspergillus fumigatus", "OBSERVATION", 396, 417], ["multiple", "OBSERVATION_MODIFIER", 440, 448], ["tracheal", "ANATOMY", 449, 457], ["aspirate", "OBSERVATION", 458, 466]]], ["No SARS-CoV-2 viral culture or vial load was performed, and the persistent detection of SARS-CoV-2 by RT-PCR does not necessarily correlate with underlying infectious process.", [["SARS", "DISEASE", 88, 92], ["SARS-CoV-2", "ORGANISM", 88, 98], ["SARS-CoV", "SPECIES", 88, 96], ["SARS", "PROBLEM", 3, 7], ["CoV", "TEST", 8, 11], ["viral culture", "TEST", 14, 27], ["vial load", "TEST", 31, 40], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["RT-PCR", "TEST", 102, 108], ["underlying infectious process", "PROBLEM", 145, 174], ["SARS", "OBSERVATION", 3, 7], ["persistent", "OBSERVATION_MODIFIER", 64, 74], ["not necessarily correlate with", "UNCERTAINTY", 114, 144], ["infectious", "OBSERVATION", 156, 166]]], ["Although a compelling clinical response was observed after antifungal therapy was initiated, this may reflect the natural course of severe COVID-19 recovery and the role of supportive ICU measures including empiric treatment of sepsis and prone ventilation.", [["sepsis", "DISEASE", 228, 234], ["antifungal therapy", "TREATMENT", 59, 77], ["severe COVID", "PROBLEM", 132, 144], ["supportive ICU measures", "TREATMENT", 173, 196], ["empiric treatment", "TREATMENT", 207, 224], ["sepsis", "PROBLEM", 228, 234], ["prone ventilation", "TREATMENT", 239, 256], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["sepsis", "OBSERVATION", 228, 234]]], ["Radiological improvement was more rapid than may be expected for true invasive fungal infection.", [["fungal infection", "DISEASE", 79, 95], ["true invasive fungal infection", "PROBLEM", 65, 95], ["more rapid", "OBSERVATION_MODIFIER", 29, 39], ["invasive", "OBSERVATION_MODIFIER", 70, 78], ["fungal", "OBSERVATION_MODIFIER", 79, 85], ["infection", "OBSERVATION", 86, 95]]], ["Voriconazole was well tolerated initially, with acceptable steady-state therapeutic trough levels but hepatotoxicity was noted after four weeks of therapy, and influenced the decision to cease treatment.DiscussionNo recognized predisposing host factor or acquired immunosuppression, other than severe COVID-19 infection with ARDS was identified.", [["Voriconazole", "CHEMICAL", 0, 12], ["hepatotoxicity", "DISEASE", 102, 116], ["infection", "DISEASE", 310, 319], ["ARDS", "DISEASE", 325, 329], ["Voriconazole", "CHEMICAL", 0, 12], ["Voriconazole", "SIMPLE_CHEMICAL", 0, 12], ["Voriconazole", "TREATMENT", 0, 12], ["therapeutic trough levels", "TEST", 72, 97], ["hepatotoxicity", "PROBLEM", 102, 116], ["therapy", "TREATMENT", 147, 154], ["treatment", "TREATMENT", 193, 202], ["acquired immunosuppression", "TREATMENT", 255, 281], ["severe COVID-19 infection", "PROBLEM", 294, 319], ["ARDS", "PROBLEM", 325, 329], ["infection", "OBSERVATION", 310, 319], ["ARDS", "OBSERVATION", 325, 329]]], ["The environmental source of infection was not determined, and the protective or predisposing role of facemask use prior to illness or a negative air pressure environment has not been assessed.", [["infection", "DISEASE", 28, 37], ["illness", "DISEASE", 123, 130], ["infection", "PROBLEM", 28, 37], ["illness", "PROBLEM", 123, 130], ["a negative air pressure environment", "PROBLEM", 134, 169], ["infection", "OBSERVATION", 28, 37], ["air pressure", "OBSERVATION", 145, 157]]], ["No concurrent cases of invasive aspergillosis or fungal colonisation were noted in other ventilated COVID-19 patients on screening with ETT sputum cultures (three patients), and no clusters or increased incidence of invasive aspergillosis cases have been observed hospital-wide, preceding this case or subsequently.DiscussionWe believe that in the absence of clear diagnostic criteria, consideration should be given to antifungal directed therapy if aspergillosis is suspected in severe COVID-19 associated pneumonia.", [["invasive aspergillosis", "ANATOMY", 23, 45], ["aspergillosis", "DISEASE", 32, 45], ["fungal colonisation", "DISEASE", 49, 68], ["aspergillosis", "DISEASE", 225, 238], ["aspergillosis", "DISEASE", 450, 463], ["pneumonia", "DISEASE", 507, 516], ["aspergillosis", "CANCER", 32, 45], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 163, 171], ["aspergillosis", "CANCER", 225, 238], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 163, 171], ["invasive aspergillosis", "PROBLEM", 23, 45], ["fungal colonisation", "PROBLEM", 49, 68], ["screening", "TEST", 121, 130], ["ETT sputum cultures", "TEST", 136, 155], ["clusters", "PROBLEM", 181, 189], ["invasive aspergillosis cases", "PROBLEM", 216, 244], ["antifungal directed therapy", "TREATMENT", 419, 446], ["aspergillosis", "PROBLEM", 450, 463], ["severe COVID-19 associated pneumonia", "PROBLEM", 480, 516], ["invasive", "OBSERVATION_MODIFIER", 23, 31], ["aspergillosis", "OBSERVATION", 32, 45], ["fungal", "OBSERVATION_MODIFIER", 49, 55], ["colonisation", "OBSERVATION", 56, 68], ["increased", "OBSERVATION_MODIFIER", 193, 202], ["invasive", "OBSERVATION_MODIFIER", 216, 224], ["aspergillosis", "OBSERVATION", 225, 238], ["aspergillosis", "OBSERVATION", 450, 463], ["pneumonia", "OBSERVATION", 507, 516]]], ["Prompt notification and identification of co-infections in COVID-19 in critical care settings may be enhanced with multi-disciplinary and collaborative case discussions including clinicians, microbiologists, and radiologists.DiscussionTo our knowledge, this is the first case report of COVID-19 associated pulmonary aspergillosis in NSW, Australia.", [["pulmonary", "ANATOMY", 306, 315], ["co-infections", "DISEASE", 42, 55], ["COVID-19", "CHEMICAL", 286, 294], ["pulmonary aspergillosis", "DISEASE", 306, 329], ["COVID-19", "ORGANISM", 286, 294], ["pulmonary", "ORGAN", 306, 315], ["co-infections", "PROBLEM", 42, 55], ["COVID", "TEST", 286, 291], ["pulmonary aspergillosis", "PROBLEM", 306, 329], ["co-infections", "OBSERVATION", 42, 55], ["pulmonary", "ANATOMY", 306, 315], ["aspergillosis", "OBSERVATION", 316, 329]]], ["Registries and larger case series are required to better identify and characterize the incidence, pathogenesis, geographical variation, diagnostic criteria, and treatment and prevention strategies.AcknowledgementsAuthors acknowledge David Pham and Lyn Doan for microbiology assistance.Conflicts of InterestThe Authors declare no conflict of interest.Conflicts of InterestBibliography", [["Lyn", "GENE_OR_GENE_PRODUCT", 248, 251], ["Lyn", "PROTEIN", 248, 251], ["larger case series", "TEST", 15, 33], ["pathogenesis", "PROBLEM", 98, 110], ["diagnostic criteria", "TEST", 136, 155], ["treatment", "TREATMENT", 161, 170], ["prevention strategies", "TREATMENT", 175, 196]]]], "9e45efb86c7c552be221e4d1356d9374a7ebc204": [["IntroductionCoxsackievirus B3 (CVB3), a small RNA virus in the picornaviridae family, is an important human pathogen associated with various diseases, including myocarditis, aseptic meningitis, pancreatitis and possibly insulin-dependent diabetes.", [["myocarditis", "DISEASE", 161, 172], ["aseptic meningitis", "DISEASE", 174, 192], ["pancreatitis", "DISEASE", 194, 206], ["diabetes", "DISEASE", 238, 246], ["IntroductionCoxsackievirus B3", "ORGANISM", 0, 29], ["CVB3", "ORGANISM", 31, 35], ["human", "ORGANISM", 102, 107], ["insulin", "GENE_OR_GENE_PRODUCT", 220, 227], ["human", "SPECIES", 102, 107], ["IntroductionCoxsackievirus B3", "SPECIES", 0, 29], ["CVB3", "SPECIES", 31, 35], ["human", "SPECIES", 102, 107], ["IntroductionCoxsackievirus B3 (CVB3", "PROBLEM", 0, 35], ["a small RNA virus", "PROBLEM", 38, 55], ["various diseases", "PROBLEM", 133, 149], ["myocarditis", "PROBLEM", 161, 172], ["aseptic meningitis", "PROBLEM", 174, 192], ["pancreatitis", "PROBLEM", 194, 206], ["insulin-dependent diabetes", "PROBLEM", 220, 246], ["small", "OBSERVATION_MODIFIER", 40, 45], ["RNA virus", "OBSERVATION", 46, 55], ["myocarditis", "OBSERVATION", 161, 172], ["aseptic", "OBSERVATION_MODIFIER", 174, 181], ["meningitis", "OBSERVATION", 182, 192], ["pancreatitis", "OBSERVATION", 194, 206], ["possibly", "UNCERTAINTY", 211, 219], ["insulin-dependent", "OBSERVATION_MODIFIER", 220, 237], ["diabetes", "OBSERVATION", 238, 246]]], ["We and others have shown that CVB3 infection leads to activation of several intracellular signaling pathways [1] [2] [3] [4] [5] [6] [7] , and downregulation of host proteins likely through the ubiquitin/proteasome system (UPS) [7] [8] [9] .IntroductionIt is well-established that the UPS is the major intracellular proteolytic system of all eukaryotic cells [10, 11] .", [["intracellular", "ANATOMY", 76, 89], ["intracellular", "ANATOMY", 302, 315], ["cells", "ANATOMY", 353, 358], ["CVB3 infection", "DISEASE", 30, 44], ["CVB3", "ORGANISM", 30, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 89], ["[1] [2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 109, 136], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 194, 203], ["UPS", "GENE_OR_GENE_PRODUCT", 285, 288], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 302, 315], ["cells", "CELL", 353, 358], ["host proteins", "PROTEIN", 161, 174], ["ubiquitin/proteasome system", "PROTEIN", 194, 221], ["UPS", "PROTEIN", 285, 288], ["eukaryotic cells", "CELL_TYPE", 342, 358], ["CVB3", "SPECIES", 30, 34], ["CVB3 infection", "PROBLEM", 30, 44], ["several intracellular signaling pathways", "TEST", 68, 108], ["host proteins", "TEST", 161, 174], ["the ubiquitin/proteasome system", "TREATMENT", 190, 221], ["infection", "OBSERVATION", 35, 44], ["eukaryotic cells", "OBSERVATION", 342, 358]]], ["The ATPdependent system begins with covalent attachment of ubiquitin to the ubiquitin-activating enzyme (E1).", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 59, 68], ["ubiquitin-activating enzyme", "GENE_OR_GENE_PRODUCT", 76, 103], ["ubiquitin", "PROTEIN", 59, 68], ["ubiquitin-activating enzyme", "PROTEIN", 76, 103], ["E1", "PROTEIN", 105, 107], ["The ATPdependent system", "TREATMENT", 0, 23], ["covalent attachment of ubiquitin", "TREATMENT", 36, 68], ["covalent attachment", "OBSERVATION", 36, 55]]], ["Then the ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2).", [["E2", "CHEMICAL", 69, 71], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 9, 18], ["E2", "GENE_OR_GENE_PRODUCT", 69, 71], ["ubiquitin", "PROTEIN", 9, 18], ["ubiquitin-conjugating enzyme", "PROTEIN", 39, 67], ["E2", "PROTEIN", 69, 71]]], ["Finally, ubiquitin ligase (E3) transfers the ubiquitin to the substrate protein.", [["E3", "GENE_OR_GENE_PRODUCT", 27, 29], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 45, 54], ["ubiquitin ligase", "PROTEIN", 9, 25], ["E3", "PROTEIN", 27, 29], ["ubiquitin", "PROTEIN", 45, 54], ["substrate protein", "PROTEIN", 62, 79], ["ubiquitin ligase", "OBSERVATION", 9, 25]]], ["After several cycles of ubiquitination, multiple ubiquitin molecules are attached to the substrate which is then quickly recognized and subsequently degraded by the 26S proteasome.", [["26S", "GENE_OR_GENE_PRODUCT", 165, 168], ["ubiquitin molecules", "PROTEIN", 49, 68], ["26S proteasome", "PROTEIN", 165, 179], ["ubiquitination", "TREATMENT", 24, 38], ["multiple ubiquitin molecules", "TREATMENT", 40, 68], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["ubiquitin molecules", "OBSERVATION", 49, 68], ["26S proteasome", "OBSERVATION", 165, 179]]], ["Ubiquitin is recycled through the actions of deubiquitinating enzymes (DUBs) [12, 13] .", [["Ubiquitin", "GENE_OR_GENE_PRODUCT", 0, 9], ["DUBs", "GENE_OR_GENE_PRODUCT", 71, 75], ["Ubiquitin", "PROTEIN", 0, 9], ["deubiquitinating enzymes", "PROTEIN", 45, 69], ["DUBs", "PROTEIN", 71, 75], ["deubiquitinating enzymes", "TEST", 45, 69]]], ["There are at least two classes of deubiquitinating enzymes, the ubiquitin C-terminal hydrolases (UCHs) and ubiquitin-specific processing proteases family.IntroductionIn addition to the degradation of mutant, damaged and misfolded proteins, this system is responsible for the modulation of many regulatory proteins such as cyclins [14] , inhibitors of cyclin-dependent kinases (p21, p27) [15] , tumor suppressors (p53) [16] , and inhibitor of NFkB (IkB) [17] , which are essential for a variety of cellular functions, including cell-cycle regulation, apoptosis and host immune responses [18] .", [["tumor", "ANATOMY", 394, 399], ["cellular", "ANATOMY", 497, 505], ["cell", "ANATOMY", 527, 531], ["tumor", "DISEASE", 394, 399], ["C", "CHEMICAL", 74, 75], ["UCHs", "GENE_OR_GENE_PRODUCT", 97, 101], ["ubiquitin-specific processing proteases", "GENE_OR_GENE_PRODUCT", 107, 146], ["cyclins [14]", "GENE_OR_GENE_PRODUCT", 322, 334], ["cyclin-dependent kinases", "GENE_OR_GENE_PRODUCT", 351, 375], ["p21", "GENE_OR_GENE_PRODUCT", 377, 380], ["p27", "GENE_OR_GENE_PRODUCT", 382, 385], ["15", "GENE_OR_GENE_PRODUCT", 388, 390], ["tumor", "CANCER", 394, 399], ["p53", "GENE_OR_GENE_PRODUCT", 413, 416], ["NFkB", "GENE_OR_GENE_PRODUCT", 442, 446], ["IkB) [17", "GENE_OR_GENE_PRODUCT", 448, 456], ["cellular", "CELL", 497, 505], ["cell", "CELL", 527, 531], ["deubiquitinating enzymes", "PROTEIN", 34, 58], ["ubiquitin C-terminal hydrolases", "PROTEIN", 64, 95], ["UCHs", "PROTEIN", 97, 101], ["ubiquitin-specific processing proteases family", "PROTEIN", 107, 153], ["mutant, damaged and misfolded proteins", "PROTEIN", 200, 238], ["regulatory proteins", "PROTEIN", 294, 313], ["cyclins", "PROTEIN", 322, 329], ["cyclin-dependent kinases", "PROTEIN", 351, 375], ["p21, p27) [15", "PROTEIN", 377, 390], ["tumor suppressors", "PROTEIN", 394, 411], ["p53", "PROTEIN", 413, 416], ["NFkB", "PROTEIN", 442, 446], ["IkB", "PROTEIN", 448, 451], ["deubiquitinating enzymes", "TEST", 34, 58], ["the ubiquitin C-terminal hydrolases (UCHs)", "TREATMENT", 60, 102], ["IntroductionIn", "TREATMENT", 154, 168], ["mutant, damaged and misfolded proteins", "PROBLEM", 200, 238], ["many regulatory proteins", "TREATMENT", 289, 313], ["cyclins", "TEST", 322, 329], ["inhibitors", "TREATMENT", 337, 347], ["cyclin-dependent kinases", "TREATMENT", 351, 375], ["tumor suppressors", "TREATMENT", 394, 411], ["NFkB", "TEST", 442, 446], ["cell-cycle regulation", "TREATMENT", 527, 548], ["apoptosis", "PROBLEM", 550, 559], ["deubiquitinating enzymes", "OBSERVATION", 34, 58], ["cellular functions", "OBSERVATION", 497, 515]]], ["Unlike polyubiquitination in the regulation of protein degradation, monoubiquitination of cellular proteins, such as histones, calmodulins, actin, proliferating cell nuclear antigen and receptor tyrosine kinases, plays more diversified roles involving in the regulation of chromatin remodeling, DNA repair, transcriptional regulation and endocytosis [19] .IntroductionSince the first discovery that human papillomavirus protein E6 targets the cellular tumor suppressor protein p53 for the UPSmediated degradation [16] , increasing studies, including those from our laboratory, have suggested that various viruses evolve different mechanisms to utilize or manipulate the host UPS for their own benefits [9, [20] [21] [22] [23] [24] [25] .", [["cellular", "ANATOMY", 90, 98], ["chromatin", "ANATOMY", 273, 282], ["cellular tumor", "ANATOMY", 443, 457], ["tyrosine", "CHEMICAL", 195, 203], ["tumor", "DISEASE", 452, 457], ["tyrosine", "CHEMICAL", 195, 203], ["cellular", "CELL", 90, 98], ["histones", "GENE_OR_GENE_PRODUCT", 117, 125], ["calmodulins", "GENE_OR_GENE_PRODUCT", 127, 138], ["actin", "GENE_OR_GENE_PRODUCT", 140, 145], ["proliferating cell nuclear antigen", "GENE_OR_GENE_PRODUCT", 147, 181], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 186, 211], ["chromatin", "CELLULAR_COMPONENT", 273, 282], ["DNA", "CELLULAR_COMPONENT", 295, 298], ["human papillomavirus", "ORGANISM", 399, 419], ["E6", "GENE_OR_GENE_PRODUCT", 428, 430], ["cellular tumor", "CANCER", 443, 457], ["p53", "GENE_OR_GENE_PRODUCT", 477, 480], ["UPS", "GENE_OR_GENE_PRODUCT", 675, 678], ["[20] [21] [22] [23] [24] [25]", "SIMPLE_CHEMICAL", 706, 735], ["cellular proteins", "PROTEIN", 90, 107], ["histones", "PROTEIN", 117, 125], ["calmodulins", "PROTEIN", 127, 138], ["actin", "PROTEIN", 140, 145], ["proliferating cell nuclear antigen", "PROTEIN", 147, 181], ["receptor tyrosine kinases", "PROTEIN", 186, 211], ["chromatin", "DNA", 273, 282], ["human papillomavirus protein E6", "PROTEIN", 399, 430], ["cellular tumor suppressor protein", "PROTEIN", 443, 476], ["p53", "PROTEIN", 477, 480], ["UPS", "PROTEIN", 675, 678], ["human", "SPECIES", 399, 404], ["human papillomavirus", "SPECIES", 399, 419], ["Unlike polyubiquitination", "PROBLEM", 0, 25], ["protein degradation", "PROBLEM", 47, 66], ["monoubiquitination of cellular proteins", "PROBLEM", 68, 107], ["histones", "PROBLEM", 117, 125], ["calmodulins", "PROBLEM", 127, 138], ["actin, proliferating cell nuclear antigen", "PROBLEM", 140, 181], ["receptor tyrosine kinases", "TREATMENT", 186, 211], ["chromatin remodeling", "TREATMENT", 273, 293], ["DNA repair", "TREATMENT", 295, 305], ["human papillomavirus protein E6", "TREATMENT", 399, 430], ["the cellular tumor suppressor protein p53", "TREATMENT", 439, 480], ["the UPSmediated degradation", "PROBLEM", 485, 512], ["increasing studies", "TEST", 520, 538], ["various viruses", "PROBLEM", 597, 612], ["polyubiquitination", "OBSERVATION", 7, 25], ["protein degradation", "OBSERVATION", 47, 66], ["cellular proteins", "OBSERVATION", 90, 107], ["more diversified", "OBSERVATION_MODIFIER", 219, 235], ["chromatin remodeling", "OBSERVATION", 273, 293], ["DNA repair", "OBSERVATION", 295, 305]]], ["We have previously shown that CVB3 infection results in downregulation of several host proteins [7, 9] , such as cell-cycle protein cyclin D1, tumor suppressor p53, and transcription activator b-catenin in infected HeLa cells.", [["cell", "ANATOMY", 113, 117], ["tumor", "ANATOMY", 143, 148], ["HeLa cells", "ANATOMY", 215, 225], ["CVB3 infection", "DISEASE", 30, 44], ["tumor", "DISEASE", 143, 148], ["CVB3", "ORGANISM", 30, 34], ["9", "GENE_OR_GENE_PRODUCT", 100, 101], ["cell", "CELL", 113, 117], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 132, 141], ["tumor", "CANCER", 143, 148], ["p53", "GENE_OR_GENE_PRODUCT", 160, 163], ["b-catenin", "GENE_OR_GENE_PRODUCT", 193, 202], ["HeLa cells", "CELL", 215, 225], ["cell-cycle protein", "PROTEIN", 113, 131], ["cyclin D1", "PROTEIN", 132, 141], ["tumor suppressor p53", "PROTEIN", 143, 163], ["transcription activator", "PROTEIN", 169, 192], ["b-catenin", "PROTEIN", 193, 202], ["infected HeLa cells", "CELL_LINE", 206, 225], ["CVB3", "SPECIES", 30, 34], ["CVB3 infection", "PROBLEM", 30, 44], ["several host proteins", "TEST", 74, 95], ["cell", "TEST", 113, 117], ["cycle protein cyclin D1", "TREATMENT", 118, 141], ["tumor suppressor p53", "TREATMENT", 143, 163], ["transcription activator b-catenin", "TREATMENT", 169, 202], ["infected HeLa cells", "PROBLEM", 206, 225], ["infection", "OBSERVATION", 35, 44], ["infected HeLa cells", "OBSERVATION", 206, 225]]], ["The downregulation of host proteins following CVB3 infection is most likely through the UPS.", [["CVB3 infection", "DISEASE", 46, 60], ["CVB3", "ORGANISM", 46, 50], ["UPS", "GENE_OR_GENE_PRODUCT", 88, 91], ["host proteins", "PROTEIN", 22, 35], ["UPS", "PROTEIN", 88, 91], ["CVB3", "SPECIES", 46, 50], ["host proteins", "PROBLEM", 22, 35], ["CVB3 infection", "PROBLEM", 46, 60], ["host proteins", "OBSERVATION_MODIFIER", 22, 35], ["CVB3 infection", "OBSERVATION", 46, 60], ["most likely", "UNCERTAINTY", 64, 75]]], ["Specific inhibitors to 26S proteasome reverse the degradation of proteins in HeLa cells [7, 9] and reduce CVB3 replication in murine cardiomyocytes [26] .IntroductionIn this study, we investigated the possible underlying mechanisms by which the UPS regulates CVB3 replication.", [["HeLa cells", "ANATOMY", 77, 87], ["cardiomyocytes", "ANATOMY", 133, 147], ["26S", "GENE_OR_GENE_PRODUCT", 23, 26], ["HeLa cells", "CELL", 77, 87], ["CVB3", "ORGANISM", 106, 110], ["murine", "ORGANISM", 126, 132], ["cardiomyocytes", "CELL", 133, 147], ["UPS", "GENE_OR_GENE_PRODUCT", 245, 248], ["CVB3", "ORGANISM", 259, 263], ["26S proteasome", "PROTEIN", 23, 37], ["HeLa cells", "CELL_LINE", 77, 87], ["murine cardiomyocytes", "CELL_TYPE", 126, 147], ["UPS", "PROTEIN", 245, 248], ["murine", "SPECIES", 126, 132], ["CVB3", "SPECIES", 106, 110], ["CVB3", "SPECIES", 259, 263], ["Specific inhibitors", "TREATMENT", 0, 19], ["26S proteasome", "TREATMENT", 23, 37], ["the degradation of proteins in HeLa cells", "TREATMENT", 46, 87], ["CVB3 replication", "TREATMENT", 106, 122], ["this study", "TEST", 169, 179], ["underlying mechanisms", "PROBLEM", 210, 231], ["CVB3 replication", "TREATMENT", 259, 275]]], ["We demonstrated that protein ubiquitination was enhanced after coxsackievirus infection.", [["coxsackievirus infection", "DISEASE", 63, 87], ["coxsackievirus", "ORGANISM", 63, 77], ["protein ubiquitination", "PROBLEM", 21, 43], ["coxsackievirus infection", "PROBLEM", 63, 87], ["protein ubiquitination", "OBSERVATION", 21, 43]]], ["We further showed that knockdown of ubiquitin expression by small-interfering RNA (siRNA) decreased CVB3 infection, likely through the downregulation of ubiquitination and subsequent alteration of protein function and/or degradation.", [["CVB3 infection", "DISEASE", 100, 114], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 36, 45], ["CVB3", "ORGANISM", 100, 104], ["ubiquitin", "PROTEIN", 36, 45], ["CVB3", "SPECIES", 100, 104], ["ubiquitin expression", "PROBLEM", 36, 56], ["small-interfering RNA (siRNA)", "PROBLEM", 60, 89], ["CVB3 infection", "PROBLEM", 100, 114], ["the downregulation of ubiquitination", "PROBLEM", 131, 167], ["subsequent alteration of protein function", "PROBLEM", 172, 213], ["ubiquitin expression", "OBSERVATION", 36, 56], ["small", "OBSERVATION_MODIFIER", 60, 65], ["interfering RNA", "OBSERVATION", 66, 81], ["decreased", "OBSERVATION_MODIFIER", 90, 99], ["CVB3 infection", "OBSERVATION", 100, 114], ["ubiquitination", "OBSERVATION_MODIFIER", 153, 167], ["protein function", "OBSERVATION", 197, 213]]], ["In addition, we showed that inhibition of deubiquitinating enzyme increased the inhibitory effects of proteasome inhibitors on CVB3 replication.", [["CVB3", "ORGANISM", 127, 131], ["deubiquitinating enzyme", "PROTEIN", 42, 65], ["proteasome", "PROTEIN", 102, 112], ["CVB3", "SPECIES", 127, 131], ["deubiquitinating enzyme", "PROBLEM", 42, 65], ["proteasome inhibitors", "TREATMENT", 102, 123], ["CVB3 replication", "TREATMENT", 127, 143]]], ["We also found that CVB3 RNA-dependent RNA polymerase 3D (3D pol ) was modified by ubiquitination.", [["CVB3", "ORGANISM", 19, 23], ["RNA polymerase 3D", "GENE_OR_GENE_PRODUCT", 38, 55], ["3D pol", "GENE_OR_GENE_PRODUCT", 57, 63], ["CVB3 RNA", "RNA", 19, 27], ["RNA polymerase 3D", "PROTEIN", 38, 55], ["3D pol", "PROTEIN", 57, 63], ["CVB3", "SPECIES", 19, 23], ["CVB3 RNA", "PROBLEM", 19, 27], ["dependent RNA polymerase 3D (3D pol )", "TREATMENT", 28, 65], ["CVB3 RNA", "OBSERVATION", 19, 27]]], ["Taken together, our study suggests an important role of ubiquitination in the regulation of coxsackieviral replication.Proteasome inhibition reduces CVB3 infection in HeLa cellsTo uncover the underlying mechanisms of the antiviral activities of proteasome inhibitors, we chose to use the well-characterized HeLa cells to further our study.", [["HeLa cells", "ANATOMY", 167, 177], ["HeLa cells", "ANATOMY", 307, 317], ["CVB3 infection", "DISEASE", 149, 163], ["coxsackieviral", "GENE_OR_GENE_PRODUCT", 92, 106], ["Proteasome", "GENE_OR_GENE_PRODUCT", 119, 129], ["CVB3", "ORGANISM", 149, 153], ["HeLa cells", "CELL", 167, 177], ["HeLa cells", "CELL", 307, 317], ["HeLa cells", "CELL_LINE", 167, 177], ["HeLa cells", "CELL_LINE", 307, 317], ["CVB3", "SPECIES", 149, 153], ["our study", "TEST", 16, 25], ["coxsackieviral replication", "TREATMENT", 92, 118], ["Proteasome inhibition", "TREATMENT", 119, 140], ["CVB3 infection in HeLa cells", "PROBLEM", 149, 177], ["proteasome inhibitors", "TREATMENT", 245, 266], ["our study", "TEST", 329, 338], ["ubiquitination", "OBSERVATION", 56, 70], ["coxsackieviral replication", "OBSERVATION", 92, 118], ["infection", "OBSERVATION", 154, 163], ["HeLa cells", "OBSERVATION", 167, 177]]], ["We first examined the role of proteasome inhibition in CVB3 replication.", [["proteasome", "GENE_OR_GENE_PRODUCT", 30, 40], ["CVB3", "ORGANISM", 55, 59], ["proteasome", "PROTEIN", 30, 40], ["CVB3", "SPECIES", 55, 59], ["proteasome inhibition", "TREATMENT", 30, 51], ["CVB3 replication", "TREATMENT", 55, 71]]], ["As shown in Fig. 1 , we found that proteasome inhibitor, MG132, significantly reduced CVB3 viral RNA synthesis (Fig. 1A) .", [["MG132", "CHEMICAL", 57, 62], ["MG132", "CHEMICAL", 57, 62], ["MG132", "SIMPLE_CHEMICAL", 57, 62], ["CVB3", "ORGANISM", 86, 90], ["CVB3 viral RNA", "RNA", 86, 100], ["CVB3", "SPECIES", 86, 90], ["proteasome inhibitor", "TREATMENT", 35, 55], ["MG132", "TREATMENT", 57, 62], ["CVB3 viral RNA synthesis", "TREATMENT", 86, 110], ["Fig", "OBSERVATION", 12, 15]]], ["Both proteasome inhibitors used in the study, MG132 and lactacystin, decreased the synthesis of CVB3 capsid protein, VP1, in a dose-dependent manner (Fig. 1B ).", [["MG132", "CHEMICAL", 46, 51], ["lactacystin", "CHEMICAL", 56, 67], ["MG132", "CHEMICAL", 46, 51], ["lactacystin", "CHEMICAL", 56, 67], ["MG132", "SIMPLE_CHEMICAL", 46, 51], ["lactacystin", "SIMPLE_CHEMICAL", 56, 67], ["CVB3", "ORGANISM", 96, 100], ["VP1", "GENE_OR_GENE_PRODUCT", 117, 120], ["CVB3 capsid protein", "PROTEIN", 96, 115], ["VP1", "PROTEIN", 117, 120], ["CVB3", "SPECIES", 96, 100], ["Both proteasome inhibitors", "TREATMENT", 0, 26], ["the study", "TEST", 35, 44], ["MG132", "TREATMENT", 46, 51], ["lactacystin", "TREATMENT", 56, 67], ["CVB3 capsid protein", "TREATMENT", 96, 115], ["VP1", "TEST", 117, 120], ["proteasome inhibitors", "OBSERVATION", 5, 26]]], ["In addition, two inhibitors inhibited CVB3 viral titers by up to fifteen folds (Fig. 1C) .", [["CVB3", "ORGANISM", 38, 42], ["CVB3", "SPECIES", 38, 42], ["two inhibitors", "TREATMENT", 13, 27], ["CVB3 viral titers", "TREATMENT", 38, 55]]], ["Although MG132 and lactacystin significantly inhibited cellular 20S proteasome activities, we have previously demonstrated there was no apparent difference in proteasome activities between CVB3-infected and sham-infected HeLa cells [9] .", [["cellular", "ANATOMY", 55, 63], ["HeLa cells", "ANATOMY", 221, 231], ["MG132", "CHEMICAL", 9, 14], ["lactacystin", "CHEMICAL", 19, 30], ["CVB3-infected", "DISEASE", 189, 202], ["MG132", "CHEMICAL", 9, 14], ["lactacystin", "CHEMICAL", 19, 30], ["MG132", "SIMPLE_CHEMICAL", 9, 14], ["lactacystin", "SIMPLE_CHEMICAL", 19, 30], ["cellular", "CELL", 55, 63], ["CVB3", "ORGANISM", 189, 193], ["HeLa cells", "CELL", 221, 231], ["20S proteasome", "PROTEIN", 64, 78], ["proteasome", "PROTEIN", 159, 169], ["HeLa cells", "CELL_LINE", 221, 231], ["CVB3", "SPECIES", 189, 193], ["MG132", "TEST", 9, 14], ["lactacystin", "TREATMENT", 19, 30], ["cellular 20S proteasome activities", "PROBLEM", 55, 89], ["apparent difference in proteasome activities", "PROBLEM", 136, 180], ["CVB3", "TEST", 189, 193], ["infected HeLa cells", "PROBLEM", 212, 231], ["20S proteasome", "OBSERVATION", 64, 78], ["no apparent", "UNCERTAINTY", 133, 144], ["HeLa cells", "OBSERVATION", 221, 231]]], ["Together, these results suggest that efficient replication of CVB3 requires the intact UPS function rather than the core proteasome activity alone.Proteasome inhibition reduces CVB3 infection in HeLa cellsWe also performed cell viability assay and morphological examination to determine whether inhibiting viral replication by proteasome inhibitors is due to the toxicity.", [["HeLa cells", "ANATOMY", 195, 205], ["cell", "ANATOMY", 223, 227], ["CVB3 infection", "DISEASE", 177, 191], ["toxicity", "DISEASE", 363, 371], ["CVB3", "ORGANISM", 62, 66], ["UPS", "GENE_OR_GENE_PRODUCT", 87, 90], ["Proteasome", "GENE_OR_GENE_PRODUCT", 147, 157], ["CVB3", "ORGANISM", 177, 181], ["HeLa cells", "CELL", 195, 205], ["cell", "CELL", 223, 227], ["UPS", "PROTEIN", 87, 90], ["proteasome", "PROTEIN", 121, 131], ["HeLa cells", "CELL_LINE", 195, 205], ["proteasome", "PROTEIN", 327, 337], ["CVB3", "SPECIES", 62, 66], ["CVB3", "SPECIES", 177, 181], ["CVB3", "PROBLEM", 62, 66], ["Proteasome inhibition", "TREATMENT", 147, 168], ["CVB3 infection in HeLa cells", "PROBLEM", 177, 205], ["cell viability assay", "TEST", 223, 243], ["morphological examination", "TEST", 248, 273], ["inhibiting viral replication", "PROBLEM", 295, 323], ["proteasome inhibitors", "TREATMENT", 327, 348], ["the toxicity", "PROBLEM", 359, 371], ["efficient", "OBSERVATION_MODIFIER", 37, 46], ["replication", "OBSERVATION", 47, 58], ["CVB3", "OBSERVATION", 62, 66], ["infection", "OBSERVATION", 182, 191], ["HeLa cells", "OBSERVATION", 195, 205]]], ["We found that there was no measurable cell death throughout the incubation period for all doses of proteasome inhibitors used in this study (Fig. 1D) .", [["cell", "ANATOMY", 38, 42], ["cell", "CELL", 38, 42], ["proteasome", "PROTEIN", 99, 109], ["measurable cell death", "PROBLEM", 27, 48], ["proteasome inhibitors", "TREATMENT", 99, 120], ["this study", "TEST", 129, 139], ["no", "UNCERTAINTY", 24, 26], ["measurable cell death", "OBSERVATION", 27, 48]]], ["On the contrary, virus-induced cell death was markedly inhibited after the treatment of proteasome inhibitors as a result of decreased viral replication (Fig. 1D ).CVB3 infection promotes protein ubiquitinationAs alluded to earlier, two successive steps are involved in protein degradation: (1) covalent attachment of ubiquitins to the target protein substrate, and (2) degradation of the polyubiquitinated protein by the 26S proteasome with the release of ubiquitin for recycling.", [["cell", "ANATOMY", 31, 35], ["death", "DISEASE", 36, 41], ["CVB3 infection", "DISEASE", 164, 178], ["cell", "CELL", 31, 35], ["CVB3", "ORGANISM", 164, 168], ["26S", "GENE_OR_GENE_PRODUCT", 422, 425], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 457, 466], ["proteasome", "PROTEIN", 88, 98], ["protein ubiquitinationAs", "PROTEIN", 188, 212], ["ubiquitins", "PROTEIN", 318, 328], ["polyubiquitinated protein", "PROTEIN", 389, 414], ["26S proteasome", "PROTEIN", 422, 436], ["ubiquitin", "PROTEIN", 457, 466], ["CVB3", "SPECIES", 164, 168], ["induced cell death", "PROBLEM", 23, 41], ["proteasome inhibitors", "TREATMENT", 88, 109], ["decreased viral replication", "PROBLEM", 125, 152], ["CVB3 infection", "PROBLEM", 164, 178], ["ubiquitins", "TREATMENT", 318, 328], ["the polyubiquitinated protein", "TREATMENT", 385, 414], ["the 26S proteasome", "TREATMENT", 418, 436], ["the release of ubiquitin", "TREATMENT", 442, 466], ["cell death", "OBSERVATION", 31, 41], ["decreased", "OBSERVATION_MODIFIER", 125, 134], ["viral replication", "OBSERVATION", 135, 152], ["infection", "OBSERVATION", 169, 178]]], ["To dissect out the role of ubiquitination and degradation in CVB3 infection, we next decided to investigate the protein ubiquitination after CVB3 infection.", [["CVB3 infection", "DISEASE", 61, 75], ["CVB3 infection", "DISEASE", 141, 155], ["CVB3", "ORGANISM", 61, 65], ["CVB3", "ORGANISM", 141, 145], ["CVB3", "SPECIES", 61, 65], ["CVB3", "SPECIES", 141, 145], ["ubiquitination", "PROBLEM", 27, 41], ["CVB3 infection", "PROBLEM", 61, 75], ["the protein ubiquitination", "PROBLEM", 108, 134], ["CVB3 infection", "PROBLEM", 141, 155], ["ubiquitination", "OBSERVATION", 27, 41], ["infection", "OBSERVATION", 66, 75], ["infection", "OBSERVATION", 146, 155]]], ["As shown in Fig. 2A , protein ubiquitination was gradually increased along the time-course of CVB3 infection, which was accompanied by a decrease of free ubiquitin levels.", [["CVB3 infection", "DISEASE", 94, 108], ["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["CVB3", "ORGANISM", 94, 98], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 154, 163], ["ubiquitin", "PROTEIN", 154, 163], ["CVB3", "SPECIES", 94, 98], ["protein ubiquitination", "TEST", 22, 44], ["CVB3 infection", "PROBLEM", 94, 108], ["a decrease of free ubiquitin levels", "PROBLEM", 135, 170], ["Fig", "OBSERVATION", 12, 15], ["ubiquitination", "OBSERVATION_MODIFIER", 30, 44], ["gradually", "OBSERVATION_MODIFIER", 49, 58], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["CVB3 infection", "OBSERVATION", 94, 108], ["decrease", "OBSERVATION_MODIFIER", 137, 145], ["free ubiquitin levels", "OBSERVATION", 149, 170]]], ["Densitometric analysis further demonstrated that the increases in protein ubiquitination at 3 h, 5 h, and 7 h post-infection were statistically significant as compared to sham infection (Fig. 2B) .", [["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 176, 185], ["Densitometric analysis", "TEST", 0, 22], ["the increases in protein ubiquitination", "PROBLEM", 49, 88], ["infection", "PROBLEM", 115, 124], ["sham infection", "PROBLEM", 171, 185], ["increases", "OBSERVATION_MODIFIER", 53, 62], ["protein ubiquitination", "OBSERVATION", 66, 88], ["infection", "OBSERVATION", 115, 124], ["infection", "OBSERVATION", 176, 185]]], ["We have previously demonstrated that 26S proteasome activities were unchanged during CVB3 infection [9] .", [["CVB3 infection", "DISEASE", 85, 99], ["26S", "GENE_OR_GENE_PRODUCT", 37, 40], ["CVB3", "ORGANISM", 85, 89], ["26S proteasome", "PROTEIN", 37, 51], ["CVB3", "SPECIES", 85, 89], ["26S proteasome activities", "PROBLEM", 37, 62], ["CVB3 infection", "PROBLEM", 85, 99], ["unchanged", "OBSERVATION_MODIFIER", 68, 77]]], ["Thus, the finding of increased accumulation of ubiquitinated proteins is likely due to enhanced protein ubiquitination as opposed to reduced proteasome activity.", [["ubiquitinated proteins", "PROTEIN", 47, 69], ["proteasome", "PROTEIN", 141, 151], ["increased accumulation of ubiquitinated proteins", "PROBLEM", 21, 69], ["enhanced protein ubiquitination", "PROBLEM", 87, 118], ["reduced proteasome activity", "PROBLEM", 133, 160], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["accumulation of", "OBSERVATION", 31, 46], ["ubiquitinated proteins", "OBSERVATION", 47, 69], ["is likely due to", "UNCERTAINTY", 70, 86], ["enhanced", "OBSERVATION_MODIFIER", 87, 95], ["protein ubiquitination", "OBSERVATION", 96, 118], ["reduced", "OBSERVATION_MODIFIER", 133, 140], ["proteasome activity", "OBSERVATION", 141, 160]]], ["Decreased levels of free ubiquitin could be a direct consequence of the increased protein ubiquitination.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 25, 34], ["ubiquitin", "PROTEIN", 25, 34], ["Decreased levels of free ubiquitin", "PROBLEM", 0, 34], ["the increased protein ubiquitination", "PROBLEM", 68, 104], ["free ubiquitin", "OBSERVATION", 20, 34], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["protein ubiquitination", "OBSERVATION", 82, 104]]], ["These results suggest that enhanced ubiquitin conjugation may be a prerequisite for efficient synthesis of CVB3 viral RNA and continuation of its lifecycle.Knockdown of ubiquitin by siRNA reduces CVB3 infectionIn addition to blocking proteasome proteolytic activities, proteasome inhibitors are known to reduce free ubiquitin levels in treated cells [27] .", [["cells", "ANATOMY", 344, 349], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 36, 45], ["CVB3", "ORGANISM", 107, 111], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 169, 178], ["CVB3", "ORGANISM", 196, 200], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 316, 325], ["cells", "CELL", 344, 349], ["CVB3 viral RNA", "RNA", 107, 121], ["ubiquitin", "PROTEIN", 169, 178], ["proteasome", "PROTEIN", 234, 244], ["treated cells", "CELL_LINE", 336, 349], ["CVB3", "SPECIES", 107, 111], ["CVB3", "SPECIES", 196, 200], ["enhanced ubiquitin conjugation", "PROBLEM", 27, 57], ["CVB3 viral RNA", "TREATMENT", 107, 121], ["Knockdown of ubiquitin", "TREATMENT", 156, 178], ["CVB3 infectionIn", "PROBLEM", 196, 212], ["blocking proteasome proteolytic activities", "TREATMENT", 225, 267], ["proteasome inhibitors", "TREATMENT", 269, 290], ["free ubiquitin levels", "TEST", 311, 332]]], ["It has been suggested that proteasome inhibition negatively affects the budding of retroviruses through reducing free ubiquitin level and subsequently interfering with ubiquitination of viral Gag proteins [22, 24, 25] .", [["retroviruses", "ORGANISM", 83, 95], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 118, 127], ["proteasome", "PROTEIN", 27, 37], ["viral Gag proteins", "PROTEIN", 186, 204], ["proteasome inhibition", "TREATMENT", 27, 48], ["viral Gag proteins", "TEST", 186, 204], ["retroviruses", "OBSERVATION", 83, 95]]], ["Ubiquitin is generated in the cell by proteolysis of polyubiquitinated proteins or ubiquitin fused to carboxyl extension proteins (CEPs) [28] .", [["cell", "ANATOMY", 30, 34], ["carboxyl", "CHEMICAL", 102, 110], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 0, 9], ["cell", "CELL", 30, 34], ["ubiquitin fused to carboxyl extension proteins", "GENE_OR_GENE_PRODUCT", 83, 129], ["Ubiquitin", "PROTEIN", 0, 9], ["polyubiquitinated proteins", "PROTEIN", 53, 79], ["ubiquitin", "PROTEIN", 83, 92], ["carboxyl extension proteins", "PROTEIN", 102, 129], ["CEPs", "PROTEIN", 131, 135], ["polyubiquitinated proteins", "PROBLEM", 53, 79], ["carboxyl extension proteins", "TEST", 102, 129], ["polyubiquitinated proteins", "OBSERVATION", 53, 79]]], ["To investigate whether protein ubiquitination is beneficial to CVB3 replication in HeLa cells, we used the ubiquitin-specific siRNA to gene-silence the expression of human ubiquitin-CEP Uba80, which codes for ubiquitin fused to ribosomal protein S27a [29] .", [["HeLa cells", "ANATOMY", 83, 93], ["CVB3", "ORGANISM", 63, 67], ["HeLa cells", "CELL", 83, 93], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 107, 116], ["human", "ORGANISM", 166, 171], ["ubiquitin-CEP Uba80", "GENE_OR_GENE_PRODUCT", 172, 191], ["ribosomal", "CELLULAR_COMPONENT", 228, 237], ["HeLa cells", "CELL_LINE", 83, 93], ["ubiquitin", "PROTEIN", 107, 116], ["human ubiquitin", "PROTEIN", 166, 181], ["CEP Uba80", "PROTEIN", 182, 191], ["ubiquitin", "PROTEIN", 209, 218], ["ribosomal protein S27a", "PROTEIN", 228, 250], ["human", "SPECIES", 166, 171], ["CVB3", "SPECIES", 63, 67], ["human", "SPECIES", 166, 171], ["protein ubiquitination", "PROBLEM", 23, 45], ["CVB3 replication in HeLa cells", "TREATMENT", 63, 93], ["the ubiquitin-specific siRNA", "TREATMENT", 103, 131], ["human ubiquitin-CEP Uba80", "TREATMENT", 166, 191], ["HeLa cells", "OBSERVATION_MODIFIER", 83, 93]]], ["As shown in Fig. 3A , both ubiquitin conjugates and free ubiquitin levels were markedly knocked down after the treatment of ubiquitin siRNA.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 27, 36], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 124, 133], ["both ubiquitin conjugates", "TREATMENT", 22, 47], ["free ubiquitin levels", "TEST", 52, 73], ["the treatment of ubiquitin siRNA", "TREATMENT", 107, 139], ["Fig", "OBSERVATION", 12, 15], ["ubiquitin siRNA", "OBSERVATION", 124, 139]]], ["We further showed that viral titers were significantly reduced in the ubiquitin siRNA-transfected cells as compared to scramble siRNA control (Fig. 3B ), suggesting that protein ubiquitination is a critical process adopted by coxsackievirus for the successful completion of its lifecycle.DUB inhibition further enhances the inhibitory effects of proteasome inhibitor on CVB3 replicationIt has been demonstrated that protein ubiquitination can also be regulated by deubiquitinating enzymes that specifically cleave ubiquitin from ubiquitin-conjugated protein substrates [12, 13, 30] .", [["cells", "ANATOMY", 98, 103], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 70, 79], ["cells", "CELL", 98, 103], ["coxsackievirus", "ORGANISM", 226, 240], ["DUB", "GENE_OR_GENE_PRODUCT", 288, 291], ["CVB3", "ORGANISM", 370, 374], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 514, 523], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 529, 538], ["ubiquitin siRNA-transfected cells", "CELL_LINE", 70, 103], ["DUB", "PROTEIN", 288, 291], ["proteasome", "PROTEIN", 346, 356], ["deubiquitinating enzymes", "PROTEIN", 464, 488], ["ubiquitin-conjugated protein substrates", "PROTEIN", 529, 568], ["CVB3", "SPECIES", 370, 374], ["viral titers", "TEST", 23, 35], ["the ubiquitin siRNA", "PROBLEM", 66, 85], ["transfected cells", "PROBLEM", 86, 103], ["scramble siRNA control", "TREATMENT", 119, 141], ["protein ubiquitination", "PROBLEM", 170, 192], ["a critical process", "PROBLEM", 196, 214], ["coxsackievirus", "PROBLEM", 226, 240], ["DUB inhibition", "PROBLEM", 288, 302], ["proteasome inhibitor", "TREATMENT", 346, 366], ["CVB3 replication", "TREATMENT", 370, 386], ["protein ubiquitination", "PROBLEM", 416, 438], ["deubiquitinating enzymes", "TEST", 464, 488], ["ubiquitin-conjugated protein substrates", "TREATMENT", 529, 568], ["viral titers", "OBSERVATION", 23, 35], ["ubiquitin siRNA", "OBSERVATION", 70, 85], ["transfected cells", "OBSERVATION", 86, 103], ["protein ubiquitination", "OBSERVATION", 170, 192], ["protein ubiquitination", "OBSERVATION", 416, 438]]], ["To further explore the role of protein ubiquitination in viral replication, we examined the influence of DUB inhibition on viral protein expression.", [["DUB", "GENE_OR_GENE_PRODUCT", 105, 108], ["DUB", "PROTEIN", 105, 108], ["protein ubiquitination", "TREATMENT", 31, 53], ["viral replication", "TREATMENT", 57, 74], ["DUB inhibition", "PROBLEM", 105, 119], ["viral protein expression", "TREATMENT", 123, 147], ["viral replication", "OBSERVATION", 57, 74], ["viral protein expression", "OBSERVATION", 123, 147]]], ["Two commercially available ubiquitin cterminal hydrolase inhibitors, UCH L1 and UCH L3 inhibitors, were used for this study.", [["UCH L1", "GENE_OR_GENE_PRODUCT", 69, 75], ["UCH L3", "GENE_OR_GENE_PRODUCT", 80, 86], ["ubiquitin cterminal hydrolase inhibitors", "TREATMENT", 27, 67], ["UCH L1 and UCH L3 inhibitors", "TREATMENT", 69, 97], ["this study", "TEST", 113, 123]]], ["As shown in Fig. 4 , specific inhibition of UCH L1 or UCH L3 further reduced CVB3 protein expression and virus titers in proteasome inhibitor-treated cells, suggesting that these enzymes may be involved in the lifecycle of CVB3.", [["cells", "ANATOMY", 150, 155], ["UCH L1", "GENE_OR_GENE_PRODUCT", 44, 50], ["UCH L3", "GENE_OR_GENE_PRODUCT", 54, 60], ["CVB3", "ORGANISM", 77, 81], ["cells", "CELL", 150, 155], ["CVB3", "ORGANISM", 223, 227], ["UCH L1", "PROTEIN", 44, 50], ["UCH L3", "PROTEIN", 54, 60], ["CVB3 protein", "PROTEIN", 77, 89], ["proteasome inhibitor-treated cells", "CELL_LINE", 121, 155], ["CVB3", "SPECIES", 77, 81], ["CVB3", "SPECIES", 223, 227], ["specific inhibition of UCH L1", "PROBLEM", 21, 50], ["reduced CVB3 protein expression", "PROBLEM", 69, 100], ["virus titers", "TEST", 105, 117], ["proteasome inhibitor", "TREATMENT", 121, 141], ["these enzymes", "TEST", 173, 186], ["CVB3", "PROBLEM", 223, 227], ["L3", "ANATOMY", 58, 60]]], ["Nevertheless, it was found that inhibition of the UCH L1 and L3 activities alone was not sufficient to block coxsackievirus replication since no significant changes in viral protein expression and CVB3 titers were observed in cells treated with two UCH inhibitors either separately or in combination (Fig. 4) .", [["cells", "ANATOMY", 226, 231], ["UCH L1", "GENE_OR_GENE_PRODUCT", 50, 56], ["coxsackievirus", "ORGANISM", 109, 123], ["CVB3", "ORGANISM", 197, 201], ["cells", "CELL", 226, 231], ["UCH", "SIMPLE_CHEMICAL", 249, 252], ["CVB3", "SPECIES", 197, 201], ["inhibition of the UCH L1 and L3 activities", "PROBLEM", 32, 74], ["block coxsackievirus replication", "PROBLEM", 103, 135], ["significant changes in viral protein expression", "PROBLEM", 145, 192], ["CVB3 titers", "TEST", 197, 208], ["two UCH inhibitors", "TREATMENT", 245, 263], ["L3", "ANATOMY", 61, 63], ["no", "UNCERTAINTY", 142, 144], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["viral protein expression", "OBSERVATION", 168, 192]]], ["As discussed earlier, stabilization of short-lived host proteins and prevention of protein ubiquitination by reducing recycled ubiquitin likely contribute to the inhibitory effect of proteasome inhibition on viral replication.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 127, 136], ["proteasome", "GENE_OR_GENE_PRODUCT", 183, 193], ["short-lived host proteins", "PROTEIN", 39, 64], ["ubiquitin", "PROTEIN", 127, 136], ["proteasome", "PROTEIN", 183, 193], ["short-lived host proteins", "PROBLEM", 39, 64], ["protein ubiquitination", "PROBLEM", 83, 105], ["reducing recycled ubiquitin", "TREATMENT", 109, 136], ["proteasome inhibition", "TREATMENT", 183, 204], ["viral replication", "TREATMENT", 208, 225], ["protein ubiquitination", "OBSERVATION", 83, 105], ["viral replication", "OBSERVATION", 208, 225]]], ["Thus, it is speculated that DUB inhibition by UCHL1/L3 inhibitors alone, in the absence of apparent inhibition of protein degradation, is not sufficient enough to block viral replication.", [["DUB", "GENE_OR_GENE_PRODUCT", 28, 31], ["UCHL1", "GENE_OR_GENE_PRODUCT", 46, 51], ["DUB", "PROTEIN", 28, 31], ["UCHL1", "PROTEIN", 46, 51], ["DUB inhibition", "PROBLEM", 28, 42], ["UCHL1/L3 inhibitors", "TREATMENT", 46, 65], ["protein degradation", "PROBLEM", 114, 133], ["L3", "ANATOMY", 52, 54], ["protein degradation", "OBSERVATION", 114, 133]]], ["However, additional reduction of recycled free ubiquitin by DUB inhibition can further enhance the inhibitory effect of proteasome inhibitor.DUB inhibition further enhances the inhibitory effects of proteasome inhibitor on CVB3 replicationCVB3 RNA-dependent RNA polymerase 3D is ubiquitinated Some virus RNA-dependent RNA polymerases including the sindbis virus and the turnip yellow mosaic virus RNA polymerases have been demonstrated to be phosphorylated and ubiquitinated [31] .", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 47, 56], ["DUB", "GENE_OR_GENE_PRODUCT", 60, 63], ["DUB", "GENE_OR_GENE_PRODUCT", 141, 144], ["CVB3", "ORGANISM", 223, 227], ["replicationCVB3", "ORGANISM", 228, 243], ["RNA polymerase 3D", "GENE_OR_GENE_PRODUCT", 258, 275], ["sindbis virus", "ORGANISM", 348, 361], ["turnip yellow mosaic virus", "ORGANISM", 370, 396], ["ubiquitin", "PROTEIN", 47, 56], ["DUB", "PROTEIN", 60, 63], ["proteasome", "PROTEIN", 120, 130], ["DUB", "PROTEIN", 141, 144], ["proteasome", "PROTEIN", 199, 209], ["CVB3 replicationCVB3 RNA-dependent RNA polymerase 3D", "RNA", 223, 275], ["ubiquitinated Some virus RNA", "RNA", 279, 307], ["RNA polymerases", "PROTEIN", 318, 333], ["turnip yellow mosaic virus RNA polymerases", "PROTEIN", 370, 412], ["turnip yellow mosaic virus", "SPECIES", 370, 396], ["CVB3", "SPECIES", 223, 227], ["sindbis virus", "SPECIES", 348, 361], ["turnip yellow mosaic virus", "SPECIES", 370, 396], ["recycled free ubiquitin", "TREATMENT", 33, 56], ["DUB inhibition", "TREATMENT", 60, 74], ["proteasome inhibitor", "TREATMENT", 120, 140], ["DUB inhibition", "PROBLEM", 141, 155], ["proteasome inhibitor", "TREATMENT", 199, 219], ["CVB3 replicationCVB3 RNA", "TREATMENT", 223, 247], ["dependent RNA polymerase", "PROBLEM", 248, 272], ["Some virus RNA", "PROBLEM", 293, 307], ["dependent RNA polymerases", "PROBLEM", 308, 333], ["the sindbis virus", "PROBLEM", 344, 361], ["the turnip yellow mosaic virus RNA polymerases", "PROBLEM", 366, 412], ["reduction", "OBSERVATION_MODIFIER", 20, 29], ["free ubiquitin", "OBSERVATION", 42, 56], ["virus RNA", "OBSERVATION", 298, 307], ["RNA polymerases", "OBSERVATION", 318, 333], ["sindbis virus", "OBSERVATION", 348, 361]]], ["Although the role of ubiquitination of these RNA polymerases in the regulation of virus replication remains to be determined, such observation raises the interesting possibility that the ubiquitin/proteasome system may regulate CVB3 replication through ubiquitinating viral polymerase 3D, which is essential for initiating viral RNA replication.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 187, 196], ["CVB3", "ORGANISM", 228, 232], ["viral polymerase 3D", "GENE_OR_GENE_PRODUCT", 268, 287], ["RNA polymerases", "PROTEIN", 45, 60], ["ubiquitinating viral polymerase 3D", "PROTEIN", 253, 287], ["CVB3", "SPECIES", 228, 232], ["these RNA polymerases", "TREATMENT", 39, 60], ["virus replication", "TREATMENT", 82, 99], ["the ubiquitin/proteasome system", "TREATMENT", 183, 214], ["CVB3 replication", "TREATMENT", 228, 244], ["ubiquitinating viral polymerase 3D", "PROBLEM", 253, 287], ["viral RNA replication", "TREATMENT", 323, 344], ["RNA polymerases", "OBSERVATION", 45, 60]]], ["To examine whether coxsackieviral proteins are subjected to ubiquitination during viral infection, we performed immunoprecipitation with anti-ubiquitin antibody, followed by immunoblots using antibodies against 3D pol and viral capsid protein VP1, respectively.", [["viral infection", "DISEASE", 82, 97], ["antibodies against 3D pol", "GENE_OR_GENE_PRODUCT", 192, 217], ["VP1", "GENE_OR_GENE_PRODUCT", 243, 246], ["coxsackieviral proteins", "PROTEIN", 19, 42], ["anti-ubiquitin antibody", "PROTEIN", 137, 160], ["antibodies", "PROTEIN", 192, 202], ["3D pol", "PROTEIN", 211, 217], ["viral capsid protein VP1", "PROTEIN", 222, 246], ["coxsackieviral proteins", "PROBLEM", 19, 42], ["viral infection", "PROBLEM", 82, 97], ["immunoprecipitation", "TEST", 112, 131], ["anti-ubiquitin antibody", "TREATMENT", 137, 160], ["immunoblots", "TEST", 174, 185], ["antibodies", "TEST", 192, 202], ["3D pol", "TREATMENT", 211, 217], ["viral capsid protein VP1", "TREATMENT", 222, 246]]], ["As shown in Fig. 5 , immunoreactive bands of around 60 kDa were detected in CVB3infected cells.", [["CVB3infected cells", "ANATOMY", 76, 94], ["CVB3infected cells", "CELL", 76, 94], ["CVB3infected cells", "CELL_LINE", 76, 94], ["immunoreactive bands", "PROBLEM", 21, 41], ["immunoreactive", "OBSERVATION_MODIFIER", 21, 35], ["bands", "OBSERVATION_MODIFIER", 36, 41], ["CVB3infected cells", "OBSERVATION", 76, 94]]], ["Non-modified 3D pol has a molecular weight of about 53 kDa, thus this observation suggests that 3D pol likely undergoes post-translational modification by monoubiquitination.", [["Non-modified 3D pol", "GENE_OR_GENE_PRODUCT", 0, 19], ["3D pol", "GENE_OR_GENE_PRODUCT", 96, 102], ["Non-modified 3D pol", "PROTEIN", 0, 19], ["3D pol", "PROTEIN", 96, 102], ["this observation", "TEST", 65, 81], ["3D pol", "TREATMENT", 96, 102], ["post-translational modification", "TREATMENT", 120, 151]]], ["No protein ubiquitination was observed for VP1 (data not shown).", [["VP1", "PROTEIN", 43, 46], ["protein ubiquitination", "PROBLEM", 3, 25], ["VP1 (data", "TEST", 43, 52], ["protein ubiquitination", "OBSERVATION", 3, 25]]], ["Our results implicate that the ubiquitination process of CVB3 viral proteins might be required for successful replication of the virus.Effects of CVB3 infection on protein expression of several key enzymes involved in the process of ubiquitination and deubiquitinationIn trying to understand the mechanisms by which CVB3 manipulates the UPS, we examined the protein expression of several key enzymes involved in the process of protein ubiquitination and deubiquitination.", [["CVB3 infection", "DISEASE", 146, 160], ["CVB3", "ORGANISM", 57, 61], ["CVB3", "ORGANISM", 146, 150], ["CVB3", "ORGANISM", 316, 320], ["UPS", "GENE_OR_GENE_PRODUCT", 337, 340], ["CVB3 viral proteins", "PROTEIN", 57, 76], ["UPS", "PROTEIN", 337, 340], ["CVB3", "SPECIES", 57, 61], ["CVB3", "SPECIES", 146, 150], ["CVB3", "SPECIES", 316, 320], ["the ubiquitination process", "PROBLEM", 27, 53], ["CVB3 viral proteins", "PROBLEM", 57, 76], ["the virus", "PROBLEM", 125, 134], ["CVB3 infection", "PROBLEM", 146, 160], ["protein expression", "TEST", 164, 182], ["several key enzymes", "TEST", 186, 205], ["ubiquitination", "PROBLEM", 233, 247], ["deubiquitination", "PROBLEM", 252, 268], ["several key enzymes", "TEST", 380, 399], ["protein ubiquitination", "TREATMENT", 427, 449], ["CVB3", "OBSERVATION_MODIFIER", 146, 150], ["infection", "OBSERVATION", 151, 160], ["ubiquitination", "OBSERVATION", 233, 247], ["deubiquitination", "OBSERVATION", 252, 268], ["protein ubiquitination", "OBSERVATION", 427, 449]]], ["We measured expression levels of ubiquitin-activating enzyme E1A/E1B, ubiquitin-conjugating enzyme Ubc H7, ubiquitin C-terminal hydrolase and two p53related E3 ligases, human papillomavirus E6-associated protein and mouse double minute 2 homolog.", [["C", "CHEMICAL", 117, 118], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 33, 42], ["E1A", "GENE_OR_GENE_PRODUCT", 61, 64], ["E1B", "GENE_OR_GENE_PRODUCT", 65, 68], ["ubiquitin-conjugating enzyme Ubc H7", "GENE_OR_GENE_PRODUCT", 70, 105], ["ubiquitin C-terminal hydrolase", "GENE_OR_GENE_PRODUCT", 107, 137], ["E3", "GENE_OR_GENE_PRODUCT", 157, 159], ["human papillomavirus E6", "ORGANISM", 169, 192], ["mouse double minute 2 homolog", "GENE_OR_GENE_PRODUCT", 216, 245], ["ubiquitin-activating enzyme", "PROTEIN", 33, 60], ["E1A", "PROTEIN", 61, 64], ["E1B", "PROTEIN", 65, 68], ["ubiquitin-conjugating enzyme", "PROTEIN", 70, 98], ["Ubc H7", "PROTEIN", 99, 105], ["ubiquitin C-terminal hydrolase", "PROTEIN", 107, 137], ["p53related E3 ligases", "PROTEIN", 146, 167], ["human papillomavirus E6-associated protein", "PROTEIN", 169, 211], ["mouse double minute 2 homolog", "PROTEIN", 216, 245], ["human", "SPECIES", 169, 174], ["mouse", "SPECIES", 216, 221], ["human papillomavirus E6", "SPECIES", 169, 192], ["mouse", "SPECIES", 216, 221], ["expression levels", "TEST", 12, 29], ["ubiquitin", "TEST", 33, 42], ["enzyme E1A", "TEST", 54, 64], ["ubiquitin", "TEST", 70, 79], ["ubiquitin C-terminal hydrolase", "TREATMENT", 107, 137], ["two p53related E3 ligases", "TREATMENT", 142, 167], ["human papillomavirus E6", "TREATMENT", 169, 192]]], ["However, no apparent changes were observed during the time-course of CVB3 infection (data not shown).", [["CVB3 infection", "DISEASE", 69, 83], ["CVB3", "ORGANISM", 69, 73], ["CVB3", "SPECIES", 69, 73], ["apparent changes", "PROBLEM", 12, 28], ["CVB3 infection", "PROBLEM", 69, 83], ["no apparent", "UNCERTAINTY", 9, 20], ["infection", "OBSERVATION", 74, 83]]], ["These results indicate that the manipulation of the UPS by CVB3 is unlikely regulated by the above-examined ubiquitin-related key enzymes or molecules.", [["UPS", "GENE_OR_GENE_PRODUCT", 52, 55], ["CVB3", "ORGANISM", 59, 63], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 108, 117], ["UPS", "PROTEIN", 52, 55], ["ubiquitin-related key enzymes", "PROTEIN", 108, 137], ["CVB3", "SPECIES", 59, 63]]], ["Future studies will determine whether CVB3 infection targets on specific ubiquitin ligases or deubiquitinating enzymes.DiscussionIn the present study, we have provided further evidence that CVB3 manipulates the UPS for its infection.", [["CVB3 infection", "DISEASE", 38, 52], ["infection", "DISEASE", 223, 232], ["CVB3", "ORGANISM", 38, 42], ["CVB3", "ORGANISM", 190, 194], ["UPS", "GENE_OR_GENE_PRODUCT", 211, 214], ["ubiquitin ligases", "PROTEIN", 73, 90], ["deubiquitinating enzymes", "PROTEIN", 94, 118], ["UPS", "PROTEIN", 211, 214], ["CVB3", "SPECIES", 38, 42], ["CVB3", "SPECIES", 190, 194], ["Future studies", "TEST", 0, 14], ["CVB3 infection", "PROBLEM", 38, 52], ["specific ubiquitin ligases", "TEST", 64, 90], ["deubiquitinating enzymes", "TEST", 94, 118], ["the present study", "TEST", 132, 149], ["CVB3", "PROBLEM", 190, 194], ["its infection", "PROBLEM", 219, 232], ["CVB3", "OBSERVATION", 190, 194], ["infection", "OBSERVATION", 223, 232]]], ["CVB3 infection results in increased protein polyubiquitination and a subsequent decrease in free ubiquitin levels.", [["CVB3 infection", "DISEASE", 0, 14], ["CVB3", "ORGANISM", 0, 4], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 97, 106], ["ubiquitin", "PROTEIN", 97, 106], ["CVB3", "SPECIES", 0, 4], ["CVB3 infection", "PROBLEM", 0, 14], ["increased protein polyubiquitination", "PROBLEM", 26, 62], ["a subsequent decrease in free ubiquitin levels", "PROBLEM", 67, 113], ["infection", "OBSERVATION", 5, 14], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["protein polyubiquitination", "OBSERVATION", 36, 62], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["free ubiquitin levels", "OBSERVATION", 92, 113]]], ["Knockdown of ubiquitin and ubiquitinmediated protein modification and/or degradation by siRNA It is increasingly apparent that viruses can evolve various strategies to utilize the host UPS for their own benefits.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 13, 22], ["UPS", "GENE_OR_GENE_PRODUCT", 185, 188], ["ubiquitin", "PROTEIN", 13, 22], ["ubiquitin and ubiquitinmediated protein modification", "TREATMENT", 13, 65], ["viruses", "PROBLEM", 127, 134], ["ubiquitin", "OBSERVATION_MODIFIER", 13, 22], ["protein modification", "OBSERVATION", 45, 65], ["viruses", "OBSERVATION", 127, 134]]], ["The UPS has been suggested to play a critical role in the different steps of viral lifecycle, including viral entry, viral replication, maturation, viral progeny release, and latent virus reactivation [32] [33] [34] .", [["UPS", "GENE_OR_GENE_PRODUCT", 4, 7], ["UPS", "PROTEIN", 4, 7], ["viral lifecycle", "TREATMENT", 77, 92], ["viral entry", "PROBLEM", 104, 115], ["viral replication", "TREATMENT", 117, 134], ["viral progeny release", "PROBLEM", 148, 169], ["latent virus reactivation", "PROBLEM", 175, 200], ["viral replication", "OBSERVATION", 117, 134]]], ["The mechanisms that the UPS regulates viral infection involve degrading intracellular proteins or excessive viral proteins that are against efficient viral replication and modulating viral protein function through ubiquitin-mediated modification or by directly encoding ubiquitin-related enzymes [35] .", [["intracellular", "ANATOMY", 72, 85], ["viral infection", "DISEASE", 38, 53], ["UPS", "GENE_OR_GENE_PRODUCT", 24, 27], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 214, 223], ["ubiquitin-related enzymes", "GENE_OR_GENE_PRODUCT", 270, 295], ["UPS", "PROTEIN", 24, 27], ["intracellular proteins", "PROTEIN", 72, 94], ["excessive viral proteins", "PROTEIN", 98, 122], ["ubiquitin", "PROTEIN", 214, 223], ["ubiquitin-related enzymes", "PROTEIN", 270, 295], ["viral infection", "PROBLEM", 38, 53], ["intracellular proteins", "PROBLEM", 72, 94], ["excessive viral proteins", "PROBLEM", 98, 122], ["efficient viral replication", "PROBLEM", 140, 167], ["modulating viral protein function", "PROBLEM", 172, 205], ["ubiquitin-mediated modification", "TREATMENT", 214, 245], ["viral protein", "OBSERVATION", 183, 196]]], ["The finding in this study that CVB3 infection stimulates protein ubiquitination without inhibition of the core 20S proteasome activity highlights the possibility that CVB3 manipulates the UPS to destabilize or modulate the host and viral proteins.", [["CVB3 infection", "DISEASE", 31, 45], ["CVB3", "ORGANISM", 31, 35], ["20S", "GENE_OR_GENE_PRODUCT", 111, 114], ["CVB3", "ORGANISM", 167, 171], ["UPS", "GENE_OR_GENE_PRODUCT", 188, 191], ["20S proteasome", "PROTEIN", 111, 125], ["UPS", "PROTEIN", 188, 191], ["host and viral proteins", "PROTEIN", 223, 246], ["CVB3", "SPECIES", 31, 35], ["CVB3", "SPECIES", 167, 171], ["this study", "TEST", 15, 25], ["CVB3 infection", "PROBLEM", 31, 45], ["protein ubiquitination", "PROBLEM", 57, 79], ["the core 20S proteasome activity", "TREATMENT", 102, 134], ["CVB3", "PROBLEM", 167, 171], ["viral proteins", "PROBLEM", 232, 246], ["infection", "OBSERVATION", 36, 45]]], ["Polyubiquitination and degradation of host antiviral proteins has been suggested to be a mechanism of HIV-1 replication [36] .", [["HIV-1", "ORGANISM", 102, 107], ["host antiviral proteins", "PROTEIN", 38, 61], ["HIV-1", "SPECIES", 102, 107], ["HIV-1", "SPECIES", 102, 107], ["Polyubiquitination", "PROBLEM", 0, 18], ["host antiviral proteins", "TREATMENT", 38, 61], ["HIV", "PROBLEM", 102, 105]]], ["We have previously identified several proteins, such as cyclin D1, p53 and b-catenin, which are downregulated through the UPS after CVB3 infection [7, 9] .", [["CVB3 infection", "DISEASE", 132, 146], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 56, 65], ["p53", "GENE_OR_GENE_PRODUCT", 67, 70], ["b-catenin", "GENE_OR_GENE_PRODUCT", 75, 84], ["UPS", "GENE_OR_GENE_PRODUCT", 122, 125], ["CVB3", "ORGANISM", 132, 136], ["cyclin D1", "PROTEIN", 56, 65], ["p53", "PROTEIN", 67, 70], ["b-catenin", "PROTEIN", 75, 84], ["UPS", "PROTEIN", 122, 125], ["CVB3", "SPECIES", 132, 136], ["several proteins", "PROBLEM", 30, 46], ["cyclin D1", "TREATMENT", 56, 65], ["p53", "TEST", 67, 70], ["b-catenin", "TEST", 75, 84], ["CVB3 infection", "PROBLEM", 132, 146], ["infection", "OBSERVATION", 137, 146]]], ["Destabilization of these short-lived host proteins is likely required for CVB3 viral RNA and protein synthesis in its lifecycle.", [["CVB3", "ORGANISM", 74, 78], ["short-lived host proteins", "PROTEIN", 25, 50], ["CVB3 viral RNA", "RNA", 74, 88], ["CVB3", "SPECIES", 74, 78], ["these short-lived host proteins", "PROBLEM", 19, 50], ["CVB3 viral RNA", "PROBLEM", 74, 88], ["protein synthesis in its lifecycle", "PROBLEM", 93, 127], ["short", "OBSERVATION_MODIFIER", 25, 30]]], ["Moreover, it is speculated that nonstructural viral proteins of CVB3 could also be potential targets of the UPS for degradation.", [["CVB3", "ORGANISM", 64, 68], ["UPS", "GENE_OR_GENE_PRODUCT", 108, 111], ["nonstructural viral proteins", "PROTEIN", 32, 60], ["UPS", "PROTEIN", 108, 111], ["CVB3", "SPECIES", 64, 68], ["nonstructural viral proteins of CVB3", "PROBLEM", 32, 68]]], ["Previous studies on picornavirus have shown that several viral proteins, such as encephalomyocarditis virus (EMCV) 3C protease and hepatitis A virus (HAV) 3C protease, are ubiquitinated and present in low concentrations in infected cells [37] [38] [39] .", [["cells", "ANATOMY", 232, 237], ["hepatitis A", "DISEASE", 131, 142], ["encephalomyocarditis virus", "ORGANISM", 81, 107], ["EMCV) 3C", "ORGANISM", 109, 117], ["hepatitis A virus", "ORGANISM", 131, 148], ["HAV) 3C protease", "GENE_OR_GENE_PRODUCT", 150, 166], ["cells", "CELL", 232, 237], ["viral proteins", "PROTEIN", 57, 71], ["encephalomyocarditis virus (EMCV) 3C protease", "PROTEIN", 81, 126], ["hepatitis A virus (HAV) 3C protease", "PROTEIN", 131, 166], ["infected cells", "CELL_TYPE", 223, 237], ["encephalomyocarditis virus", "SPECIES", 81, 107], ["hepatitis A virus", "SPECIES", 131, 148], ["encephalomyocarditis virus", "SPECIES", 81, 107], ["EMCV", "SPECIES", 109, 113], ["hepatitis A virus", "SPECIES", 131, 148], ["HAV", "SPECIES", 150, 153], ["Previous studies", "TEST", 0, 16], ["picornavirus", "PROBLEM", 20, 32], ["several viral proteins", "PROBLEM", 49, 71], ["encephalomyocarditis virus", "PROBLEM", 81, 107], ["3C protease", "TREATMENT", 115, 126], ["hepatitis A virus", "PROBLEM", 131, 148], ["3C protease", "TREATMENT", 155, 166], ["low concentrations in infected cells", "PROBLEM", 201, 237], ["viral proteins", "OBSERVATION", 57, 71], ["low concentrations", "OBSERVATION_MODIFIER", 201, 219]]], ["Several E3 ubiquitin ligases, such as human E3a ubiquitin ligase, have been shown to catalyze the ubiquitination of these viral proteins [38, 39] .", [["E3", "GENE_OR_GENE_PRODUCT", 8, 10], ["human", "ORGANISM", 38, 43], ["E3a", "GENE_OR_GENE_PRODUCT", 44, 47], ["E3 ubiquitin ligases", "PROTEIN", 8, 28], ["human E3a ubiquitin ligase", "PROTEIN", 38, 64], ["viral proteins", "PROTEIN", 122, 136], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["Several E3 ubiquitin ligases", "PROBLEM", 0, 28], ["human E3a ubiquitin ligase", "TREATMENT", 38, 64], ["these viral proteins", "TEST", 116, 136], ["ubiquitin ligases", "OBSERVATION", 11, 28]]], ["Although the exact role of ubiquitination and subsequent degradation of nonstructural viral proteins of EMCV and HAV in infected cells remains elusive, such rapid turnover may be required for efficient viral RNA replication, viral protein synthesis and virus maturation.DiscussionAs alluded to earlier, DUBs are a large family of cysteine protease responsible for the removal of ubiquitin from substrate proteins [40] .", [["cells", "ANATOMY", 129, 134], ["HAV", "DISEASE", 113, 116], ["cysteine", "CHEMICAL", 330, 338], ["EMCV", "ORGANISM", 104, 108], ["HAV", "ORGANISM", 113, 116], ["cells", "CELL", 129, 134], ["DUBs", "GENE_OR_GENE_PRODUCT", 303, 307], ["cysteine", "AMINO_ACID", 330, 338], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 379, 388], ["nonstructural viral proteins", "PROTEIN", 72, 100], ["infected cells", "CELL_TYPE", 120, 134], ["viral protein", "PROTEIN", 225, 238], ["DUBs", "PROTEIN", 303, 307], ["cysteine protease", "PROTEIN", 330, 347], ["ubiquitin", "PROTEIN", 379, 388], ["substrate proteins", "PROTEIN", 394, 412], ["EMCV", "SPECIES", 104, 108], ["HAV", "SPECIES", 113, 116], ["ubiquitination", "PROBLEM", 27, 41], ["nonstructural viral proteins", "TREATMENT", 72, 100], ["EMCV", "PROBLEM", 104, 108], ["HAV in infected cells", "PROBLEM", 113, 134], ["viral RNA replication", "TREATMENT", 202, 223], ["viral protein synthesis", "TREATMENT", 225, 248], ["virus maturation", "TREATMENT", 253, 269], ["cysteine protease", "TREATMENT", 330, 347], ["the removal of ubiquitin from substrate proteins", "TREATMENT", 364, 412], ["infected cells", "OBSERVATION", 120, 134]]], ["It is estimated that the human genome encodes more than 100 DUBs.", [["human", "ORGANISM", 25, 30], ["human genome", "DNA", 25, 37], ["DUBs", "PROTEIN", 60, 64], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30]]], ["Although UCHL1 is identified as an important DUB, inhibition of UCHL1 alone has been shown to only partially block the activities of DUBs [41] .", [["UCHL1", "GENE_OR_GENE_PRODUCT", 9, 14], ["DUB", "GENE_OR_GENE_PRODUCT", 45, 48], ["UCHL1", "GENE_OR_GENE_PRODUCT", 64, 69], ["DUBs", "GENE_OR_GENE_PRODUCT", 133, 137], ["UCHL1", "PROTEIN", 9, 14], ["DUB", "PROTEIN", 45, 48], ["UCHL1", "PROTEIN", 64, 69], ["DUBs", "PROTEIN", 133, 137], ["UCHL1", "PROBLEM", 9, 14], ["inhibition of UCHL1", "TREATMENT", 50, 69], ["important", "OBSERVATION_MODIFIER", 35, 44], ["DUB", "OBSERVATION", 45, 48]]], ["Thus, the finding in this study that UCHL1/L3 inhibition is not as efficient in blocking viral replication as general inhibition of proteasome function or knockdown of ubiquitin is likely attributed to incomplete inhibition of DUBs by UCHL1/L3 inhibitors.DiscussionIn addition to protein degradation, ubiquitin-modification has been suggested to be involved in the regulation of protein function.", [["UCHL1", "GENE_OR_GENE_PRODUCT", 37, 42], ["L3", "GENE_OR_GENE_PRODUCT", 43, 45], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 168, 177], ["DUBs", "GENE_OR_GENE_PRODUCT", 227, 231], ["UCHL1", "GENE_OR_GENE_PRODUCT", 235, 240], ["L3", "GENE_OR_GENE_PRODUCT", 241, 243], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 301, 310], ["UCHL1", "PROTEIN", 37, 42], ["proteasome", "PROTEIN", 132, 142], ["ubiquitin", "PROTEIN", 168, 177], ["DUBs", "PROTEIN", 227, 231], ["UCHL1", "PROTEIN", 235, 240], ["ubiquitin", "PROTEIN", 301, 310], ["this study", "TEST", 21, 31], ["UCHL1/L3 inhibition", "TREATMENT", 37, 56], ["blocking viral replication", "TREATMENT", 80, 106], ["proteasome function", "TREATMENT", 132, 151], ["knockdown of ubiquitin", "PROBLEM", 155, 177], ["incomplete inhibition of DUBs", "PROBLEM", 202, 231], ["UCHL1/L3 inhibitors", "TREATMENT", 235, 254], ["protein degradation", "TREATMENT", 280, 299], ["ubiquitin-modification", "TREATMENT", 301, 323], ["L3", "ANATOMY", 43, 45], ["likely attributed to", "UNCERTAINTY", 181, 201], ["L3", "ANATOMY", 241, 243]]], ["It was reported that monoubiquitination of the Gag protein of retroviruses is required for virus budding [22, 24, 25] .", [["Gag", "GENE_OR_GENE_PRODUCT", 47, 50], ["retroviruses", "ORGANISM", 62, 74], ["Gag protein", "PROTEIN", 47, 58], ["the Gag protein of retroviruses", "PROBLEM", 43, 74], ["virus budding", "PROBLEM", 91, 104]]], ["Depletion of free ubiquitin by proteasome inhibitors prevents Gag ubiquitination, subsequently blocks virus progeny release/budding.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 18, 27], ["Gag", "GENE_OR_GENE_PRODUCT", 62, 65], ["Gag", "PROTEIN", 62, 65], ["Depletion of free ubiquitin", "TREATMENT", 0, 27], ["proteasome inhibitors", "TREATMENT", 31, 52], ["Gag ubiquitination", "PROBLEM", 62, 80], ["free ubiquitin", "OBSERVATION", 13, 27], ["Gag ubiquitination", "OBSERVATION", 62, 80]]], ["In addition, ubiquitination of human immunodeficiency virus type 1 Tat protein and human T-cell leukemia virus type 1 Tax protein has been shown to modulate their transactivation activities [20, 23] .", [["human immunodeficiency virus type 1", "ORGANISM", 31, 66], ["Tat", "ORGANISM", 67, 70], ["human T-cell leukemia virus type 1", "ORGANISM", 83, 117], ["Tax", "GENE_OR_GENE_PRODUCT", 118, 121], ["human immunodeficiency virus type 1 Tat protein", "PROTEIN", 31, 78], ["human T-cell leukemia virus type 1 Tax protein", "PROTEIN", 83, 129], ["human immunodeficiency virus type 1", "SPECIES", 31, 66], ["human", "SPECIES", 83, 88], ["T-cell leukemia virus type 1", "SPECIES", 89, 117], ["human immunodeficiency virus type 1", "SPECIES", 31, 66], ["human T-cell leukemia virus type 1", "SPECIES", 83, 117], ["human immunodeficiency virus", "PROBLEM", 31, 59], ["Tat protein", "TEST", 67, 78], ["human T-cell leukemia virus type", "PROBLEM", 83, 115], ["Tax protein", "TEST", 118, 129], ["human immunodeficiency", "OBSERVATION", 31, 53], ["cell leukemia", "OBSERVATION", 91, 104]]], ["We speculate that monoubiquitination is also an important machinery for post-translational modification and activation of CVB3 viral proteins.", [["CVB3", "ORGANISM", 122, 126], ["CVB3 viral proteins", "PROTEIN", 122, 141], ["CVB3", "SPECIES", 122, 126], ["post-translational modification", "TREATMENT", 72, 103], ["CVB3 viral proteins", "TREATMENT", 122, 141], ["monoubiquitination", "OBSERVATION", 18, 36]]], ["In the current study, we have shown that CVB3 RNA-dependent RNA polymerase 3D is posttranslationally modified by ubiquitination, suggesting a critical role of protein ubiquitination in the regulation of viral protein functions.DiscussionBased on the results in the manuscript, in combination of our previous findings that CVB3 infection promotes host protein degradation, including cyclin D1, p53 and b-catenin, a model system on the role of the UPS in CVB3 replication is proposed in Fig. 6 .", [["CVB3 infection", "DISEASE", 322, 336], ["CVB3", "ORGANISM", 41, 45], ["RNA polymerase 3D", "GENE_OR_GENE_PRODUCT", 60, 77], ["CVB3", "ORGANISM", 322, 326], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 382, 391], ["p53", "GENE_OR_GENE_PRODUCT", 393, 396], ["b-catenin", "GENE_OR_GENE_PRODUCT", 401, 410], ["UPS", "GENE_OR_GENE_PRODUCT", 446, 449], ["CVB3", "ORGANISM", 453, 457], ["CVB3 RNA", "RNA", 41, 49], ["RNA polymerase 3D", "PROTEIN", 60, 77], ["cyclin D1", "PROTEIN", 382, 391], ["p53", "PROTEIN", 393, 396], ["b-catenin", "PROTEIN", 401, 410], ["UPS", "PROTEIN", 446, 449], ["CVB3", "SPECIES", 41, 45], ["CVB3", "SPECIES", 322, 326], ["CVB3", "SPECIES", 453, 457], ["the current study", "TEST", 3, 20], ["CVB3 RNA-dependent RNA polymerase 3D", "PROBLEM", 41, 77], ["protein ubiquitination", "PROBLEM", 159, 181], ["viral protein functions", "PROBLEM", 203, 226], ["CVB3 infection", "PROBLEM", 322, 336], ["host protein degradation", "PROBLEM", 346, 370], ["cyclin D1", "TREATMENT", 382, 391], ["p53", "TEST", 393, 396], ["b-catenin", "TREATMENT", 401, 410], ["CVB3 replication", "TREATMENT", 453, 469], ["CVB3", "OBSERVATION", 41, 45], ["protein ubiquitination", "OBSERVATION", 159, 181], ["viral protein functions", "OBSERVATION", 203, 226]]], ["Coxsackievirus infection facilitates host protein polyubiquitination, which subsequently increases intracellular protein degradation by the proteasome and/or viral protein modification, such as 3D pol , by monoubiquitination.", [["intracellular", "ANATOMY", 99, 112], ["Coxsackievirus infection", "DISEASE", 0, 24], ["Coxsackievirus", "ORGANISM", 0, 14], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 112], ["3D pol", "GENE_OR_GENE_PRODUCT", 194, 200], ["proteasome", "PROTEIN", 140, 150], ["viral protein", "PROTEIN", 158, 171], ["3D pol", "PROTEIN", 194, 200], ["Coxsackievirus infection", "PROBLEM", 0, 24], ["host protein polyubiquitination", "PROBLEM", 37, 68], ["intracellular protein degradation", "PROBLEM", 99, 132], ["the proteasome", "TREATMENT", 136, 150], ["viral protein modification", "TREATMENT", 158, 184], ["3D pol", "TREATMENT", 194, 200], ["infection", "OBSERVATION", 15, 24], ["host protein polyubiquitination", "OBSERVATION", 37, 68], ["increases", "OBSERVATION_MODIFIER", 89, 98], ["intracellular protein degradation", "OBSERVATION", 99, 132], ["viral protein modification", "OBSERVATION", 158, 184]]], ["Degradation of host antiviral proteins provides a favorable environment for virus to achieve successful replication.", [["host antiviral proteins", "PROTEIN", 15, 38], ["host antiviral proteins", "TREATMENT", 15, 38], ["virus", "PROBLEM", 76, 81], ["successful replication", "TREATMENT", 93, 115], ["host antiviral", "OBSERVATION", 15, 29]]], ["Knockdown of ubiquitin decreases host protein degradation and viral protein ubiquitination.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 13, 22], ["ubiquitin", "PROTEIN", 13, 22], ["viral protein", "PROTEIN", 62, 75], ["Knockdown of ubiquitin", "PROBLEM", 0, 22], ["host protein degradation", "PROBLEM", 33, 57], ["viral protein ubiquitination", "PROBLEM", 62, 90], ["ubiquitin", "OBSERVATION_MODIFIER", 13, 22], ["decreases", "OBSERVATION_MODIFIER", 23, 32], ["host protein degradation", "OBSERVATION", 33, 57], ["viral protein ubiquitination", "OBSERVATION", 62, 90]]], ["Proteasome inhibition blocks host protein degradation and viral protein ubiquitination by reducing recycled ubiquitin.", [["Proteasome", "GENE_OR_GENE_PRODUCT", 0, 10], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 108, 117], ["Proteasome", "PROTEIN", 0, 10], ["viral protein", "PROTEIN", 58, 71], ["ubiquitin", "PROTEIN", 108, 117], ["Proteasome inhibition blocks", "TREATMENT", 0, 28], ["host protein degradation", "TREATMENT", 29, 53], ["viral protein ubiquitination", "TREATMENT", 58, 86], ["recycled ubiquitin", "TREATMENT", 99, 117], ["host protein degradation", "OBSERVATION", 29, 53], ["viral protein ubiquitination", "OBSERVATION", 58, 86]]], ["DUB inhibitors further decreases the viral replication when used together with proteasome inhibitors through the additional reduction of recycled free ubiquitin.DiscussionIn conclusion, we have demonstrated for the first time that CVB3 infection results in increased protein ubiquitination and consequent decreases in free ubiquitin levels.", [["CVB3 infection", "DISEASE", 231, 245], ["DUB", "GENE_OR_GENE_PRODUCT", 0, 3], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 151, 160], ["CVB3", "ORGANISM", 231, 235], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 323, 332], ["DUB", "PROTEIN", 0, 3], ["proteasome", "PROTEIN", 79, 89], ["ubiquitin", "PROTEIN", 151, 160], ["CVB3", "SPECIES", 231, 235], ["DUB inhibitors", "TREATMENT", 0, 14], ["the viral replication", "TREATMENT", 33, 54], ["proteasome inhibitors", "TREATMENT", 79, 100], ["the additional reduction of recycled free ubiquitin", "TREATMENT", 109, 160], ["CVB3 infection", "PROBLEM", 231, 245], ["increased protein ubiquitination", "PROBLEM", 257, 289], ["consequent decreases in free ubiquitin levels", "PROBLEM", 294, 339], ["viral replication", "OBSERVATION", 37, 54], ["free ubiquitin", "OBSERVATION", 146, 160], ["infection", "OBSERVATION", 236, 245], ["increased", "OBSERVATION_MODIFIER", 257, 266], ["protein ubiquitination", "OBSERVATION", 267, 289], ["decreases", "OBSERVATION_MODIFIER", 305, 314], ["free ubiquitin levels", "OBSERVATION", 318, 339]]], ["We further demonstrate that protein ubiquitination is required for the completion of viral lifecycle, likely through ubiquitin modification of viral polymerase.Cell culture, virus, and materialsHeLa cells (American Type Culture Collection) were grown and maintained in complete medium [Dulbecco's modified Eagle's media (DMEM) supplemented with 10% heat-inactivated newborn calf serum (NCS) (Invitrogen)].", [["Cell", "ANATOMY", 160, 164], ["HeLa cells", "ANATOMY", 194, 204], ["serum", "ANATOMY", 379, 384], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 117, 126], ["Cell", "CELL", 160, 164], ["HeLa cells", "CELL", 194, 204], ["calf", "ORGANISM", 374, 378], ["serum", "ORGANISM_SUBSTANCE", 379, 384], ["viral polymerase", "PROTEIN", 143, 159], ["HeLa cells", "CELL_LINE", 194, 204], ["calf", "SPECIES", 374, 378], ["protein ubiquitination", "PROBLEM", 28, 50], ["viral lifecycle", "PROBLEM", 85, 100], ["viral polymerase", "PROBLEM", 143, 159], ["Cell culture", "TEST", 160, 172], ["virus", "PROBLEM", 174, 179], ["HeLa cells", "PROBLEM", 194, 204], ["Culture Collection", "TEST", 220, 238], ["Dulbecco's modified Eagle's media (DMEM", "TREATMENT", 286, 325], ["protein ubiquitination", "OBSERVATION", 28, 50], ["viral polymerase", "OBSERVATION", 143, 159]]], ["CVB3 (Kandolf strain) was propagated in HeLa cells and stored at 280uC.", [["HeLa cells", "ANATOMY", 40, 50], ["CVB3", "ORGANISM", 0, 4], ["Kandolf strain", "ORGANISM", 6, 20], ["HeLa cells", "CELL", 40, 50], ["HeLa cells", "CELL_LINE", 40, 50], ["CVB3", "SPECIES", 0, 4], ["CVB3 (Kandolf strain", "TREATMENT", 0, 20], ["HeLa cells", "TREATMENT", 40, 50], ["HeLa cells", "OBSERVATION", 40, 50]]], ["Virus titer was routinely determined by a plaque assay prior to infection as described below.Cell culture, virus, and materialsThe monoclonal anti-b-actin and anti-ubiquitin antibodies were purchased from Sigma-Aldrich.", [["plaque", "ANATOMY", 42, 48], ["Cell", "ANATOMY", 93, 97], ["infection", "DISEASE", 64, 73], ["Virus", "ORGANISM", 0, 5], ["Cell", "CELL", 93, 97], ["anti-b-actin", "GENE_OR_GENE_PRODUCT", 142, 154], ["anti-ubiquitin antibodies", "GENE_OR_GENE_PRODUCT", 159, 184], ["Sigma-Aldrich", "ORGANISM", 205, 218], ["monoclonal anti-b-actin", "PROTEIN", 131, 154], ["anti-ubiquitin antibodies", "PROTEIN", 159, 184], ["Virus titer", "TEST", 0, 11], ["a plaque assay", "TEST", 40, 54], ["infection", "PROBLEM", 64, 73], ["Cell culture", "TEST", 93, 105], ["virus", "PROBLEM", 107, 112], ["The monoclonal anti-b-actin and anti-ubiquitin antibodies", "TREATMENT", 127, 184], ["plaque", "OBSERVATION", 42, 48], ["infection", "OBSERVATION", 64, 73], ["monoclonal anti-b-actin", "OBSERVATION", 131, 154]]], ["The monoclonal anti-VP1 antibody was obtained from DakoCytomation.", [["anti-VP1", "GENE_OR_GENE_PRODUCT", 15, 23], ["DakoCytomation", "GENE_OR_GENE_PRODUCT", 51, 65], ["monoclonal anti-VP1 antibody", "PROTEIN", 4, 32], ["The monoclonal anti-VP1 antibody", "TEST", 0, 32]]], ["The ubiquitin siRNA, scramble control siRNA, and horseradish peroxidaseconjugated secondary antibodies were obtained from Santa Cruz Biotechnology.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 4, 13], ["horseradish", "SIMPLE_CHEMICAL", 49, 60], ["horseradish peroxidaseconjugated secondary antibodies", "PROTEIN", 49, 102], ["Santa Cruz Biotechnology", "PROTEIN", 122, 146], ["horseradish", "SPECIES", 49, 60], ["The ubiquitin siRNA", "TREATMENT", 0, 19], ["scramble control siRNA", "TREATMENT", 21, 43], ["horseradish peroxidaseconjugated secondary antibodies", "PROBLEM", 49, 102], ["ubiquitin siRNA", "OBSERVATION", 4, 19]]], ["The proteasome inhibitors, MG132 and lactacystin, the UCH L1 inhibitor (LDN-57444) and the UCH L3 inhibitor (4,5,6,7-Tetrachloroindan-1,3-dione), and the polyclonal anti-ubiquitin antibody were obtained from Calbiochem.", [["MG132", "CHEMICAL", 27, 32], ["lactacystin", "CHEMICAL", 37, 48], ["LDN-57444", "CHEMICAL", 72, 81], ["4,5,6,7-Tetrachloroindan-1,3-dione", "CHEMICAL", 109, 143], ["MG132", "CHEMICAL", 27, 32], ["lactacystin", "CHEMICAL", 37, 48], ["LDN-57444", "CHEMICAL", 72, 81], ["(4,5,6,7-Tetrachloroindan-1,3-dione", "CHEMICAL", 108, 143], ["MG132", "SIMPLE_CHEMICAL", 27, 32], ["lactacystin", "SIMPLE_CHEMICAL", 37, 48], ["UCH L1", "GENE_OR_GENE_PRODUCT", 54, 60], ["LDN-57444", "SIMPLE_CHEMICAL", 72, 81], ["UCH L3", "GENE_OR_GENE_PRODUCT", 91, 97], ["4,5,6,7-Tetrachloroindan-1,3-dione", "SIMPLE_CHEMICAL", 109, 143], ["Calbiochem", "ORGANISM_SUBSTANCE", 208, 218], ["polyclonal anti-ubiquitin antibody", "PROTEIN", 154, 188], ["The proteasome inhibitors", "TREATMENT", 0, 25], ["MG132", "TREATMENT", 27, 32], ["lactacystin", "TREATMENT", 37, 48], ["the UCH L1 inhibitor", "TREATMENT", 50, 70], ["LDN", "TEST", 72, 75], ["the UCH L3 inhibitor", "TREATMENT", 87, 107], ["Tetrachloroindan", "TREATMENT", 117, 133], ["the polyclonal anti-ubiquitin antibody", "TEST", 150, 188], ["L3", "ANATOMY", 95, 97]]], ["The polyclonal anti-3D pol antibody was a generous gift from Dr. Karin Klingel (University Hospital Tuebingen, Germany).Virus infectionHeLa cells were grown in complete medium to 70-80% confluence, and then infected at a multiplicity of infection (MOI) of 10 with CVB3 or sham-infected with phosphate-buffered saline (PBS) for 1 h in serum-free DMEM.", [["infectionHeLa cells", "ANATOMY", 126, 145], ["serum", "ANATOMY", 334, 339], ["infection", "DISEASE", 237, 246], ["phosphate", "CHEMICAL", 291, 300], ["phosphate", "CHEMICAL", 291, 300], ["Virus infectionHeLa cells", "CELL", 120, 145], ["CVB3", "ORGANISM", 264, 268], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 291, 316], ["serum", "ORGANISM_SUBSTANCE", 334, 339], ["polyclonal anti-3D pol antibody", "PROTEIN", 4, 35], ["Virus infectionHeLa cells", "CELL_TYPE", 120, 145], ["CVB3", "SPECIES", 264, 268], ["The polyclonal anti-3D pol antibody", "TREATMENT", 0, 35], ["Virus infectionHeLa cells", "PROBLEM", 120, 145], ["infection", "PROBLEM", 237, 246], ["CVB3", "PROBLEM", 264, 268], ["phosphate", "TREATMENT", 291, 300], ["buffered saline (PBS", "TREATMENT", 301, 321], ["infectionHeLa cells", "OBSERVATION", 126, 145], ["complete", "OBSERVATION_MODIFIER", 160, 168], ["medium", "OBSERVATION_MODIFIER", 169, 175], ["infection", "OBSERVATION", 237, 246], ["free DMEM", "OBSERVATION", 340, 349]]], ["Cells were then washed with PBS and cultured in serum-free medium.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 48, 53], ["Cells", "CELL", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["PBS", "TREATMENT", 28, 31], ["serum", "TEST", 48, 53]]], ["For inhibition experiments, HeLa cells were infected with CVB3 for 1 h, washed with PBS, and then incubated with DMEM containing various concentrations of inhibitors.", [["HeLa cells", "ANATOMY", 28, 38], ["HeLa cells", "CELL", 28, 38], ["CVB3", "ORGANISM", 58, 62], ["HeLa cells", "CELL_LINE", 28, 38], ["CVB3", "SPECIES", 58, 62], ["inhibition experiments", "TREATMENT", 4, 26], ["HeLa cells", "PROBLEM", 28, 38], ["CVB3", "TREATMENT", 58, 62], ["PBS", "TREATMENT", 84, 87], ["DMEM", "TREATMENT", 113, 117], ["various concentrations of inhibitors", "TREATMENT", 129, 165]]], ["Immunoprecipitation and immunoblot analysis Cell lysates were prepared using lysis buffer (50 mM pyrophosphate, 50 mM NaF, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 100 mM Na 3 VO 4 , 10 mM HEPES (pH 7.4), 0.1% Triton X-100, and the protease inhibitor cocktail) as described previously [2] .", [["Cell lysates", "ANATOMY", 44, 56], ["pyrophosphate", "CHEMICAL", 97, 110], ["NaF", "CHEMICAL", 118, 121], ["NaCl", "CHEMICAL", 129, 133], ["EGTA", "CHEMICAL", 151, 155], ["Na", "CHEMICAL", 164, 166], ["Triton X-100", "CHEMICAL", 203, 215], ["pyrophosphate", "CHEMICAL", 97, 110], ["NaF", "CHEMICAL", 118, 121], ["NaCl", "CHEMICAL", 129, 133], ["EDTA", "CHEMICAL", 140, 144], ["EGTA", "CHEMICAL", 151, 155], ["Na 3 VO 4", "CHEMICAL", 164, 173], ["HEPES", "CHEMICAL", 182, 187], ["Triton X-100", "CHEMICAL", 203, 215], ["Cell lysates", "CELL", 44, 56], ["pyrophosphate", "SIMPLE_CHEMICAL", 97, 110], ["NaF", "SIMPLE_CHEMICAL", 118, 121], ["EDTA", "SIMPLE_CHEMICAL", 140, 144], ["EGTA", "SIMPLE_CHEMICAL", 151, 155], ["Triton X-100", "SIMPLE_CHEMICAL", 203, 215], ["Immunoprecipitation", "TEST", 0, 19], ["immunoblot analysis", "TEST", 24, 43], ["Cell lysates", "TEST", 44, 56], ["lysis buffer", "TREATMENT", 77, 89], ["pyrophosphate", "TEST", 97, 110], ["5 mM EDTA", "TREATMENT", 135, 144], ["5 mM EGTA", "TREATMENT", 146, 155], ["10 mM HEPES", "TREATMENT", 176, 187], ["pH", "TEST", 189, 191], ["the protease inhibitor cocktail", "TREATMENT", 221, 252]]], ["For immunoblot analysis, equal amounts of protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membranes (GE Healthcare).", [["membranes", "ANATOMY", 176, 185], ["sodium dodecyl sulfate-polyacrylamide", "CHEMICAL", 68, 105], ["sodium dodecyl sulfate", "CHEMICAL", 68, 90], ["polyacrylamide", "CHEMICAL", 91, 105], ["nitrocellulose", "CHEMICAL", 161, 175], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 68, 90], ["membranes", "CELLULAR_COMPONENT", 176, 185], ["immunoblot analysis", "TEST", 4, 23], ["protein", "TEST", 42, 49], ["sodium dodecyl sulfate", "TREATMENT", 68, 90], ["polyacrylamide gel electrophoresis", "TREATMENT", 91, 125], ["nitrocellulose membranes", "TREATMENT", 161, 185]]], ["Membranes were blocked for 1 h with nonfat dry milk solution (5% in PBS) containing 0.1% Tween 20.", [["Membranes", "ANATOMY", 0, 9], ["Tween 20", "CHEMICAL", 89, 97], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["nonfat dry milk solution", "TREATMENT", 36, 60]]], ["Blots were then incubated for 1 h with the primary antibody followed by incubation for 1 h with the secondary antibody.", [["primary antibody", "PROTEIN", 43, 59], ["secondary antibody", "PROTEIN", 100, 118], ["the primary antibody", "TREATMENT", 39, 59], ["the secondary antibody", "PROBLEM", 96, 118]]], ["Immunoreactive bands were visualized by enhanced chemiluminescence (GE Healthcare).", [["Immunoreactive bands", "PROBLEM", 0, 20]]], ["When protein ubiquitination was examined, membrane was heat-activated by autoclaving at 121uC for 35 min prior to blocking with nonfat dry milk solution to enhance antigenic site recognition.Virus infectionFor immunoprecipitation, cells were lysed using the abovedescribed lysis buffer with freshly added 20 mM iodoacetamide.", [["membrane", "ANATOMY", 42, 50], ["cells", "ANATOMY", 231, 236], ["Virus infection", "DISEASE", 191, 206], ["iodoacetamide", "CHEMICAL", 311, 324], ["iodoacetamide", "CHEMICAL", 311, 324], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["milk", "ORGANISM_SUBSTANCE", 139, 143], ["Virus", "ORGANISM", 191, 196], ["cells", "CELL", 231, 236], ["iodoacetamide", "SIMPLE_CHEMICAL", 311, 324], ["nonfat dry milk solution", "TREATMENT", 128, 152], ["Virus infection", "PROBLEM", 191, 206], ["the abovedescribed lysis buffer", "TREATMENT", 254, 285], ["20 mM iodoacetamide", "TREATMENT", 305, 324]]], ["A total of 500 mg of cell lysates were incubated with a monoclonal anti-ubiquitin antibody (1:100) at 4uC overnight, followed by 2 h incubation with protein G-agorose beads (Amersham).", [["cell lysates", "ANATOMY", 21, 33], ["cell lysates", "ORGANISM_SUBSTANCE", 21, 33], ["G-agorose beads", "SIMPLE_CHEMICAL", 157, 172], ["monoclonal anti-ubiquitin antibody", "PROTEIN", 56, 90], ["protein G", "PROTEIN", 149, 158], ["cell lysates", "TREATMENT", 21, 33], ["a monoclonal anti-ubiquitin antibody", "TREATMENT", 54, 90], ["protein G-agorose beads", "TREATMENT", 149, 172]]], ["Immunocomplexes were washed five times with the lysis buffer containing 20 mM iodoacetamide, and then boiled for 5 min in the 26 nonreducing sample buffer which lacks both b-mercaptoethanol and DTT, but with addition of 20 mM iodoacetamide.", [["iodoacetamide", "CHEMICAL", 78, 91], ["b-mercaptoethanol", "CHEMICAL", 172, 189], ["DTT", "CHEMICAL", 194, 197], ["iodoacetamide", "CHEMICAL", 226, 239], ["iodoacetamide", "CHEMICAL", 78, 91], ["b-mercaptoethanol", "CHEMICAL", 172, 189], ["DTT", "CHEMICAL", 194, 197], ["iodoacetamide", "CHEMICAL", 226, 239], ["iodoacetamide", "SIMPLE_CHEMICAL", 78, 91], ["b-mercaptoethanol", "SIMPLE_CHEMICAL", 172, 189], ["DTT", "SIMPLE_CHEMICAL", 194, 197], ["iodoacetamide", "SIMPLE_CHEMICAL", 226, 239], ["Immunocomplexes", "TREATMENT", 0, 15], ["the lysis buffer", "TREATMENT", 44, 60], ["20 mM iodoacetamide", "TREATMENT", 72, 91], ["DTT", "TREATMENT", 194, 197], ["20 mM iodoacetamide", "TREATMENT", 220, 239]]], ["After centrifugation, the precipitated proteins were separated by SDS-PAGE.", [["precipitated proteins", "PROTEIN", 26, 47], ["centrifugation", "TREATMENT", 6, 20], ["the precipitated proteins", "PROBLEM", 22, 47]]], ["Ubiquitin conjugates were analyzed by immunoblot using polyclonal anti-3D pol antibody.Viral RNA in situ hybridizationHeLa cells were grown and maintained on two-chamber culture slides (Becton Dickinson Labware).", [["HeLa cells", "ANATOMY", 118, 128], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 0, 9], ["HeLa cells", "CELL", 118, 128], ["polyclonal anti-3D pol antibody", "PROTEIN", 55, 86], ["Viral RNA", "RNA", 87, 96], ["HeLa cells", "CELL_LINE", 118, 128], ["Ubiquitin conjugates", "TREATMENT", 0, 20], ["immunoblot", "TEST", 38, 48], ["polyclonal anti-3D pol antibody", "TREATMENT", 55, 86], ["Viral RNA in situ hybridizationHeLa cells", "PROBLEM", 87, 128], ["RNA", "OBSERVATION", 93, 96], ["HeLa cells", "OBSERVATION", 118, 128]]], ["Subconfluent cells were infected with either PBS or CVB3 (MOI = 10).", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["CVB3", "ORGANISM", 52, 56], ["Subconfluent cells", "CELL_TYPE", 0, 18], ["CVB3", "SPECIES", 52, 56], ["Subconfluent cells", "PROBLEM", 0, 18], ["PBS", "TEST", 45, 48], ["CVB3", "TEST", 52, 56], ["MOI", "TEST", 58, 61]]], ["Following 1 h of incubation at 37uC, cells were washed with PBS and replenished with complete medium in the absence and presence of MG132.", [["cells", "ANATOMY", 37, 42], ["MG132", "CHEMICAL", 132, 137], ["MG132", "CHEMICAL", 132, 137], ["cells", "CELL", 37, 42], ["MG132", "SIMPLE_CHEMICAL", 132, 137], ["incubation", "TREATMENT", 17, 27], ["PBS", "TREATMENT", 60, 63], ["MG132", "PROBLEM", 132, 137]]], ["HeLa cells were incubated for an additional 6 h.", [["HeLa cells", "ANATOMY", 0, 10], ["HeLa cells", "CELL", 0, 10], ["HeLa cells", "CELL_LINE", 0, 10], ["HeLa cells", "PROBLEM", 0, 10]]], ["The culture slides were then washed gently with PBS, fixed with formalin buffer for 15 min, and then air-dried at room temperature.", [["formalin", "CHEMICAL", 64, 72], ["formalin", "CHEMICAL", 64, 72], ["The culture slides", "TEST", 0, 18], ["PBS", "TREATMENT", 48, 51], ["formalin buffer", "TREATMENT", 64, 79]]], ["Culture slides were then subjected to in situ hybridization assays to detect the sense-strand of CVB3 genomic RNA as previously described [26] .Viral RNA in situ hybridizationPlaque assay CVB3 titer in cell supernatant was determined on monolayers of HeLa cells by an agar overlay plaque assay in triplicate as described previously [2] .", [["Plaque", "ANATOMY", 175, 181], ["cell supernatant", "ANATOMY", 202, 218], ["monolayers", "ANATOMY", 237, 247], ["HeLa cells", "ANATOMY", 251, 261], ["plaque", "ANATOMY", 281, 287], ["CVB3", "ORGANISM", 97, 101], ["CVB3", "ORGANISM", 188, 192], ["cell", "CELL", 202, 206], ["monolayers", "CELL", 237, 247], ["HeLa cells", "CELL", 251, 261], ["CVB3 genomic RNA", "RNA", 97, 113], ["Viral RNA", "RNA", 144, 153], ["HeLa cells", "CELL_LINE", 251, 261], ["CVB3", "SPECIES", 97, 101], ["CVB3", "SPECIES", 188, 192], ["Culture slides", "TEST", 0, 14], ["situ hybridization assays", "TEST", 41, 66], ["CVB3 genomic RNA", "PROBLEM", 97, 113], ["Viral RNA", "TREATMENT", 144, 153], ["Plaque assay CVB3 titer in cell supernatant", "PROBLEM", 175, 218], ["HeLa cells", "TREATMENT", 251, 261], ["an agar overlay plaque assay", "PROBLEM", 265, 293], ["CVB3 genomic RNA", "OBSERVATION", 97, 113], ["RNA", "OBSERVATION", 150, 153], ["HeLa cells", "OBSERVATION", 251, 261], ["plaque", "OBSERVATION", 281, 287]]], ["Briefly, samples were serially diluted and overlaid on monolayer of HeLa cells.", [["samples", "ANATOMY", 9, 16], ["monolayer", "ANATOMY", 55, 64], ["HeLa cells", "ANATOMY", 68, 78], ["monolayer", "CELL", 55, 64], ["HeLa cells", "CELL", 68, 78], ["HeLa cells", "CELL_LINE", 68, 78], ["monolayer of HeLa cells", "TREATMENT", 55, 78], ["HeLa cells", "OBSERVATION", 68, 78]]], ["Cells were incubated for 72 h, then fixed with Carnoy's fixative (75% ethanol-25% acetic acid), and stained with 1% crystal violet.", [["Cells", "ANATOMY", 0, 5], ["ethanol", "CHEMICAL", 70, 77], ["acetic acid", "CHEMICAL", 82, 93], ["ethanol", "CHEMICAL", 70, 77], ["acetic acid", "CHEMICAL", 82, 93], ["Cells", "CELL", 0, 5], ["Carnoy", "SIMPLE_CHEMICAL", 47, 53], ["ethanol", "SIMPLE_CHEMICAL", 70, 77], ["acetic acid", "SIMPLE_CHEMICAL", 82, 93], ["crystal violet", "SIMPLE_CHEMICAL", 116, 130], ["Cells", "TEST", 0, 5], ["Carnoy's fixative", "TEST", 47, 64], ["ethanol", "TEST", 70, 77], ["acetic acid", "TEST", 82, 93], ["1% crystal violet", "PROBLEM", 113, 130], ["crystal violet", "OBSERVATION", 116, 130]]], ["Plaques were counted and viral titer was calculated as plaque forming unit (PFU) per milliliter.Cell Viability AssayMTS (3, 4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt, Promega) assay was performed to determine cell viability as previously described [7] .", [["Plaques", "ANATOMY", 0, 7], ["plaque", "ANATOMY", 55, 61], ["Cell", "ANATOMY", 96, 100], ["cell", "ANATOMY", 260, 264], ["3, 4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 121, 211], ["3, 4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt", "CHEMICAL", 121, 216], ["Cell", "CELL", 96, 100], ["3, 4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt", "SIMPLE_CHEMICAL", 121, 216], ["cell", "CELL", 260, 264], ["Plaques", "PROBLEM", 0, 7], ["viral titer", "TEST", 25, 36], ["Cell Viability AssayMTS", "TEST", 96, 119], ["dimethylthiazol", "TREATMENT", 129, 144], ["carboxymethoxy phenyl)", "TREATMENT", 156, 178], ["tetrazolium salt", "TREATMENT", 200, 216]]], ["Briefly, cells were incubated with MTS solution for 2 h prior to collection.", [["cells", "ANATOMY", 9, 14], ["MTS", "CHEMICAL", 35, 38], ["MTS", "CHEMICAL", 35, 38], ["cells", "CELL", 9, 14], ["MTS solution", "TREATMENT", 35, 47]]], ["Absorbance was measured at a wave length of 490 nm using an ELISA reader.Ubiquitin siRNA transfectionHeLa cells were grown to 50% confluency and then transiently transfected with ubiquitin-specific siRNA (200 nM) using oligofectamine according to the manufacturer's suggestion (Invitrogen).", [["transfectionHeLa cells", "ANATOMY", 89, 111], ["oligofectamine", "CHEMICAL", 219, 233], ["oligofectamine", "CHEMICAL", 219, 233], ["Ubiquitin", "GENE_OR_GENE_PRODUCT", 73, 82], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 179, 188], ["oligofectamine", "SIMPLE_CHEMICAL", 219, 233], ["transfectionHeLa cells", "CELL_LINE", 89, 111], ["ubiquitin", "PROTEIN", 179, 188], ["Absorbance", "TEST", 0, 10], ["Ubiquitin siRNA transfectionHeLa cells", "PROBLEM", 73, 111], ["ubiquitin-specific siRNA", "TREATMENT", 179, 203], ["oligofectamine", "TREATMENT", 219, 233], ["transfectionHeLa cells", "OBSERVATION", 89, 111]]], ["A scramble siRNA (200 nM) was used as a control.", [["A scramble siRNA", "TREATMENT", 0, 16], ["scramble siRNA", "OBSERVATION", 2, 16]]], ["The silencing efficiency was detected by immunoblot analyses using the antiubiquitin antibody.", [["antiubiquitin antibody", "GENE_OR_GENE_PRODUCT", 71, 93], ["antiubiquitin antibody", "PROTEIN", 71, 93], ["The silencing efficiency", "PROBLEM", 0, 24], ["immunoblot analyses", "TEST", 41, 60], ["the antiubiquitin antibody", "TREATMENT", 67, 93], ["silencing efficiency", "OBSERVATION", 4, 24]]], ["After 24 h of transfection, cells were infected with CVB3 as indicated.Statistical analysisStatistical analysis was performed using the paired Student's t test.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["CVB3", "ORGANISM", 53, 57], ["CVB3", "SPECIES", 53, 57], ["transfection", "TREATMENT", 14, 26], ["CVB3", "TREATMENT", 53, 57], ["Statistical analysisStatistical analysis", "TEST", 71, 111]]], ["A p value of less than or equal to 0.05 was considered statistically significant.", [["A p value", "TEST", 0, 9]]]], "5ffe9a1602b9c0959380eb15dfb78906ced112b4": [["ABSTRACT (197 of 200 words)In the age of a pandemic, such as the ongoing one caused by SARS-CoV-2, the world faces limited supply of tests, PPE and reagents, and factories are struggling to meet the growing demands.", [["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV", "SPECIES", 87, 95], ["SARS", "PROBLEM", 87, 91]]], ["This study aimed to evaluate the efficacy of pooling specimen for testing of SARS-CoV-2 virus, to determine whether costs and resource savings could be achieved without impacting the sensitivity of the testing.", [["specimen", "ANATOMY", 53, 61], ["SARS", "DISEASE", 77, 81], ["SARS-CoV-2 virus", "ORGANISM", 77, 93], ["CoV-2 virus", "SPECIES", 82, 93], ["SARS-CoV-2 virus", "SPECIES", 77, 93], ["This study", "TEST", 0, 10], ["pooling specimen", "TEST", 45, 61], ["testing", "TEST", 66, 73], ["SARS", "PROBLEM", 77, 81], ["CoV", "TEST", 82, 85], ["virus", "PROBLEM", 88, 93], ["resource savings", "TREATMENT", 126, 142], ["the testing", "TEST", 198, 209]]], ["Ten specimens were pooled for testing, containing either one or two known positive specimen of varying viral concentrations.", [["specimens", "ANATOMY", 4, 13], ["specimen", "ANATOMY", 83, 91], ["specimens", "CANCER", 4, 13], ["Ten specimens", "TEST", 0, 13], ["testing", "TEST", 30, 37], ["varying viral concentrations", "PROBLEM", 95, 123], ["positive specimen", "OBSERVATION_MODIFIER", 74, 91], ["varying", "OBSERVATION_MODIFIER", 95, 102], ["viral concentrations", "OBSERVATION", 103, 123]]], ["Pooling specimens did not affect the sensitivity of detecting SARS-CoV-2, and the PCR cycle threshold (Ct) between testing of pooling specimen and subsequent individual testing was not significantly different using paired t-test.", [["specimens", "ANATOMY", 8, 17], ["specimen", "ANATOMY", 134, 142], ["SARS", "DISEASE", 62, 66], ["SARS-CoV", "SPECIES", 62, 70], ["Pooling specimens", "TEST", 0, 17], ["SARS", "TEST", 62, 66], ["CoV", "TEST", 67, 70], ["the PCR cycle threshold", "TEST", 78, 101], ["Ct", "TEST", 103, 105], ["testing of pooling specimen", "TEST", 115, 142], ["subsequent individual testing", "TEST", 147, 176], ["paired t-test", "TEST", 215, 228]]], ["This study also identified cost savings garnered from pooling of specimen for testing at 4 differing prevalence rates, ranging from 0.1-10%.ABSTRACT (197 of 200 words)Pooling specimens to test for COVID-19 infection in low prevalence areas or in low risk population can dramatically decrease the resources burden on lab operations by up to 80%.ABSTRACT (197 of 200 words)This paves the possibility for large-scale population screening, allowing for assured policy decisions by governmental bodies to ease lockdown restrictions in areas with low incidence of infection, or with lower risk populations.ABSTRACT (197 of 200 words)KEYWORDS: COVID-19; SARS-CoV-2; pooling specimen; PCR; real-time PCR; cost efficiency .", [["specimens", "ANATOMY", 175, 184], ["infection", "DISEASE", 206, 215], ["infection", "DISEASE", 558, 567], ["COVID-19", "SPECIES", 197, 205], ["This study", "TEST", 0, 10], ["cost savings", "PROBLEM", 27, 39], ["testing", "TEST", 78, 85], ["Pooling specimens", "TEST", 167, 184], ["test", "TEST", 188, 192], ["COVID", "TEST", 197, 202], ["infection", "PROBLEM", 206, 215], ["low prevalence areas", "PROBLEM", 219, 239], ["low risk population", "PROBLEM", 246, 265], ["lab operations", "TREATMENT", 316, 330], ["large-scale population screening", "TEST", 402, 434], ["infection", "PROBLEM", 558, 567], ["lower risk populations", "PROBLEM", 577, 599], ["COVID", "TEST", 637, 642], ["SARS", "TEST", 647, 651], ["CoV", "TEST", 652, 655], ["pooling specimen", "TEST", 659, 675], ["PCR", "TEST", 677, 680], ["cost efficiency", "PROBLEM", 697, 712], ["infection", "OBSERVATION", 206, 215], ["low prevalence", "OBSERVATION_MODIFIER", 219, 233], ["low risk", "OBSERVATION_MODIFIER", 246, 254], ["low incidence", "OBSERVATION_MODIFIER", 541, 554], ["infection", "OBSERVATION", 558, 567]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprintINTRODUCTIONThe ongoing COVID-19 pandemic has highlighted the need for early diagnosis of emerging infectious diseases to better contain an outbreak.", [["CC", "CHEMICAL", 0, 2], ["infectious diseases", "DISEASE", 439, 458], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["emerging infectious diseases", "PROBLEM", 430, 458], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infectious", "OBSERVATION", 439, 449], ["outbreak", "OBSERVATION", 480, 488]]], ["Testing for SARS-CoV-2, the virus that causes COVID-19, has been limited due to factors including high cost and low availability of reagents, lack of personal protective equipment (PPE) and other consumables, and the sheer volume of samples be tested.", [["samples", "ANATOMY", 233, 240], ["SARS-CoV-2", "ORGANISM", 12, 22], ["SARS-CoV", "SPECIES", 12, 20], ["Testing", "TEST", 0, 7], ["SARS", "PROBLEM", 12, 16], ["CoV", "TEST", 17, 20], ["the virus", "PROBLEM", 24, 33], ["COVID", "TEST", 46, 51], ["high cost", "PROBLEM", 98, 107], ["reagents", "TREATMENT", 132, 140], ["personal protective equipment", "TREATMENT", 150, 179]]], ["To date, countries that are able to screen patients swiftly have fared better in containing the COVID-19 outbreak and suppressing the mortality rate associated with the disease 3 .", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["the disease 3", "PROBLEM", 165, 178], ["disease", "OBSERVATION", 169, 176]]], ["The rapid diagnosis of COVID-19 in both symptomatic and asymptomatic patients can shed light on transmission patterns and facilitate contact tracing 2,3 .", [["COVID-19", "CHEMICAL", 23, 31], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 23, 28], ["transmission patterns", "TEST", 96, 117], ["contact tracing", "TEST", 133, 148], ["symptomatic", "OBSERVATION_MODIFIER", 40, 51]]], ["Large scale population screening for COVID-19 infection is generally considered a necessary part of an exit strategy from the coronavirus lockdown, and in reinforcing infection control measures in hospitals and among health care workers.INTRODUCTIONSpecimen pooling is a method of screening large number of patients for an infection, and typically involves combining multiple patient specimens into a single test sample, then testing multiple such samples.", [["specimens", "ANATOMY", 384, 393], ["samples", "ANATOMY", 448, 455], ["COVID-19", "CHEMICAL", 37, 45], ["infection", "DISEASE", 46, 55], ["coronavirus", "DISEASE", 126, 137], ["infection", "DISEASE", 167, 176], ["infection", "DISEASE", 323, 332], ["COVID-19", "ORGANISM", 37, 45], ["coronavirus", "ORGANISM", 126, 137], ["patients", "ORGANISM", 307, 315], ["patient", "ORGANISM", 376, 383], ["patients", "SPECIES", 307, 315], ["patient", "SPECIES", 376, 383], ["COVID-19", "SPECIES", 37, 45], ["Large scale population screening", "TEST", 0, 32], ["COVID", "TEST", 37, 42], ["infection", "PROBLEM", 46, 55], ["the coronavirus lockdown", "TREATMENT", 122, 146], ["infection control measures", "TREATMENT", 167, 193], ["an infection", "PROBLEM", 320, 332], ["a single test sample", "TEST", 399, 419], ["infection", "OBSERVATION", 46, 55], ["infection", "OBSERVATION", 167, 176], ["infection", "OBSERVATION", 323, 332]]], ["This approach has the advantage of cost-effectiveness and speed, and was used to retrospectively screen for COVID-19 in specimens that were negative for common respiratory viruses earlier in the course of the pandemic in the United States 4 , and in France to rapidly screen multiple returning expatriates from China with low suspicion of infection 5 .", [["specimens", "ANATOMY", 120, 129], ["respiratory viruses", "DISEASE", 160, 179], ["infection", "DISEASE", 339, 348], ["specimens", "CANCER", 120, 129], ["COVID", "TEST", 108, 113], ["specimens", "TEST", 120, 129], ["common respiratory viruses", "PROBLEM", 153, 179], ["infection", "PROBLEM", 339, 348], ["viruses", "OBSERVATION", 172, 179], ["infection", "OBSERVATION", 339, 348]]], ["Specimen pooling has also been used in screening efforts for several other infectious diseases, including donated blood samples for HIV 6-9 .INTRODUCTION. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)INTRODUCTIONThe copyright holder for this preprint this version posted May 6, 2020.", [["blood samples", "ANATOMY", 114, 127], ["infectious diseases", "DISEASE", 75, 94], ["HIV 6-9", "CHEMICAL", 132, 139], ["CC", "CHEMICAL", 155, 157], ["blood samples", "ORGANISM_SUBSTANCE", 114, 127], ["HIV", "SPECIES", 132, 135], ["Specimen pooling", "PROBLEM", 0, 16], ["screening efforts", "TEST", 39, 56], ["several other infectious diseases", "PROBLEM", 61, 94], ["blood samples", "TEST", 114, 127], ["HIV", "PROBLEM", 132, 135], ["CC", "TEST", 155, 157], ["ND", "PROBLEM", 164, 166], ["infectious", "OBSERVATION", 75, 85], ["NC", "ANATOMY", 161, 163], ["med", "ANATOMY", 260, 263]]], ["Pooling nasopharyngeal and throat swab (NT) specimens would be more economical than individually testing all specimens from low-risk populations, particularly in limited-resource settings 10 .", [["nasopharyngeal", "ANATOMY", 8, 22], ["throat swab", "ANATOMY", 27, 38], ["NT) specimens", "ANATOMY", 40, 53], ["specimens", "ANATOMY", 109, 118], ["nasopharyngeal", "CANCER", 8, 22], ["throat swab", "MULTI-TISSUE_STRUCTURE", 27, 38], ["Pooling nasopharyngeal and throat swab (NT) specimens", "TEST", 0, 53], ["testing all specimens", "TEST", 97, 118], ["low-risk populations", "PROBLEM", 124, 144], ["nasopharyngeal", "ANATOMY", 8, 22], ["throat", "ANATOMY", 27, 33]]], ["The current study was undertaken to compare laboratory results from sample pooling (10 samples) with the standard real-time polymerase chain reaction (qPCR) testing without pooling, as a means of preparing for a broad pooling-based screening effort to ensure that detection accuracy will not be compromised.INTRODUCTION. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)INTRODUCTIONThe copyright holder for this preprint this version posted May 6, 2020.", [["samples", "ANATOMY", 87, 94], ["CC", "CHEMICAL", 321, 323], ["The current study", "TEST", 0, 17], ["sample pooling", "TEST", 68, 82], ["qPCR) testing", "TEST", 151, 164], ["a broad pooling", "TREATMENT", 210, 225], ["detection accuracy", "TEST", 264, 282], ["CC", "TEST", 321, 323], ["ND", "PROBLEM", 330, 332], ["NC", "ANATOMY", 327, 329], ["med", "ANATOMY", 426, 429]]], ["This study used magnetic extraction-based assay (NUCLISENS\u00ae, easyMag\u00ae, bioM\u00e9rieux, Marcy-l'\u00c9toile, France) based on the Boom method to extract DNA and RNA, which allows a maximum specimen volume of 1.0mL 11 .", [["specimen", "ANATOMY", 179, 187], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["This study", "TEST", 0, 10], ["magnetic extraction", "TEST", 16, 35], ["a maximum specimen volume", "TEST", 169, 194]]], ["By using magnetic beads to capture DNA and RNA during the extraction step, pooling 10 specimens of 0.1mL each (total of 1.0 mL extraction sample) can result in the same extraction capability as 0.1mL if the elution volume at the end is equal and there is no PCR interference from the specimen such as lipid, protein or cell debris.INTRODUCTIONTwo pooling ratios were evaluated in this study, termed 1X and 2X.", [["specimens", "ANATOMY", 86, 95], ["specimen", "ANATOMY", 284, 292], ["cell", "ANATOMY", 319, 323], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["lipid", "SIMPLE_CHEMICAL", 301, 306], ["cell", "CELL", 319, 323], ["magnetic beads", "TREATMENT", 9, 23], ["DNA", "PROBLEM", 35, 38], ["RNA", "TREATMENT", 43, 46], ["the extraction step", "TREATMENT", 54, 73], ["1.0 mL extraction sample", "TREATMENT", 120, 144], ["the elution volume", "TEST", 203, 221], ["PCR interference", "PROBLEM", 258, 274], ["the specimen", "TEST", 280, 292], ["cell debris", "PROBLEM", 319, 330], ["pooling ratios", "TEST", 347, 361], ["this study", "TEST", 380, 390], ["equal", "OBSERVATION", 236, 241], ["no", "UNCERTAINTY", 255, 257], ["cell debris", "OBSERVATION", 319, 330]]], ["In the 1X ratio, 0.1mL of NT-VTM from one SARS-CoV-2 positive specimen was combined with 0.9 mL pooled .", [["specimen", "ANATOMY", 62, 70], ["NT-VTM", "CHEMICAL", 26, 32], ["NT-VTM", "SIMPLE_CHEMICAL", 26, 32], ["NT-VTM", "TREATMENT", 26, 32], ["one SARS", "TEST", 38, 46], ["CoV", "TEST", 47, 50]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprint 7 negative NT-VTM, thus modeling a 10% infection rate.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 380, 389], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["a 10% infection rate", "PROBLEM", 374, 394], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Correspondingly, in the 2X ratio, 0.1mL of NT-VTM each from two SARS-CoV-2 positive specimens were pooled with 0.8 mL pooled negative NT-VTM, thus modeling a 20% infection rate (see Figure 1 ).", [["specimens", "ANATOMY", 84, 93], ["NT-VTM", "CHEMICAL", 43, 49], ["infection", "DISEASE", 162, 171], ["NT-VTM", "TREATMENT", 43, 49], ["two SARS", "TEST", 60, 68], ["CoV", "TEST", 69, 72], ["a 20% infection rate", "PROBLEM", 156, 176]]], ["All 1.0 mL pooled samples in this study were then processed for nucleic acid extraction using NUCLISENS\u00ae easyMAG\u00ae instrument (bioM\u00e9rieux).", [["samples", "ANATOMY", 18, 25], ["nucleic acid", "CHEMICAL", 64, 76], ["this study", "TEST", 29, 39], ["nucleic acid extraction", "TREATMENT", 64, 87], ["NUCLISENS\u00ae easyMAG\u00ae instrument (bioM\u00e9rieux)", "TREATMENT", 94, 137]]], ["In addition, 0.1mL of the same positive specimens that were used in the pooled samples were re-tested for sensitivity comparison using a separate extraction system (EZ1, Qiagen, Hilden, Germany).", [["specimens", "ANATOMY", 40, 49], ["samples", "ANATOMY", 79, 86], ["the pooled samples", "TEST", 68, 86], ["a separate extraction system", "TREATMENT", 135, 163]]], ["Real-time PCR (qPCR) for detection of SARS-CoV-2 was performed using a commercial kit which targets the ORF1ab gene as per the manufacturer's protocol (BGI, Shenzhen, China).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 104, 110], ["ORF1ab gene", "DNA", 104, 115], ["SARS-CoV", "SPECIES", 38, 46], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["a commercial kit", "TEST", 69, 85]]], ["The protocol's stated limit of detection of ORF1ab real-time PCR was 100 copies/mL and the cutoff PCR cycle threshold (Ct) was 38.(which was not certified by peer review)Previously positive specimens with high and low-concentrations of RNA, as determined by PCR cycle threshold (Ct) values at the time of detection, were selected to determine the effect of viral load on pooling to ensure sensitivity and accuracy of the assays is maintained (Table 1) .", [["specimens", "ANATOMY", 190, 199], ["ORF1ab", "PROTEIN", 44, 50], ["PCR", "TEST", 61, 64], ["the cutoff PCR cycle threshold", "TEST", 87, 117], ["Ct", "TEST", 119, 121], ["Previously positive specimens", "PROBLEM", 170, 199], ["high and low-concentrations of RNA", "PROBLEM", 205, 239], ["PCR cycle threshold", "TEST", 258, 277], ["Ct) values", "TEST", 279, 289], ["viral load", "PROBLEM", 357, 367], ["sensitivity", "TEST", 389, 400], ["the assays", "TEST", 417, 427], ["high", "OBSERVATION_MODIFIER", 205, 209]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The sensitivity of viral RNA detection for each pool was compared with the sensitivity of PCR results for the individually tested positive specimen in that pool.", [["specimen", "ANATOMY", 139, 147], ["viral RNA", "RNA", 19, 28], ["viral RNA detection", "TEST", 19, 38], ["PCR", "TEST", 90, 93]]], ["For 2X ratio pools, the positive specimen with the lower Ct value, when individually tested, was used for comparison (Table 1) .(which was not certified by peer review).", [["specimen", "ANATOMY", 33, 41], ["the lower Ct value", "TEST", 47, 65]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprintRESULTSAll 1X ratio pools were positive, with Ct value difference within a range of -1.36 to +1.59 when compared to individual (non-pooled) testing.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprintRESULTSAll 1X ratio pools", "TEST", 324, 365], ["Ct value difference", "TEST", 386, 405], ["individual (non-pooled) testing", "TEST", 456, 487], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Negative and positive values of Ct indicates higher and lower sensitivity of pooling, respectively.", [["Ct", "TEST", 32, 34], ["lower sensitivity of pooling", "PROBLEM", 56, 84], ["positive values", "OBSERVATION_MODIFIER", 13, 28], ["higher", "OBSERVATION_MODIFIER", 45, 51], ["lower sensitivity", "OBSERVATION_MODIFIER", 56, 73], ["pooling", "OBSERVATION", 77, 84]]], ["All 2X ratio pools were positive, with Ct value difference within a range of -1.72 to +1.81 when compared to individual (non-pooled) testing (Table 1) .", [["2X", "GENE_OR_GENE_PRODUCT", 4, 6], ["All 2X ratio pools", "TEST", 0, 18], ["Ct value difference", "TEST", 39, 58], ["individual (non-pooled) testing", "TEST", 109, 140]]], ["Statistical paired t-test was calculated to compare the Ct value differences between pooled (including all patterns in Figure 1) Cost effectiveness of the pooling strategy was calculated, based on varying disease prevalence rates (0.1-10%) ( Table 2 ).", [["Statistical paired t-test", "TEST", 0, 25], ["the Ct value", "TEST", 52, 64], ["the pooling strategy", "TREATMENT", 151, 171], ["varying disease prevalence rates", "PROBLEM", 197, 229], ["varying", "OBSERVATION_MODIFIER", 197, 204], ["disease", "OBSERVATION", 205, 212]]], ["Pooling appears most cost-effective when testing among populations with lower COVID-19 prevalence.", [["lower COVID", "TEST", 72, 83]]], ["Estimated laboratory costs were reduced from $35 per patient to $3.85, $6.85, $17.54, $26.30 at prevalences of COVID-19 in the tested population of 0.1%, 1, 5%, and 10% respectively.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["COVID", "TEST", 111, 116], ["the tested population", "TEST", 123, 144]]], ["By this estimation, pooledspecimen testing of 1,000,000 subjects in a population with 1% COVID-19 prevalence would save approximately $28.15 million, assuming evenly distributed positive specimens in each pool ( Table 2) .RESULTS. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020.DISCUSSIONThis study demonstrates that pooling specimens does not compromise the sensitivity of detecting SARS-CoV-2, regardless of viral load.", [["specimens", "ANATOMY", 187, 196], ["specimens", "ANATOMY", 550, 559], ["CC", "CHEMICAL", 231, 233], ["SARS", "DISEASE", 609, 613], ["CoV-2", "ORGANISM", 614, 619], ["SARS-CoV", "SPECIES", 609, 617], ["pooledspecimen testing", "TEST", 20, 42], ["1% COVID", "TREATMENT", 86, 94], ["CC", "TEST", 231, 233], ["ND", "PROBLEM", 240, 242], ["The copyright holder", "TREATMENT", 432, 452], ["DISCUSSIONThis study", "TEST", 503, 523], ["pooling specimens", "PROBLEM", 542, 559], ["SARS", "TEST", 609, 613], ["CoV", "TEST", 614, 617], ["viral load", "PROBLEM", 635, 645], ["NC", "ANATOMY", 237, 239], ["med", "ANATOMY", 336, 339], ["viral load", "OBSERVATION", 635, 645]]], ["The lowest viral concentration used in this study was at Ct 35.49 which was detected from both pooled and individual testing.", [["The lowest viral concentration", "PROBLEM", 0, 30], ["this study", "TEST", 39, 49], ["Ct", "TEST", 57, 59], ["individual testing", "TEST", 106, 124], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["viral concentration", "OBSERVATION", 11, 30]]], ["Ct value more than 35 was considered weakly positive, and the effect of pooling on these samples will need to be further studied.", [["samples", "ANATOMY", 89, 96], ["Ct value", "TEST", 0, 8], ["weakly positive", "PROBLEM", 37, 52], ["pooling on these samples", "PROBLEM", 72, 96], ["positive", "OBSERVATION", 44, 52]]], ["In 2X ratio pooling, RT PCR testing detected higher viral concentrations (lower PCR Ct) compared to those of the corresponding positive specimens when tested individually.", [["specimens", "ANATOMY", 136, 145], ["2X ratio pooling", "TREATMENT", 3, 19], ["RT PCR testing", "TEST", 21, 35], ["higher viral concentrations", "PROBLEM", 45, 72], ["lower PCR Ct", "TEST", 74, 86], ["the corresponding positive specimens", "TEST", 109, 145]]], ["This suggests that pooling specimens did not lower the sensitivity of PCR testing but actually increased the viral concentration when more than one positive sample was present in the same pool which combined the viral amount from 2 samples in the same extraction tube.", [["specimens", "ANATOMY", 27, 36], ["sample", "ANATOMY", 157, 163], ["tube", "TISSUE", 263, 267], ["pooling specimens", "TEST", 19, 36], ["PCR testing", "TEST", 70, 81], ["the viral concentration", "PROBLEM", 105, 128], ["the same extraction tube", "TREATMENT", 243, 267], ["viral concentration", "OBSERVATION", 109, 128], ["viral", "OBSERVATION_MODIFIER", 212, 217], ["amount", "OBSERVATION_MODIFIER", 218, 224], ["extraction tube", "OBSERVATION", 252, 267]]], ["The nucleic extraction system used in this study allowed nucleic acid extraction from 1.0 mL of NT specimens without reducing the sensitivity as compared to 0.1 mL of individual extraction.", [["specimens", "ANATOMY", 99, 108], ["nucleic acid", "CHEMICAL", 57, 69], ["The nucleic extraction system", "TREATMENT", 0, 29], ["this study", "TEST", 38, 48], ["nucleic acid extraction", "TREATMENT", 57, 80], ["NT specimens", "TREATMENT", 96, 108], ["the sensitivity", "TEST", 126, 141], ["individual extraction", "TREATMENT", 167, 188]]], ["Further, similar PCR Ct values (within +/-2 Ct; statistically not significant) between pooled and non-pooled specimens indicated there was no interference of PCR inhibitor from 1.0 mL pooled specimens in one extraction tube.DISCUSSIONBeyond maintaining accuracy, specimen pooling will almost certainly reduce cost.", [["specimens", "ANATOMY", 109, 118], ["specimens", "ANATOMY", 191, 200], ["specimen", "ANATOMY", 263, 271], ["tube", "TISSUE", 219, 223], ["similar PCR Ct values", "TEST", 9, 30], ["Ct", "TEST", 44, 46], ["pooled and non-pooled specimens", "TEST", 87, 118], ["PCR inhibitor", "TREATMENT", 158, 171], ["one extraction tube", "TREATMENT", 204, 223], ["tube", "OBSERVATION", 219, 223]]], ["For example, if 1% of the population is infected, pooling 10 specimens can reduce the cost of laboratory operation by about 80% (Table 2 ).", [["specimens", "ANATOMY", 61, 70], ["infected", "PROBLEM", 40, 48], ["laboratory operation", "TREATMENT", 94, 114], ["infected", "OBSERVATION", 40, 48]]], ["However, in the case of 10% prevalence, pooling specimens will only save 24.87%, as positive pooled samples will need to be individually tested.", [["specimens", "ANATOMY", 48, 57], ["samples", "ANATOMY", 100, 107], ["pooling specimens", "TEST", 40, 57], ["positive pooled samples", "PROBLEM", 84, 107]]], ["Thus, this is especially useful in areas with low prevalence rates, or when conducting pro-active surveillance in areas of low infection rate.", [["infection", "DISEASE", 127, 136], ["conducting pro-active surveillance", "TEST", 76, 110], ["low infection rate", "PROBLEM", 123, 141], ["low prevalence", "OBSERVATION_MODIFIER", 46, 60], ["low", "OBSERVATION_MODIFIER", 123, 126], ["infection", "OBSERVATION", 127, 136]]], ["Proactive surveillance, particularly in asymptomatic cases, remains a challenge to overcome in order to exit lockdown, where screening on a massive scale is required.DISCUSSION. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprint A previous study found that pooling at ratio of 1 to 5 (50 \u03bcL of each specimen for total of 250 \u03bcL pooled extraction) retained accuracy of the test and resulted in greater efficiency of test resources 10 as well as demonstrating that when the prevalence of COVID-19 is 1%, the optimal specimen pool size is 11 with an overall increase in testing efficiency calculated at 400%.", [["specimen", "ANATOMY", 804, 812], ["CC", "CHEMICAL", 178, 180], ["Proactive surveillance", "TEST", 0, 22], ["a massive scale", "TREATMENT", 138, 153], ["CC", "TEST", 178, 180], ["ND", "PROBLEM", 187, 189], ["The copyright holder", "TREATMENT", 379, 399], ["A previous study", "TEST", 519, 535], ["pooling at ratio", "TEST", 547, 563], ["\u03bcL pooled extraction", "TREATMENT", 615, 635], ["the test", "TEST", 658, 666], ["test resources", "TEST", 705, 719], ["COVID", "TEST", 776, 781], ["the optimal specimen pool size", "TEST", 792, 822], ["testing efficiency", "TEST", 857, 875], ["NC", "ANATOMY", 184, 186], ["med", "ANATOMY", 283, 286], ["greater", "OBSERVATION_MODIFIER", 683, 690], ["size", "OBSERVATION_MODIFIER", 818, 822], ["increase", "OBSERVATION_MODIFIER", 845, 853]]], ["In this study, a 10-specimen pool size (100 \u03bcL each specimen) was chosen based on the capacity of the RNA extraction system in the laboratory where this study was performed, and the result was similar to 5 samples pooling 10 .(which was not certified by peer review)A limitation of this study is the maximum number of two positive specimens in the 10specimen pool.", [["specimen", "ANATOMY", 52, 60], ["specimens", "ANATOMY", 331, 340], ["this study", "TEST", 3, 13], ["this study", "TEST", 148, 158], ["this study", "TEST", 282, 292], ["size", "OBSERVATION_MODIFIER", 34, 38]]], ["In theory, more positive specimens in a pool could decrease the sensitivity of qPCR as it would result in too many viral copies, causing an insufficiency of PCR enzyme and other reagents in the mix to amplify all the viral copies.", [["specimens", "ANATOMY", 25, 34], ["PCR enzyme", "PROTEIN", 157, 167], ["more positive specimens", "PROBLEM", 11, 34], ["qPCR", "TEST", 79, 83], ["too many viral copies", "PROBLEM", 106, 127], ["an insufficiency of PCR enzyme", "PROBLEM", 137, 167], ["other reagents", "TREATMENT", 172, 186], ["insufficiency", "OBSERVATION", 140, 153], ["viral copies", "OBSERVATION", 217, 229]]], ["Practically, however, this does not affect the overall testing results, since positive pools would require individual testing in any case.(which was not certified by peer review)Rapid identification of SARS-CoV-2 infection is crucial to curb the COVID-19 pandemic.", [["SARS", "DISEASE", 202, 206], ["infection", "DISEASE", 213, 222], ["SARS-CoV-2", "ORGANISM", 202, 212], ["CoV-2", "SPECIES", 207, 212], ["SARS-CoV-2", "SPECIES", 202, 212], ["positive pools", "PROBLEM", 78, 92], ["individual testing", "TEST", 107, 125], ["SARS", "PROBLEM", 202, 206], ["CoV", "PROBLEM", 207, 210], ["2 infection", "PROBLEM", 211, 222], ["the COVID", "TEST", 242, 251], ["pandemic", "PROBLEM", 255, 263], ["SARS", "OBSERVATION", 202, 206], ["infection", "OBSERVATION", 213, 222]]], ["The current gold standard for testing SARS-CoV-2 is real-time PCR, which requires resources that are currently limited, along with specialized equipment and technically skilled labor.(which was not certified by peer review)Shortage of testing reagents and equipment in countries where there is no capability to produce their own tests may result in delays in testing and result in reduced effectiveness in containing the outbreak.", [["SARS", "DISEASE", 38, 42], ["SARS-CoV", "SPECIES", 38, 46], ["testing SARS", "TEST", 30, 42], ["CoV", "TEST", 43, 46], ["testing reagents", "TREATMENT", 235, 251], ["their own tests", "TEST", 319, 334], ["delays in testing", "TEST", 349, 366]]], ["Pooled specimen testing would enable substantial savings in reagent costs, technical burden and time to generate laboratory results.(which was not certified by peer review).", [["specimen", "ANATOMY", 7, 15], ["Pooled specimen testing", "TEST", 0, 23]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 324, 340], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. *% of pool with no infection = (% of non-infected samples in one pool)^number of samples per pools .", [["samples", "ANATOMY", 323, 330], ["samples", "ANATOMY", 354, 361], ["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 292, 301], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["infection", "PROBLEM", 292, 301], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 292, 301]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprint", "TREATMENT", 365, 381], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.02.20087221 doi: medRxiv preprint Figure 1 Illustrates the experimental design of the pooling strategies tested in this study", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprint Figure", "TREATMENT", 365, 388], ["the pooling strategies", "TREATMENT", 430, 452], ["this study", "TEST", 463, 473], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "f0d3cca322c1e8d9413b4b2e81ba2fa4bac09e05": [["IntroductionThe high infectiousness of SARS-CoV-2 with its ability to transmit during incubation period or by subclinical cases results in global pandemic.", [["SARS", "DISEASE", 39, 43], ["SARS-CoV-2", "ORGANISM", 39, 49], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["global pandemic", "PROBLEM", 139, 154], ["high infectiousness", "OBSERVATION_MODIFIER", 16, 35], ["global", "OBSERVATION_MODIFIER", 139, 145], ["pandemic", "OBSERVATION", 146, 154]]], ["The virus has caused 1,923,937 infections and 119,618 deaths worldwide (as of April 13) [1] .", [["infections", "DISEASE", 31, 41], ["deaths", "DISEASE", 54, 60], ["The virus", "PROBLEM", 0, 9], ["infections", "PROBLEM", 31, 41], ["virus", "OBSERVATION", 4, 9], ["infections", "OBSERVATION", 31, 41]]], ["A previous modeling study [2] showed that a combination of contact tracing and cases isolation is beneficial to the containment of COVID-19.", [["COVID-19", "CHEMICAL", 131, 139], ["COVID-19", "DNA", 131, 139], ["A previous modeling study", "TEST", 0, 25], ["contact tracing", "TEST", 59, 74], ["cases isolation", "TREATMENT", 79, 94], ["COVID", "TEST", 131, 136]]], ["However, the presence of subclinical transmission hampers greatly the effect of such control measures because those unidentified cases might become the source of community outbreaks.", [["subclinical transmission hampers", "PROBLEM", 25, 57], ["such control measures", "TREATMENT", 80, 101], ["community outbreaks", "PROBLEM", 162, 181], ["subclinical", "OBSERVATION_MODIFIER", 25, 36]]], ["A common approach of testing on at-risk people could only identify part of the subclinical cases.IntroductionIt is therefore extremely difficult to contain the spread of SARS-CoV-2.IntroductionAround eighty miles from the coast of mainland China, Taiwan had been predicted to be the \"second highest import risk\" of COVID-19 in the world [3] .", [["SARS", "DISEASE", 170, 174], ["people", "ORGANISM", 40, 46], ["SARS-CoV-2", "ORGANISM", 170, 180], ["people", "SPECIES", 40, 46], ["SARS-CoV", "SPECIES", 170, 178], ["testing", "TEST", 21, 28], ["COVID", "TEST", 315, 320], ["subclinical", "OBSERVATION", 79, 90]]], ["The lack of large-scale outbreaks could be attributable to immediate quarantine upon identification of all at-risk people and follow-up, which mainly prevents the subclinical spread ( Figure 2 ) [6] .", [["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121], ["large-scale outbreaks", "PROBLEM", 12, 33], ["the subclinical spread", "PROBLEM", 159, 181], ["large", "OBSERVATION_MODIFIER", 12, 17], ["-scale", "OBSERVATION_MODIFIER", 17, 23], ["subclinical", "OBSERVATION_MODIFIER", 163, 174]]], ["However, these measures may not be feasible in all countries.", [["may not be", "UNCERTAINTY", 24, 34]]], ["Due to a variety of control strategies worldwide, we used a stochastic transmission model, initially proposed by For each case of COVID-19, we assumed that the incubation period of each case was drawn from a Weibull distribution.", [["a stochastic transmission model", "TREATMENT", 58, 89]]], ["That is, assumed that a random variable X represents the incubation period and follows a Weibull distribution with a shape parameter k and a scale parameter \uf06c , where the corresponding probability density function isIntroductionThe mean and the variance are J o u r n a l P r e -p r o o fIntroductionrespectively, where \u0393 is the gamma function.", [["\u0393", "PROTEIN", 320, 321], ["a random variable X", "PROBLEM", 22, 41], ["fIntroductionrespectively", "PROBLEM", 287, 312], ["density", "OBSERVATION", 197, 204], ["gamma function", "OBSERVATION", 329, 343]]], ["The parameters k and \uf06c were determined once mean and variance have been given (please see the incubation period in Table 1 ).", [["The parameters k", "TEST", 0, 16]]], ["Similarly, we assumed that the delay between symptom onset and isolation for each case was drawn from a Weibull distribution.IntroductionLet Y be the number of potential secondary cases produced by each primary case.IntroductionAssume that Y follows a negative binomial distribution with a mean equal to a reproduction number R. Each potential new infection was assigned a time of infection drawn from the serial interval distribution.", [["infection", "DISEASE", 348, 357], ["infection", "DISEASE", 381, 390], ["the delay between symptom onset", "PROBLEM", 27, 58], ["new infection", "PROBLEM", 344, 357], ["infection", "PROBLEM", 381, 390], ["new", "OBSERVATION_MODIFIER", 344, 347], ["infection", "OBSERVATION", 348, 357], ["infection", "OBSERVATION", 381, 390], ["distribution", "OBSERVATION_MODIFIER", 422, 434]]], ["The corresponding serial interval for each case was drawn from a skew normal distribution.", [["normal", "OBSERVATION", 70, 76], ["distribution", "OBSERVATION_MODIFIER", 77, 89]]], ["More specifically, let S be a random variable to represent a time of infection for each new case and S follows a skew normal distribution [7] .", [["infection", "DISEASE", 69, 78], ["let S", "GENE_OR_GENE_PRODUCT", 19, 24], ["infection", "PROBLEM", 69, 78], ["infection", "OBSERVATION", 69, 78]]], ["Then the corresponding probability density function isIntroductionwhere \uf066 and \uf046 are the standard normal probability density function and the corresponding cumulative distribution function, respectively.", [["probability", "OBSERVATION_MODIFIER", 23, 34], ["density", "OBSERVATION", 35, 42], ["probability density", "OBSERVATION", 104, 123], ["cumulative", "OBSERVATION_MODIFIER", 155, 165], ["distribution", "OBSERVATION_MODIFIER", 166, 178]]], ["The location parameter \uf078 of this skew normal distribution was set to drawn from the incubation period for the case and the scale parameter \uf077 is 2.", [["the scale parameter", "TEST", 119, 138], ["normal", "OBSERVATION", 38, 44], ["distribution", "OBSERVATION_MODIFIER", 45, 57]]], ["Serial interval Incubation period (2) Assumed.FixedInitial cases 5, 20, 40 [10] J o u r n a l P r e -p r o o f We considered the effect of the three strategies in different scenarios that varied in the number of initial cases (5, 20, and 40), the reproduction number (R; 1.5, 2, 2.5, and 3.5), the proportion of at-risk people being investigated (40%, 60%, 80%, and 90%), the delay from symptom onset to isolation (long and short), and the proportion of transmission that occurred before symptom onset (<1%, 15%, and 30%).", [["people", "ORGANISM", 320, 326], ["people", "SPECIES", 320, 326], ["Serial interval Incubation period", "TREATMENT", 0, 33], ["FixedInitial cases", "TEST", 46, 64], ["a l P r e -p r o o f", "TEST", 90, 110], ["the delay", "PROBLEM", 372, 381], ["symptom", "PROBLEM", 387, 394], ["isolation", "TEST", 404, 413], ["different scenarios", "OBSERVATION", 163, 182], ["varied", "OBSERVATION_MODIFIER", 188, 194], ["number", "OBSERVATION_MODIFIER", 202, 208]]], ["We assumed isolation prevented all further transmission in the model.", [["isolation", "TREATMENT", 11, 20], ["isolation", "OBSERVATION", 11, 20]]], ["Outbreak control was defined as no new infected cases between 12 and 16 weeks; outbreaks that", [["Outbreak control", "TREATMENT", 0, 16], ["new infected cases", "PROBLEM", 35, 53], ["no", "UNCERTAINTY", 32, 34], ["new", "OBSERVATION_MODIFIER", 35, 38], ["infected", "OBSERVATION", 39, 47]]]], "0806adecd9cbd03af312c9687bcc87fe36c4f856": [["The 2019 novel coronavirus , also named as severe acute respiratory syndrome corona virus-2 (SARS-CoV-2), has caused a serious pneumonia pandemic.", [["coronavirus", "DISEASE", 15, 26], ["acute respiratory syndrome", "DISEASE", 50, 76], ["pneumonia", "DISEASE", 127, 136], ["coronavirus", "ORGANISM", 15, 26], ["severe acute respiratory syndrome corona virus-2", "ORGANISM", 43, 91], ["SARS-CoV-2", "ORGANISM", 93, 103], ["corona virus-2", "SPECIES", 77, 91], ["severe acute respiratory syndrome corona virus-2", "SPECIES", 43, 91], ["SARS-CoV-2", "SPECIES", 93, 103], ["novel coronavirus", "PROBLEM", 9, 26], ["severe acute respiratory syndrome corona virus", "PROBLEM", 43, 89], ["a serious pneumonia pandemic", "PROBLEM", 117, 145], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory syndrome", "OBSERVATION", 56, 76], ["corona virus", "OBSERVATION", 77, 89], ["serious", "OBSERVATION_MODIFIER", 119, 126], ["pneumonia", "OBSERVATION", 127, 136]]], ["Advanced age, male gender, and comorbidities such as immunosuppression are the main mortality risk factors.", [["comorbidities", "PROBLEM", 31, 44], ["immunosuppression", "TREATMENT", 53, 70]]], ["A low mortality rate has been reported in healthy individuals while COVID-19 can be life-threatening due to sepsis, multi-organ failure, and acute respiratory distress syndrome (ARDS).", [["multi-organ", "ANATOMY", 116, 127], ["respiratory", "ANATOMY", 147, 158], ["COVID-19", "CHEMICAL", 68, 76], ["sepsis", "DISEASE", 108, 114], ["multi-organ failure", "DISEASE", 116, 135], ["acute respiratory distress syndrome", "DISEASE", 141, 176], ["ARDS", "DISEASE", 178, 182], ["A low mortality rate", "PROBLEM", 0, 20], ["COVID", "TEST", 68, 73], ["sepsis", "PROBLEM", 108, 114], ["multi-organ failure", "PROBLEM", 116, 135], ["acute respiratory distress syndrome", "PROBLEM", 141, 176], ["ARDS", "PROBLEM", 178, 182], ["low", "OBSERVATION_MODIFIER", 2, 5], ["sepsis", "OBSERVATION", 108, 114], ["multi-organ", "ANATOMY", 116, 127], ["failure", "OBSERVATION", 128, 135], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["respiratory distress syndrome", "OBSERVATION", 147, 176], ["ARDS", "OBSERVATION", 178, 182]]], ["1 Generally, autoimmune bullous disorders (AIBDs) such as BP patients who are under immunosuppressive treatment are at increased risk of developing opportunistic infections including viral infections, and microbial pathogens which may potentially trigger the bullous diseases.", [["autoimmune bullous disorders", "DISEASE", 13, 41], ["AIBDs", "DISEASE", 43, 48], ["opportunistic infections", "DISEASE", 148, 172], ["viral infections", "DISEASE", 183, 199], ["bullous diseases", "DISEASE", 259, 275], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["autoimmune bullous disorders", "PROBLEM", 13, 41], ["immunosuppressive treatment", "TREATMENT", 84, 111], ["opportunistic infections", "PROBLEM", 148, 172], ["viral infections", "PROBLEM", 183, 199], ["microbial pathogens", "PROBLEM", 205, 224], ["the bullous diseases", "PROBLEM", 255, 275], ["autoimmune", "OBSERVATION_MODIFIER", 13, 23], ["bullous", "OBSERVATION", 24, 31], ["opportunistic", "OBSERVATION_MODIFIER", 148, 161], ["infections", "OBSERVATION", 162, 172], ["viral", "OBSERVATION_MODIFIER", 183, 188], ["infections", "OBSERVATION", 189, 199], ["microbial pathogens", "OBSERVATION", 205, 224], ["may potentially trigger", "UNCERTAINTY", 231, 254], ["bullous", "OBSERVATION", 259, 266]]], ["Of note, the risk of death in patients with BP is increased especially due to pneumonia.", [["death", "DISEASE", 21, 26], ["pneumonia", "DISEASE", 78, 87], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["death", "PROBLEM", 21, 26], ["BP", "TEST", 44, 46], ["pneumonia", "PROBLEM", 78, 87], ["pneumonia", "OBSERVATION", 78, 87]]], ["2, 3 A higher risk of infection with corticosteroids during COVID-19 restricts its administration.", [["infection", "DISEASE", 22, 31], ["corticosteroids", "CHEMICAL", 37, 52], ["COVID-19", "CHEMICAL", 60, 68], ["corticosteroids", "CHEMICAL", 37, 52], ["COVID-19", "CHEMICAL", 60, 68], ["COVID-19", "SIMPLE_CHEMICAL", 60, 68], ["infection", "PROBLEM", 22, 31], ["corticosteroids", "TREATMENT", 37, 52], ["COVID", "TREATMENT", 60, 65], ["infection", "OBSERVATION", 22, 31]]], ["4 AIBD patients on immunomodulatory treatment, especially old age in the presence of co-morbidities, may be at higher risk of poor outcomes of COVID-19.", [["AIBD", "DISEASE", 2, 6], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["immunomodulatory treatment", "TREATMENT", 19, 45], ["co-morbidities", "PROBLEM", 85, 99], ["COVID", "TEST", 143, 148], ["co-morbidities", "OBSERVATION", 85, 99]]], ["5 However, their suppressive effects on inflammation and the presence of pulmonary inflammation and over activation of the immune system induced by COVID-19 attracted the physicians during the COVID-19 outbreak.", [["pulmonary", "ANATOMY", 73, 82], ["immune system", "ANATOMY", 123, 136], ["inflammation", "DISEASE", 40, 52], ["pulmonary inflammation", "DISEASE", 73, 95], ["COVID-19", "CHEMICAL", 148, 156], ["COVID-19", "CHEMICAL", 148, 156], ["pulmonary", "ORGAN", 73, 82], ["inflammation", "PROBLEM", 40, 52], ["pulmonary inflammation", "PROBLEM", 73, 95], ["the COVID", "TEST", 189, 198], ["suppressive", "OBSERVATION_MODIFIER", 17, 28], ["inflammation", "OBSERVATION", 40, 52], ["pulmonary", "ANATOMY", 73, 82], ["inflammation", "OBSERVATION", 83, 95]]], ["1, 6 Data about the administration of steroidsparing immunosuppressive drugs during COVD-19 are scarce and inconclusive.", [["COVD-19", "CHEMICAL", 84, 91], ["steroidsparing immunosuppressive drugs", "TREATMENT", 38, 76], ["COVD", "TEST", 84, 88]]], ["4 Patients should consult with their dermatologist before discontinuing any medications.", [["Patients", "ORGANISM", 2, 10], ["Patients", "SPECIES", 2, 10], ["any medications", "TREATMENT", 72, 87]]], ["Current guidelines for handling immunosuppression in autoimmune disease patients at risk for contracting COVID-19 advice for outpatients with known contact, who are under quarantine and for certain patients who are experiencing symptoms of COVID-19 and are under investigation for the disease, it may be prudent to hold maintenance immunosuppression for 2 weeks following contact or travel.", [["autoimmune disease", "DISEASE", 53, 71], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 198, 206], ["Current guidelines", "TREATMENT", 0, 18], ["handling immunosuppression", "TREATMENT", 23, 49], ["autoimmune disease", "PROBLEM", 53, 71], ["symptoms", "PROBLEM", 228, 236], ["COVID", "TEST", 240, 245], ["the disease", "PROBLEM", 281, 292], ["maintenance immunosuppression", "TREATMENT", 320, 349]]], ["But autoimmune diseases patients without obvious evidence of exposure should continue their treatments.", [["autoimmune diseases", "DISEASE", 4, 23], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["autoimmune diseases", "PROBLEM", 4, 23], ["their treatments", "TREATMENT", 86, 102], ["autoimmune", "OBSERVATION", 4, 14]]], ["7, 8, 9 Some authors recommend that during COVID-19 pandemic, AIBD patients treated with immunomodulating therapy, keep immunomodulatory therapy as needed because unjustified withdrawal might lead to uncontrolled activity of AIBD which results in high morbidity and mortality.", [["pandemic", "DISEASE", 52, 60], ["AIBD", "DISEASE", 62, 66], ["AIBD", "DISEASE", 225, 229], ["AIBD", "ORGANISM", 62, 66], ["patients", "ORGANISM", 67, 75], ["AIBD", "CANCER", 225, 229], ["patients", "SPECIES", 67, 75], ["immunomodulating therapy", "TREATMENT", 89, 113], ["immunomodulatory therapy", "TREATMENT", 120, 144], ["unjustified withdrawal", "PROBLEM", 163, 185], ["uncontrolled activity of AIBD", "PROBLEM", 200, 229], ["high morbidity and mortality", "PROBLEM", 247, 275], ["high", "OBSERVATION_MODIFIER", 247, 251], ["morbidity", "OBSERVATION", 252, 261]]], ["2, 3, 9 Others suggest that the basic principle of treatment, including corticosteroids and immune suppressants, such as azathioprine and mycophenolate mofetil, should be reduced to the lowest effective dose.", [["azathioprine", "CHEMICAL", 121, 133], ["mycophenolate mofetil", "CHEMICAL", 138, 159], ["azathioprine", "CHEMICAL", 121, 133], ["mycophenolate mofetil", "CHEMICAL", 138, 159], ["azathioprine", "SIMPLE_CHEMICAL", 121, 133], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 138, 159], ["treatment", "TREATMENT", 51, 60], ["corticosteroids", "TREATMENT", 72, 87], ["immune suppressants", "TREATMENT", 92, 111], ["azathioprine", "TREATMENT", 121, 133], ["mycophenolate mofetil", "TREATMENT", 138, 159]]], ["10 For BP patients infected with COIVID-19 on immunomodulating therapy it is recommended that confirmed cases of COVID-19 should undergo risk evaluation at first and these drugs are only discontinued in proven cases of active COVID-19 after an individual risk-benefit analysis.", [["COIVID-19", "CHEMICAL", 33, 42], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["BP", "TEST", 7, 9], ["COIVID", "TEST", 33, 39], ["immunomodulating therapy", "TREATMENT", 46, 70], ["COVID", "TEST", 113, 118], ["risk evaluation", "TEST", 137, 152], ["these drugs", "TREATMENT", 166, 177], ["active COVID", "TEST", 219, 231], ["infected", "OBSERVATION", 19, 27]]], ["3, 8, 9 The immunomodulating medications which are considered to impose the highest risks in patients with COVID-19 are azathioprine, mycophenolate mofetil/sodium, cyclophosphamide, and methotrexate, while topical corticosteroids, prednisolone \u226410 mg/d, dapsone/sulfapyridine, doxycycline/tetracycline, colchicine, and IVIG can be continued.", [["COVID-19", "CHEMICAL", 107, 115], ["azathioprine", "CHEMICAL", 120, 132], ["mycophenolate mofetil", "CHEMICAL", 134, 155], ["sodium", "CHEMICAL", 156, 162], ["cyclophosphamide", "CHEMICAL", 164, 180], ["methotrexate", "CHEMICAL", 186, 198], ["prednisolone", "CHEMICAL", 231, 243], ["dapsone", "CHEMICAL", 254, 261], ["sulfapyridine", "CHEMICAL", 262, 275], ["doxycycline", "CHEMICAL", 277, 288], ["tetracycline", "CHEMICAL", 289, 301], ["colchicine", "CHEMICAL", 303, 313], ["COVID-19", "CHEMICAL", 107, 115], ["azathioprine", "CHEMICAL", 120, 132], ["mycophenolate mofetil", "CHEMICAL", 134, 155], ["sodium", "CHEMICAL", 156, 162], ["cyclophosphamide", "CHEMICAL", 164, 180], ["methotrexate", "CHEMICAL", 186, 198], ["corticosteroids", "CHEMICAL", 214, 229], ["prednisolone", "CHEMICAL", 231, 243], ["dapsone", "CHEMICAL", 254, 261], ["sulfapyridine", "CHEMICAL", 262, 275], ["doxycycline", "CHEMICAL", 277, 288], ["tetracycline", "CHEMICAL", 289, 301], ["colchicine", "CHEMICAL", 303, 313], ["patients", "ORGANISM", 93, 101], ["azathioprine", "SIMPLE_CHEMICAL", 120, 132], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 134, 155], ["sodium", "SIMPLE_CHEMICAL", 156, 162], ["cyclophosphamide", "SIMPLE_CHEMICAL", 164, 180], ["methotrexate", "SIMPLE_CHEMICAL", 186, 198], ["prednisolone", "SIMPLE_CHEMICAL", 231, 243], ["dapsone", "SIMPLE_CHEMICAL", 254, 261], ["sulfapyridine", "SIMPLE_CHEMICAL", 262, 275], ["doxycycline", "SIMPLE_CHEMICAL", 277, 288], ["tetracycline", "SIMPLE_CHEMICAL", 289, 301], ["colchicine", "SIMPLE_CHEMICAL", 303, 313], ["IVIG", "SIMPLE_CHEMICAL", 319, 323], ["patients", "SPECIES", 93, 101], ["The immunomodulating medications", "TREATMENT", 8, 40], ["COVID", "TREATMENT", 107, 112], ["azathioprine", "TREATMENT", 120, 132], ["mycophenolate mofetil", "TREATMENT", 134, 155], ["sodium", "TREATMENT", 156, 162], ["cyclophosphamide", "TREATMENT", 164, 180], ["methotrexate", "TREATMENT", 186, 198], ["topical corticosteroids", "TREATMENT", 206, 229], ["prednisolone \u2264", "TREATMENT", 231, 245], ["dapsone", "TREATMENT", 254, 261], ["sulfapyridine", "TREATMENT", 262, 275], ["doxycycline", "TREATMENT", 277, 288], ["tetracycline", "TREATMENT", 289, 301], ["colchicine", "TREATMENT", 303, 313], ["IVIG", "TREATMENT", 319, 323]]], ["5, 9 The anti-malarial drugs such as hydroxychloroquine, which had been suggested for COVID-19, do not seem to be effective in BP.", [["hydroxychloroquine", "CHEMICAL", 37, 55], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["COVID-19", "CHEMICAL", 86, 94], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["BP", "SIMPLE_CHEMICAL", 127, 129], ["The anti-malarial drugs", "TREATMENT", 5, 28], ["hydroxychloroquine", "TREATMENT", 37, 55], ["COVID", "TEST", 86, 91], ["BP", "TEST", 127, 129]]], ["11 Prednisone >10 mg/d may be reduced depending on the activity/severity of the BP, age, co-morbidities, and severity of COVID-19.", [["Prednisone", "CHEMICAL", 3, 13], ["Prednisone", "CHEMICAL", 3, 13], ["Prednisone", "SIMPLE_CHEMICAL", 3, 13], ["Prednisone", "TREATMENT", 3, 13], ["the BP", "TEST", 76, 82], ["co-morbidities", "PROBLEM", 89, 103], ["COVID", "TEST", 121, 126]]], ["It is generally not safe to cease chronic corticosteroids abruptly because of adrenal suppression.", [["adrenal", "ANATOMY", 78, 85], ["adrenal suppression", "DISEASE", 78, 97], ["corticosteroids", "CHEMICAL", 42, 57], ["adrenal", "ORGAN", 78, 85], ["chronic corticosteroids", "TREATMENT", 34, 57], ["adrenal suppression", "PROBLEM", 78, 97], ["corticosteroids", "OBSERVATION", 42, 57], ["adrenal suppression", "OBSERVATION", 78, 97]]], ["Until now, there is little information specifically concerning COVID-19 and BP, despite these patients usually being very elderly and often in care homes.", [["COVID-19", "CELL", 63, 71], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["COVID", "TEST", 63, 68], ["BP", "TEST", 76, 78]]]], "5d566d7f36ee3d5dce4fb6ad5110bed6f2e88bd6": [["How not frameshifting can be instructive:", [["frameshifting", "OBSERVATION", 8, 21]]]]}